<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Platinum‐based chemotherapy for early triple‐negative breast cancer - Mason, SRE - 2023 | Cochrane Library</title> <meta content="Platinum‐based chemotherapy for early triple‐negative breast cancer - Mason, SRE - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014805.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Platinum‐based chemotherapy for early triple‐negative breast cancer - Mason, SRE - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014805.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014805.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Platinum‐based chemotherapy for early triple‐negative breast cancer" name="citation_title"/> <meta content="Sofia RE Mason" name="citation_author"/> <meta content="sofia.mason@unsw.edu.au" name="citation_author_email"/> <meta content="Melina L Willson" name="citation_author"/> <meta content="NHMRC Clinical Trials Centre, The University of Sydney" name="citation_author_institution"/> <meta content="Sam J Egger" name="citation_author"/> <meta content="Jane Beith" name="citation_author"/> <meta content="Chris O'Brien Lifehouse" name="citation_author_institution"/> <meta content="Rachel F Dear" name="citation_author"/> <meta content="Annabel Goodwin" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD014805.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/09/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014805.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014805.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014805.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adjuvants, Immunologic; Anthracyclines [therapeutic use]; Carboplatin; *Febrile Neutropenia; Platinum; Quality of Life; *Triple Negative Breast Neoplasms [drug therapy]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014805.pub2&amp;doi=10.1002/14651858.CD014805.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014805\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014805\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ko","th","ms","hr","fa","id","fr","hu"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD014805.pub2",title:"Platinum\\u2010based chemotherapy for early triple\\u2010negative breast cancer",firstPublishedDate:"Sep 8, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014805.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014805.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014805.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014805.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014805.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014805.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014805.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014805.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014805.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014805.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10337 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014805.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-sec-0100"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-sec-0094"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/appendices#CD014805-sec-0105"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/supinfo/CD014805-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/supinfo/CD014805-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Platinum‐based chemotherapy for early triple‐negative breast cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information#CD014805-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Sofia RE Mason</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information#CD014805-cr-0005">Melina L Willson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information#CD014805-cr-0006">Sam J Egger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information#CD014805-cr-0007">Jane Beith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information#CD014805-cr-0008">Rachel F Dear</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information#CD014805-cr-0009">Annabel Goodwin</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information/en#CD014805-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 September 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014805.pub2">https://doi.org/10.1002/14651858.CD014805.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014805-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014805-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014805-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014805-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014805-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014805-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD014805-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014805-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014805-abs-0001" lang="en"> <section id="CD014805-sec-0001"> <h3 class="title" id="CD014805-sec-0001">Background</h3> <p>Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with shorter survival and a higher likelihood of the cancer returning. In early TNBC, platinum‐based chemotherapy has been shown to improve pathological complete response (pCR); however, its effect on long‐term survival outcomes has not been fully elucidated and recommendations to include platinum chemotherapy are not consistent in international guidelines. </p> </section> <section id="CD014805-sec-0002"> <h3 class="title" id="CD014805-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of platinum‐based chemotherapy as adjuvant and neoadjuvant treatment in people with early triple‐negative breast cancer. </p> </section> <section id="CD014805-sec-0003"> <h3 class="title" id="CD014805-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date was 4 April 2022. </p> </section> <section id="CD014805-sec-0004"> <h3 class="title" id="CD014805-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials examining neoadjuvant or adjuvant platinum chemotherapy for early TNBC. </p> </section> <section id="CD014805-sec-0005"> <h3 class="title" id="CD014805-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were disease‐free survival (DFS) and overall survival (OS). Our secondary outcomes were pCR, treatment adherence, grade III or IV toxicity related to chemotherapy, and quality of life. Prespecified subgroups included BRCA mutation status, homologous recombination deficiency (HRD) status, frequency of chemotherapy, type of platinum agent used, and the presence or absence of anthracycline chemotherapy. We assessed risk of bias using Cochrane's RoB 1 tool and certainty of evidence using the GRADE approach. </p> </section> <section id="CD014805-sec-0006"> <h3 class="title" id="CD014805-sec-0006">Main results</h3> <p>From 3972 records, we included 20 published studies involving 21 treatment comparisons, and 25 ongoing studies. For most domains, risk of bias was low across studies. There were 16 neoadjuvant chemotherapy studies (one of which combined neoadjuvant and adjuvant therapy) and four adjuvant chemotherapy trials. Most studies used carboplatin (17 studies) followed by cisplatin (two), and lobaplatin (one). Eight studies had an anthracycline‐free intervention arm, five of which had a carboplatin‐taxane intervention compared to an anthracycline‐taxane control. </p> <p>All studies reporting DFS and OS used carboplatin. Inclusion of platinum chemotherapy improved DFS in neoadjuvant and adjuvant settings (neoadjuvant: hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.53 to 0.75; 7 studies, 8 treatment comparisons, 1966 participants; high‐certainty evidence; adjuvant: HR 0.69, 95% CI 0.54 to 0.88; 4 studies, 1256 participants; high‐certainty evidence). Platinum chemotherapy in the regimen improved OS (neoadjuvant: HR 0.69, 95% CI 0.55 to 0.86; 7 studies, 8 treatment comparisons, 1973 participants; high‐certainty evidence; adjuvant: 0.70, 95% CI 0.50 to 0.96; 4 studies, 1256 participants; high‐certainty evidence). Median follow‐up for survival outcomes ranged from 36 to 97.6 months. </p> <p>Our analysis confirmed platinum chemotherapy increased pCR rates (risk ratio (RR) 1.44, 95% CI 1.31 to 1.59; 15 studies, 16 treatment comparisons, 3083 participants; high‐certainty evidence). Subgroup analyses showed no evidence of differences in DFS according to BRCA mutation status, HRD status, lymph node status, or whether the intervention arm contained anthracycline chemotherapy or not. </p> <p>Platinum chemotherapy was associated with reduced dose intensity, with participants more likely to require chemotherapy delays (RR 2.23, 95% CI 1.70 to 2.94; 4 studies, 5 treatment comparisons, 1053 participants; moderate‐certainty evidence), dose reductions (RR 1.77, 95% CI 1.56 to 2.02; 7 studies, 8 treatment comparisons, 2055 participants; moderate‐certainty evidence) and early cessation of treatment (RR 1.20, 95% CI 1.04 to 1.38; 16 studies, 17 treatment comparisons, 4178 participants; moderate‐certainty evidence). Increased haematological toxicity occurred in the platinum group who were more likely to experience grade III/IV neutropenia (RR 1.53, 95% CI 1.43 to 1.63; 19 studies, 20 treatment comparisons, 4849 participants; moderate‐certainty evidence), anaemia (RR 8.20, 95% CI 5.66 to 11.89; 18 studies, 19 treatment comparisons, 4757 participants; moderate‐certainty evidence) and thrombocytopenia (RR 7.59, 95% CI 5.10 to 11.29; 18 studies, 19 treatment comparisons, 4731 participants; moderate‐certainty evidence). There was no evidence of a difference between chemotherapy groups in febrile neutropenia (RR 1.16, 95% CI 0.89 to 1.49; 11 studies, 3771 participants; moderate‐certainty evidence). Renal impairment was very rare (0.4%, 2 events in 463 participants; note 3 studies reported 0 events in both arms; 4 studies; high‐certainty evidence). Treatment‐related death was very rare (0.2%, 7 events in 3176 participants and similar across treatment groups; RR 0.58, 95% 0.14 to 2.33; 10 studies, 11 treatment comparisons; note 8 studies reported treatment‐related deaths but recorded 0 events in both groups. Thus, the RR and CIs were calculated from 3 studies rather than 11; 3176 participants; high‐certainty evidence). Five studies collected quality of life data but did not report them. </p> </section> <section id="CD014805-sec-0007"> <h3 class="title" id="CD014805-sec-0007">Authors' conclusions</h3> <p>Platinum‐based chemotherapy using carboplatin in the adjuvant or neoadjuvant setting improves long‐term outcomes of DFS and OS in early TNBC, with no evidence of differences by subgroup. This was at the cost of more frequent chemotherapy delays and dose reductions, and greater haematological toxicity, though serious adverse events including neuropathy, febrile neutropenia or treatment‐related death were not increased. </p> <p>These findings support the use of platinum‐based chemotherapy for people with early TNBC. The optimal dose and regimen are not defined by this analysis, but there is a suggestion that similar relative benefits result from the addition of carboplatin to either anthracycline‐free regimens or those containing anthracycline agents. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014805-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014805-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD014805-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD014805-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014805-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014805-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD014805-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD014805-abs-0018">Magyar</a> </li> <li class="section-language"> <a class="" href="full/id#CD014805-abs-0015">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014805-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014805-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD014805-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014805-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014805-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014805-abs-0002" lang="en"> <h3>Platinum‐containing chemotherapy for women before or after surgery for early triple‐negative breast cancer </h3> <p><b>Key messages</b> </p> <p>Chemotherapy including the platinum‐based medicine carboplatin improves survival and reduces the chance of cancer returning for people with early triple negative breast cancer. </p> <p>However, it is also associated with increased side effects.</p> <p><b>What is triple‐negative breast cancer?</b> </p> <p>Triple‐negative breast cancer makes up 15% of breast cancer cases. It is a type of breast cancer that does not have any of the three receptors commonly found on breast cancer cells – the oestrogen, progesterone and HER2 receptors. Early breast cancer is defined as cancer limited to the breast and lymph nodes in the armpit, and it can usually be cured. </p> <p><b>How is early triple‐negative breast cancer treated?</b> </p> <p>Treatments for early triple‐negative breast cancer include:</p> <p>– surgery to remove the cancer from the breast and lymph nodes;</p> <p>– radiotherapy to the breast and lymph nodes, used to prevent the cancer from coming back in these areas; </p> <p>– chemotherapy, used to prevent the cancer from coming back anywhere in the body. This can be given before surgery (called 'neoadjuvant') or after surgery (called 'adjuvant'). </p> <p><b>What did we want to find out?</b> </p> <p>There are many types of chemotherapy used in triple‐negative breast cancer. We wanted to find out if a specific class of chemotherapy called 'platinum‐based chemotherapy' increases: </p> <p>– the length of time people stayed alive without cancer recurrence after diagnosis (disease‐free survival); </p> <p>– the total length of life after diagnosis (overall survival);</p> <p>– the likelihood that the cancer had disappeared in the removed breast and lymph node tissue when chemotherapy was given before surgery (pathological complete response). </p> <p>We also wanted to find out if platinum‐based chemotherapy was associated with more unwanted outcomes like chemotherapy delays, dose reductions or side effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies looking at chemotherapy for early triple‐negative breast cancer that compared regimens containing platinum chemotherapy to regimens without platinum chemotherapy. </p> <p>We compared and summarised the results of the studies, and rated our confidence in the evidence based on factors such as study methods and size. </p> <p><b>What did we find?</b> </p> <p>We found 20 studies that involved 4688 people with early triple‐negative breast cancer, with average follow‐up in studies ranging from three to eight years. </p> <p>Platinum chemotherapy was associated with longer disease‐free survival and overall survival, and reduced the chance of disease recurrence and death by about one third. These benefits were seen with chemotherapy used before surgery (neoadjuvant) or after surgery (adjuvant). When used before surgery, it also improved the likelihood of a pathological complete response. </p> <p>We did not find that any particular subgroup, such as people with a high‐risk gene mutation, had more benefit from platinum chemotherapy. </p> <p>However, people receiving platinum chemotherapy were more likely to need the dose of their chemotherapy to be reduced, or to have a delay in their chemotherapy. They were also more likely to stop chemotherapy early. </p> <p>Platinum chemotherapy also caused more serious side effects including low blood cell counts. It was not associated with an increase in having fevers associated with low white blood cell counts (febrile neutropenia), nerve damage symptoms (neuropathy) or death caused by treatment. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The evidence was generally of high quality and included enough data to make judgements to answer our main questions. </p> <p>However, there were many types of chemotherapy used across studies. Although we have shown that platinum chemotherapy improves long‐term outcomes, we do not know what the best chemotherapy combination is. </p> <p>None of the studies reported quality of life, which we had initially set out to measure and record. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>This evidence is up‐to‐date to April 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014805-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014805-sec-0100"></div> <h3 class="title" id="CD014805-sec-0101">Implications for practice</h3> <section id="CD014805-sec-0101"> <p>This review provides high‐certainty evidence that platinum‐based chemotherapy with carboplatin is associated with improved disease‐free survival (DFS), overall survival (OS) and pathological complete response in early triple‐negative breast cancer (TNBC). This is at the cost of increased grade III/IV haematological toxicity, though serious adverse events including febrile neutropenia or treatment‐related death were not increased. </p> <p>These findings support the use of carboplatin, but not cisplatin, for people with early TNBC. The optimal dose and regimen are not defined by this analysis, but there is a suggestion that similar relative benefits result from the addition of carboplatin to either anthracycline‐free regimens or those containing anthracycline agents. Additionally, our analysis supports a broad rather than focused use of carboplatin based on the benefit seen across the examined subgroups. </p> </section> <h3 class="title" id="CD014805-sec-0102">Implications for research</h3> <section id="CD014805-sec-0102"> <p>We examined a single trial using lobaplatin, a novel platinum agent which is reported to have a favourable toxicity profile in other cancers (<a href="./references#CD014805-bbs2-0078" title="PeraboFG , MüllerSC . New agents for treatment of advanced transitional cell carcinoma. Annals of Oncology2007;18:835-43.">Perabo 2007</a>). Further testing of other platinum compounds is justified if it may alleviate some of the additive toxicity associated with combination chemotherapy, such as the haematological toxicity reported in this review. </p> <p>In this review, we did not identify a subgroup of TNBC which may derive greater benefit from platinum chemotherapy. Refining groups who may benefit most would be helpful to guide treatment selection. It is currently unclear if emerging biomarkers including enhanced homologous recombination deficiency testing might be helpful in future for participant selection. </p> <p>Incremental improvements in DFS and OS are being provided by new anticancer agents in the setting of early disease, including immunotherapy (<a href="./references#CD014805-bbs2-0083" title="SchmidP , CortesJ , PusztaiL , McArthurH , KümmelS , BerghJ , et al. Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine2020;382(9):810-21.">Schmid 2020</a>) and poly(adenosine diphosphate‐ribose) polymerase (PARP) inhibitors (<a href="./references#CD014805-bbs2-0088" title="TuttAN , GarberJE , KaufmanB , VialeG , FumagalliD , RastogiP , et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. New England Journal of Medicine2021;384(25):2394-405.">Tutt 2021</a>). As we add new agents, we must also consider rationalising and de‐escalating treatment for certain participants at lower risk of recurrence or who have a favourable treatment response. The use of anthracycline‐free regimens is of increasing interest (<a href="./references#CD014805-bbs2-0074" title="NitzU , GluzO , ClemensM , MalterW , ReimerT , NudingB , et al. West German Study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. Journal of Clinical Oncology2019;37(10):799-808.">Nitz 2019</a>; <a href="./references#CD014805-bbs2-0090" title="YuK , LiuX , ChenL , MoM , JiongW , Guang-YuL , et al. Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: a phase III randomized non-inferiority trial. Lancet Regional Health Western Pacific2021;11:100158.">Yu 2021</a>) given these agents are implicated in long‐term cardiotoxicity and secondary leukaemia. Further research into the optimal regimen is warranted. </p> <p>Finally, this review has highlighted the need for ensuring reporting of the quality of life data collected in trials involving early breast cancer. The value of patient‐reported outcome measures is being increasingly recognised, and whilst trials are collecting data, they are not always published in a timely manner. Consideration of these outcomes from clinical trials is essential for ensuring person‐centred clinical interventions to assess objective disease control as well as more subjective health and well‐being. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014805-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014805-sec-0008"></div> <div class="table" id="CD014805-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Platinum‐containing chemotherapy compared to chemotherapy without platinum in neoadjuvant therapy for early triple‐negative breast cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐containing chemotherapy compared to chemotherapy without platinum in neoadjuvant therapy for early triple‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neoadjuvant therapy for early triple‐negative breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> platinum‐containing chemotherapy<br/><b>Comparison:</b> chemotherapy without platinum </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with chemotherapy without platinum</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with platinum‐containing chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DFS at 2 years</b><br/>assessed with: risk of recurrence<br/>follow‐up: range 3 years to 7.9 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.63</b><br/>(0.53 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1966<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b><br/>(117 to 162) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DFS at 5 years</b> </p> <p>follow‐up: range 3 years to 7.9 years</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.63</b><br/>(0.53 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1966<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>301 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b><br/>(173 to 235) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OS at 2 years</b><br/>assessed with: risk of death<br/>follow‐up: range 1.7 years to 7.9 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.69</b><br/>(0.55 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1973<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(27 to 41) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OS at 5 years</b><br/>follow‐up: range 1.7 years to 7.9 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.69</b><br/>(0.55 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1973<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b><br/>(110 to 166) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pathological complete response</b><br/>follow‐up: range 6 weeks to 9.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>305 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>440 per 1000</b><br/>(400 to 485) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.44</b><br/>(1.31 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3083<br/>(15 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>DFS:</b> disease‐free survival; <b>HR:</b> hazard ratio; <b>OS:</b> overall survival; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434916258784592377" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434916258784592377</a>. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD014805-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Platinum‐containing chemotherapy compared to chemotherapy without platinum in adjuvant therapy for early triple‐negative breast cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐containing chemotherapy compared to chemotherapy without platinum in adjuvant therapy for early triple‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adjuvant therapy for early triple‐negative breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> platinum‐containing chemotherapy<br/><b>Comparison:</b> chemotherapy without platinum </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with chemotherapy without platinum</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with platinum‐containing chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DFS at 2 years</b> </p> <p>assessed with: risk of recurrence<br/>follow‐up: range 4.3 years to 8 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.69</b><br/>(0.54 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1256<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b><br/>(83 to 131) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DFS at 5 years</b> <br/>follow‐up: range 4.3 years to 8 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.69</b><br/>(0.54 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1256<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b><br/>(95 to 150) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OS at 2 years</b><br/>assessed with: risk of death<br/>follow‐up: range 4.3 years to 8 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.70</b><br/>(0.50 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1256<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b><br/>(27 to 50) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OS at 5 years</b><br/>follow‐up: range 4.3 years to 8 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.70</b><br/>(0.50 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1256<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/>(41 to 78) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>DFS:</b> disease‐free survival; <b>HR:</b> hazard ratio; <b>OS:</b> overall survival; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434981690495911791" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434981690495911791</a>. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD014805-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Platinum‐containing chemotherapy compared to chemotherapy without platinum for early triple‐negative breast cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐containing chemotherapy compared to chemotherapy without platinum for early triple‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> early triple‐negative breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> platinum‐containing chemotherapy<br/><b>Comparison:</b> chemotherapy without platinum </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with chemotherapy without platinum</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with platinum‐containing chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants requiring chemotherapy delays</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>154 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1000</b><br/>(263 to 454) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.23</b><br/>(1.70 to 2.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1053<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants requiring dose reduction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>278 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b><br/>(433 to 561) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.77</b><br/>(1.56 to 2.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2055<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anaemia (grade III/IV)</b><br/>follow‐up: range 6 weeks to 38 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b><br/>(72 to 152) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.20</b><br/>(5.66 to 11.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4757<br/>(19 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile neutropenia (grade III/IV)</b><br/>follow‐up: range 12 weeks to 38 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><br/>(50 to 83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b><br/>(0.89 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3771<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Renal impairment (grade III/IV)</b><br/>follow‐up: range 6 weeks to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>4 studies reported renal impairment. 1 study reported 2 events in 60 people in the platinum arm (3%) and 0 events in 57 people in the non‐platinum arm. None of the other studies reported any grade III/IV events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>4 studies collected quality of life information using validated questionnaires but none of these reported data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434915765589228984" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434915765589228984</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for inconsistency due to marked variability between trials, demonstrated by a wide range of hazard ratios and confidence intervals with minimal overlap. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014805-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014805-sec-0009"></div> <section id="CD014805-sec-0010"> <h3 class="title" id="CD014805-sec-0010">Description of the condition</h3> <p>Breast cancer is the most common type of cancer in women and the most common cause of cancer death (<a href="./references#CD014805-bbs2-0064" title="FerlayJ , ErvikM , LamF , ColombetM , MeryL , PiñerosM , et al, editor(s). Cancer Today (powered by GLOBOCAN 2018) IARC CancerBase No. 15. publications.iarc.fr/Databases/Iarc-Cancerbases/Cancer-Today-Powered-By-GLOBOCAN-2018--2018 (accessed 17 July 2020).">Ferlay 2018</a>). Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer, which lacks hormone receptors and human epidermal growth factor receptor 2 (HER2) expression. It is associated with shorter survival and a higher likelihood of recurrence, and comprises about 15% of breast cancer diagnoses (<a href="./references#CD014805-bbs2-0065" title="FoulkesWD , SmithIE , Reis-FilhoJS . Triple-negative breast cancer. New England Journal of Medicine2010;363(20):1938-48.">Foulkes 2010</a>; <a href="./references#CD014805-bbs2-0071" title="LinNU , VanderplasA , HughesME , TheriaultRL , EdgeSB , WongYN , et al. Clinicopathological features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer2012;118(22):5463-72.">Lin 2012</a>). Early TNBC is defined as cancer that has not spread beyond the breast or axillary lymph nodes, and is potentially curable. Surgery, radiotherapy, and chemotherapy are used to minimise the chance of relapse. </p> <p>TNBC is more likely to be associated with heritable causes than other breast cancer subtypes. Over 10% of people diagnosed with TNBC under the age of 50 years, without known family history of breast or ovarian cancer, have a heritable mutation in either breast cancer gene 1 or gene 2 (<i>BRCA1</i> or <i>BRCA2</i>) (<a href="./references#CD014805-bbs2-0086" title="ShimelisH , LaDucaH , HuC , HartSN , NaJ , ThomasA , et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. JNCI: Journal of the National Cancer Institute2018;110(8):855-62.">Shimelis 2018</a>). Whilst <i>BRCA1</i> mutation is the most strongly associated, other heritable gene mutations (i.e. <i>BRCA2</i> ; partner and localizer of BRCA2 (<i>PALB2</i> ); RAD51 paralogue D (<i>RAD51D</i> ) and BRCA1 associated RING domain 1 (<i>BARD1</i>)) have also shown associations with TNBC and higher lifetime risks of breast cancer. These mutations are implicated in DNA repair and genomic stability. A heritable mutation in either a high‐risk or moderate‐risk breast cancer gene was found in 12% of the study population with TNBC (compared to 5% for all breast cancer cases), highlighting the importance of referring women with TNBC for genetic counselling, even when there is no known family history of cancer (<a href="./references#CD014805-bbs2-0086" title="ShimelisH , LaDucaH , HuC , HartSN , NaJ , ThomasA , et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. JNCI: Journal of the National Cancer Institute2018;110(8):855-62.">Shimelis 2018</a>). Guidelines recommend genetic testing for women who are diagnosed at young ages (less than 50 years); if there is a family history of breast, ovarian, prostate, or pancreatic cancer; or if they are of Ashkenazi Jewish ancestry. </p> </section> <section id="CD014805-sec-0011"> <h3 class="title" id="CD014805-sec-0011">Description of the intervention</h3> <p>Standard chemotherapy used in the adjuvant or neoadjuvant setting for TNBC involves anthracycline and taxane chemotherapy, combined with cyclophosphamide. The role of adjuvant chemotherapy is to treat micrometastatic systemic disease, which is not detectable by standard blood tests and imaging. Chemotherapy is indicated for most women with TNBC who are in good health. The National Comprehensive Cancer Network (NCCN) Guidelines recommend offering chemotherapy to women with TNBC whose cancer size is larger than 1 cm, or any size with involvement of their lymph nodes. Chemotherapy may also be considered for women with smaller tumours. </p> <p>The intervention being studied is platinum‐based chemotherapy (cisplatin or carboplatin) alone or in addition to the standard adjuvant or neoadjuvant chemotherapy, to determine whether this improves survival from early TNBC. Our primary outcomes were overall survival (OS) and disease‐free survival (DFS). Achieving a pathological complete response (pCR) has strong prognostic value, particularly in the TNBC subtype (<a href="./references#CD014805-bbs2-0058" title="CortazarP , ZhangL , UntchM , MehtaK , CostantinoJP , WolmarkN , et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet2014;384(9938):164-72.">Cortazar 2014</a>). Because of the assumed association between survival and pCR, many trials assess pCR while either waiting for data to mature or as their primary endpoint before deciding whether larger trials are feasible. Consequently, we reported pCR, along with OS and DFS. </p> </section> <section id="CD014805-sec-0012"> <h3 class="title" id="CD014805-sec-0012">How the intervention might work</h3> <p>Platinum agents damage DNA by causing single‐strand DNA breaks, resulting in apoptosis. DNA repair deficiencies are associated with germline or somatic mutations in <i>BRCA1</i> , <i>BRCA2</i> , and <i>PALB2</i>, which are frequently associated with TNBC. This is a proposed mechanism for the increased efficacy of the DNA‐damaging effects of platinum chemotherapy for TNBC. With genomic profiling, women identified as having basal‐type TNBC are also seen to have DNA‐repair deficiency (<a href="./references#CD014805-bbs2-0067" title="GuoW , LinL , HeX , HeF , WangC , ChenN , et al. Biomarkers of DNA repair and related pathways: significance of treatment in triple-negative breast cancer. Critical Reviews in Oncogenesis2017;22(5-6):427-37.">Guo 2017</a>). Besides breast cancer, an enhanced response to platinum‐based chemotherapy is seen in women with <i>BRCA</i> mutations who have ovarian cancer (<a href="./references#CD014805-bbs2-0077" title="PenningtonKP , WalshT , HarrellMI , LeeMK , PennilCC , et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clinical Cancer Research2014;20(3):764-75.">Pennington 2014</a>), and <i>BRCA</i>‐associated pancreatic cancer (<a href="./references#CD014805-bbs2-0075" title="O'ReillyEM , LeeJW , ZalupskiM , CapanuM , ParkJ , GolanT , et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. Journal of Clinical Oncology2020;38(13):1378-88.">O'Reilly 2020</a>). Poly(adenosine diphosphate‐ribose) polymerase (PARP) inhibitors have shown efficacy for women with advanced BRCA breast cancer, although this treatment has not been compared to their response to platinum. </p> <p>Potential adverse effects of platinum include an increase in myelosuppression, which can lead to dose omissions, interruptions or dose reduction of platinum chemotherapies, other chemotherapy drugs, or both. There are risks of additional toxicity from myelosuppression, with febrile neutropenia, anaemia or bleeding due to thrombocytopenia. Long‐term toxicities from platinum chemotherapy can include peripheral neuropathy, ototoxicity and renal impairment. </p> </section> <section id="CD014805-sec-0013"> <h3 class="title" id="CD014805-sec-0013">Why it is important to do this review</h3> <p>This review will clarify the role of platinum‐based chemotherapy in early TNBC to determine if there is a significant improvement in OS or other disease outcomes with comparable toxicity to non‐platinum‐based chemotherapy. Previous reviews on this topic suggested that the addition of platinum chemotherapy increases rates of pCR at the cost of an increase in adverse events (<a href="./references#CD014805-bbs2-0076" title="PandyJG , Balolong-GarciaJC , Cruz-OrdinarioMV , QueFV . Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer2019;19(1):1065.">Pandy 2019</a>; <a href="./references#CD014805-bbs2-0080" title="PoggioF , BruzzoneM , CeppiM , PondeNF , La ValleG , Del MastroL , et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Annals of Oncology2018;29(7):1497-508.">Poggio 2018</a>). However, new trials have been published since these reviews. </p> <p>Maximising the efficacy of treatment of early breast cancer will reduce rates of metastatic, incurable disease and premature death from this condition. However, given this is a population where the intention is long‐term survival, the prevention of permanent toxicity is also a priority. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014805-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014805-sec-0014"></div> <p>To evaluate the benefits and harms of platinum‐based chemotherapy as adjuvant and neoadjuvant treatment in people with early triple‐negative breast cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014805-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014805-sec-0015"></div> <section id="CD014805-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014805-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) examining platinum‐based chemotherapy for neoadjuvant or adjuvant treatment for people with early TNBC. This included trials which added a platinum‐based chemotherapy to another standard chemotherapy regimen, or compared a platinum regimen to a non‐platinum regimen. To be included, studies must have reported their findings for participants with TNBC separately from other participants, or only included less than 20% (a minority is less than 50%) of participants with non‐TNBC. </p> </section> <section id="CD014805-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included participants aged 18 years or older with early TNBC, defined as breast cancers with disease isolated to the breast and axillary lymph nodes that lack expression of the oestrogen receptor and progesterone receptor (as defined by the trial), and negative for human epidermal receptor 2 (HER2; negative with in situ hybridisation testing; 0 to 1+ with immunohistochemistry (IHC); or 2+ with IHC and negative with fluorescence in situ hybridisation). We included trials with all study locations, and participants of all ethnicities. We excluded trials that did not assess women for HER2 status. </p> </section> <section id="CD014805-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The intervention of interest was any chemotherapy regimen that contained platinum chemotherapy compared to regimens without platinum chemotherapy. Included studies addressed either adjuvant (postsurgery) or neoadjuvant (presurgery) delivery of chemotherapy for early TNBC. We recorded and compared the dose and duration of chemotherapy. </p> </section> <section id="CD014805-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD014805-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD014805-list-0001"> <li> <p><b>Disease‐free survival (DFS)</b>, time‐to‐event outcome defined as time from surgery (in neoadjuvant setting) or randomisation (in adjuvant setting) to first date of a local, regional or distant relapse; diagnosis of a second primary cancer; or death from any cause. We included similar outcomes, such as progression‐free survival and time‐to‐progression in this section. </p> </li> <li> <p><b>Overall survival (OS)</b>, time‐to‐event outcome defined as the time from randomisation or study entry until death from any cause. </p> </li> </ul> </p> </section> <section id="CD014805-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD014805-list-0002"> <li> <p><b>Pathological complete response (pCR)</b> (dichotomous outcome) defined as no invasive carcinoma in the breast or axillary lymph nodes (ypT0/isypN0 TNM (tumour, node, metastasis) staging; <a href="./references#CD014805-bbs2-0063" title="EdgeSB , ComptonCC . The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of Surgical Oncology2010;17(6):1471-4.">Edge 2010</a>) after neoadjuvant therapy. </p> </li> <li> <p><b>Completion of regimens</b> (dichotomous outcomes), assessed by absence of delay in treatment or dose reductions, or both, or early cessation of treatment. </p> </li> <li> <p><b>Any grade III/IV toxicity</b> related to chemotherapy (dichotomous outcomes). </p> </li> <li> <p><b>Quality of life</b> – quality of life information is typically not collected in these types of trials, we aimed to report any quality of life data as measured by the many validated tools available to trialists, and at all reported time points. </p> </li> </ul> </p> </section> </section> </section> <section id="CD014805-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD014805-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We performed a search the following databases up to the 4 April 2022.</p> <p> <ul id="CD014805-list-0003"> <li> <p>The Cochrane Breast Cancer Group's (CBCG's) Specialised Register. Details of the search strategies used by the Group for the identification of studies and the procedure used to code references are outlined in the Group's module (<a href="https://breastcancer.cochrane.org/sites/breastcancer.cochrane.org/files/public/uploads/specialised_register_details.pdf" target="_blank">breastcancer.cochrane.org/sites/breastcancer.cochrane.org/files/public/uploads/specialised_register_details.pdf</a>). We identified and considered for inclusion any trial with the keywords: 'Cisplatin', 'cisplatinum', 'carboplatin', 'carboplatinum', 'platin', 'platinum', 'platinum diamminodichloride', 'cis‐diamminedichloroplatinum', 'cis‐dichlorodiammineplatinum', 'biocisplatinum', 'dichlorodiammineplatinum', 'nsc‐119875', 'platidiam', 'platino', 'Platinol', 'cis‐diamminedichloroplatinum', 'cis‐platinum', 'cis‐diammine (cyclobutanedicarboxylato) platinum', 'cbdca', 'jm‐8', 'nsc‐241240', 'paraplatin'; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, latest issue); see <a href="./appendices#CD014805-sec-0106">Appendix 1</a> </p> </li> <li> <p>MEDLINE OvidSP (top up search to complement CBCG's Specialised Register); see <a href="./appendices#CD014805-sec-0107">Appendix 2</a> </p> </li> <li> <p>Embase OvidSP (1947 to present); see <a href="./appendices#CD014805-sec-0108">Appendix 3</a> </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal for all prospectively registered and ongoing trials (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">apps.who.int/trialsearch/Default.aspx</a>); see <a href="./appendices#CD014805-sec-0109">Appendix 4</a> </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>); see <a href="./appendices#CD014805-sec-0110">Appendix 5</a> </p> </li> </ul> </p> </section> <section id="CD014805-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We screened the reference lists of identified relevant trials or reviews to help identify additional studies. We obtained a full article or abstract for each reference reporting a potentially eligible trial. </p> <p>We searched the abstracts of recent conference proceedings not yet included in the CBCG's Specialised Register or medical databases, including the American Society of Clinical Oncology annual meeting, European Society of Medical Oncology Congress and San Antonio Breast Cancer Symposium. </p> <p>We searched systematic reviews on the topic using PubMed Clinical Queries.</p> <p>We contacted the lead investigators of potentially eligible ongoing and completed trials listed in the trial registries to see if their study was complete or study results could be provided. </p> </section> </section> <section id="CD014805-sec-0026"> <h3 class="title" id="CD014805-sec-0026">Data collection and analysis</h3> <section id="CD014805-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SM and AG) independently applied the selection criteria to each reference identified by the search strategy. There were no disagreements by review requiring resolution. </p> <p>We included English‐language studies and studies that were translated. We recorded the selection process in the PRISMA flow diagram. </p> <p>We recorded a selection of excluded studies in the <a href="./references#CD014805-sec-0120" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD014805-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We extracted data using standard extraction forms. We collected information on study design; randomisation methods; baseline characteristics of participants; setting; chemotherapy regimens (chemotherapy agent, dose, number of cycles); deliverability of treatment, assessed by dose intensity, dose delays or interruptions; and primary and secondary outcomes. We also collected details regarding type of toxicity for grade III or IV events (according to National Cancer Institute Common Terminology Criteria for Adverse Events (<a href="./references#CD014805-bbs2-0059" title="Common Terminology Criteria for Adverse Events (CTCAE) v5.0. ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (accessed 25 March 2021).">CTCAE 2017</a>)), length of follow‐up and sources of funding. </p> <p>Two review authors (SM and MW) independently extracted the data, and resolved disagreements with the support of AG and SE. For studies with more than one publication, we extracted data from all publications, and considered the most recent full‐text version of the study to be the primary reference. We combined records relating to the same study under the overall trial ID. For one included study, one colleague checked and conducted data extraction and risk of bias assessments for the translated material. </p> <p>We entered data into <a href="./references#CD014805-bbs2-0081" title="Review Manager Web (RevMan Web). Version 2.4.2. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a> for analysis. </p> </section> <section id="CD014805-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed bias using Cochrane's RoB 1 tool (<a href="./references#CD014805-bbs2-0069" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). The domains assessed were sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other potential sources of bias. In oncology, an open‐label approach is often used as it is difficult to obscure differing treatment schedules and potential toxicities from patients and care providers. Therefore, we grouped the blinding of outcome assessment domain with outcome measures from most unlikely to most likely to be influenced by a lack of blinding. The outcomes were segregated into DFS, OS, pCR, toxicity and treatment adherence, and quality of life. </p> <p>Two review authors (SM and MW) independently assessed the risk of bias, with guidance provided by two other review authors (AG and SE). We incorporated the results of this risk of bias assessment into the interpretation of results. </p> </section> <section id="CD014805-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following effect measures.</p> <p> <ul id="CD014805-list-0004"> <li> <p>Time‐to‐event outcomes (DFS, OS): expressed as a hazard ratio (HR) with 95% confidence intervals (CI). For HRs and variances which were not reported in the trial publications, we calculated summary statistics indirectly using the methods outlined in <a href="./references#CD014805-bbs2-0087" title="TierneyJ , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>. In the 'Notes' section of the <a href="./references#CD014805-sec-0119" title="">Characteristics of included studies</a> table, we recorded the use of indirect methods, and whether the trial publications reported an assessment of the proportional hazards assumption. HRs less than 1.0 favour regimens with platinum chemotherapy, and HRs greater than 1.0 favour regimens without platinum chemotherapy. </p> </li> <li> <p>Dichotomous outcomes (pCR, completion of regimens, toxicity): expressed as risk ratio (RR) with 95% CI. We reported the ratios of treatment effects for pCR (a favourable event) so that RRs greater than 1.0 favour regimens with platinum chemotherapy, and RRs less than 1.0 favour regimens without platinum chemotherapy. For completion of regimens or toxicity outcomes (unfavourable events), RRs greater than 1.0 favour regimens without platinum chemotherapy and RRs less than 1.0 favour regimens with platinum chemotherapy. Data for toxicity were the population included in the study regardless of the proportion of participants with TNBC; </p> </li> <li> <p>Continuous data (quality of life): collected but not reported in any of the studies. If sufficient quality of life data becomes available in future review updates, the effect measure would likely be a mean difference (MD) if studies used the same scales or standardised mean difference (SMD) if studies used different scales, with 95% CI. We would interpret and report SMDs in a more easily interpreted scale for readers, considering the minimal important clinical difference (MICD) to put results into context (<a href="./references#CD014805-bbs2-0073" title="McGlothlinAE , LewisRJ . Minimal clinically important difference: defining what really matters to patients. JAMA2014;312(13):1342-3.">McGlothlin 2014</a>). Each quality of life measurement scale may have a different MICD and we plan to review these estimates for each instrument. We would use an MICD of 0.2 to 0.5 as a guide for patient‐reported outcomes. </p> </li> </ul> </p> <p>Two review authors (SB and MW) extracted data from each trial and discussed any data queries with two other review authors (AG and SE). </p> </section> <section id="CD014805-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The trial participants were the unit of analysis in this review. One trial was a three‐arm study (Brightness: <a href="./references#CD014805-bbs2-0003" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;36(15 Suppl):519. ">BrighTNess comparison 1</a> and <a href="./references#CD014805-bbs2-0004" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;35(15 Suppl):519. ">BrighTNess comparison 2</a>). For this study, we halved the number of women in the control group to allow for a comparison with the two different platinum‐containing arms. The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> suggests these methods to correct for multiple intervention or control groups (<a href="./references#CD014805-bbs2-0070" title="HigginsJP , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). </p> </section> <section id="CD014805-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact authors of included studies in writing, to request missing data (e.g. dosing or toxicity). We contacted the following authors of included studies (<a href="./references#CD014805-bbs2-0002" title="AndoM , YamauchiH , AogiK , ShimizuS , IwataH , MasudaN , et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment2014;145(2):401-9. IwaseM , AndoM , AogiK , ArugaT , InoueK , ShimomuraA , et al. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment2020;180(3):687-94. TamuraK , HashimotoJ , TsudaH , YoshidaM , YamauchiH , AogiK , et al. Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. Journal of Clinical Oncology2014;32(15 Suppl):1017. UMIN000003355. Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer. Center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004074 (first received 22 March 2010). ">Ando 2014</a>; BrighTNess: <a href="./references#CD014805-bbs2-0003" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;36(15 Suppl):519. ">BrighTNess comparison 1</a> and <a href="./references#CD014805-bbs2-0004" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;35(15 Suppl):519. ">BrighTNess comparison 2</a>; <a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a>). </p> <p>We also contacted studies recorded in the WHO ICTRP and ClinicalTrials.gov that have not yet published their results. We discussed the impact of any missing data. </p> </section> <section id="CD014805-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>Recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> have guided the assessment of heterogeneity (<a href="./references#CD014805-bbs2-0061" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Deeks 2020</a>). We examined diversity by visually inspecting the forest plots, Chi² test and I² statistic. We used a cut‐off point of P = 0.10 for the Chi² test. The I² statistic "describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance)" (Section 10.10.2, <a href="./references#CD014805-bbs2-0061" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Deeks 2020</a>). We acknowledge that there is much uncertainty in measures such as I<sup>2</sup> statistic when there are few studies. Noting these limitations, we used it as a rough guide for interpretation, using these thresholds for the I² statistic: </p> <p> <ul id="CD014805-list-0005"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity and</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> <p>The importance of the observed value of the I<sup>2</sup> statistic depends on the magnitude and direction of effects, and strength of evidence for heterogeneity (e.g. P value from the Chi<sup>2</sup> test, or a CI for the I<sup>2</sup> statistic: uncertainty in the value of the I<sup>2</sup> statistic is substantial when the number of studies is small; <a href="./references#CD014805-bbs2-0061" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Deeks 2020</a>). </p> </section> <section id="CD014805-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>As there were fewer than 10 studies contributing to meta‐analyses, we were unable to investigate publication or other bias using funnel plot asymmetry. </p> <p>Where possible, we reviewed the protocols of included studies to assess outcome reporting bias. </p> </section> <section id="CD014805-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We used the following methods to synthesise the data:</p> <p> <ul id="CD014805-list-0006"> <li> <p>time‐to‐event data (DFS, OS) – we used a fixed‐effect model with an inverse‐variance model; as there was no evidence of substantial heterogeneity, a random‐effects model (DerSimonian and Laird with inverse‐variance method) was not required; </p> </li> <li> <p>dichotomous outcomes (pCR, completion of regimens, toxicity) – we used a fixed‐effect model (Mantel‐Haenszel model (<a href="./references#CD014805-bbs2-0072" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719-48.">Mantel 1959</a>)); as there was no evidence of substantial heterogeneity, a random‐effects model (DerSimonian and Laird method; (<a href="./references#CD014805-bbs2-0062" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>)) was not required; </p> </li> <li> <p>continuous data (quality of life) – no data were reported. If data are reported in future review updates, we intend to use a fixed‐effect model with an inverse variance method (<a href="./references#CD014805-bbs2-0060" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Deeks 2011</a>); or if there is evidence of substantial heterogeneity, a random‐effects model (DerSimonian and Laird with inverse‐variance method). </p> </li> </ul> </p> <p>In the case of pCR, one study was an adaptive platform trial and reported results as an estimated rate of complete response with a 95% Bayesian probability interval. In order to include these data in the meta‐analysis, we calculated the discrete number of events in each group by using the adjusted probabilities of pCR. </p> <p>Though there were occasional zero event toxicity outcomes in a single arm for dichotomous outcomes, the Mantel‐Haenszel methods requires zero‐cell corrections only if the same cell is zero in all the included studies (<a href="./references#CD014805-bbs2-0061" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Deeks 2020</a>), which was not the case in our data. In instances where there were no events in both arms of study, we followed the standard practice of excluding that study from the meta‐analysis. The rationale behind this is that these studies do not offer any insight into the direction or magnitude of the relative effect of the treatment (<a href="./references#CD014805-bbs2-0061" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Deeks 2020</a>). </p> </section> <section id="CD014805-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We examined the following subgroups</p> <p> <ul id="CD014805-list-0007"> <li> <p>Germline BRCA mutations</p> </li> <li> <p>Somatic mutation of HRD</p> </li> <li> <p>Lymph node status</p> </li> <li> <p>Type of platinum agent used in the platinum arm</p> </li> <li> <p>Types of chemotherapy</p> <ul id="CD014805-list-0008"> <li> <p>Trials where the only difference across treatment arms was the use of platinum, that is platinum plus regimen A versus regimen A, described as same backbone chemotherapy with or without platinum </p> </li> <li> <p>Anthracycline‐containing regimens (may include taxane) versus non‐anthracycline regimen</p> </li> </ul> </li> <li> <p>Timing of platinum agent, that is weekly versus every two weeks versus every three weeks </p> </li> </ul> </p> <p>We conducted subgroup analyses to assess the effects of the above factors on clinical outcomes and heterogeneity. </p> </section> <section id="CD014805-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted the following sensitivity analyses based on:</p> <p> <ul id="CD014805-list-0009"> <li> <p>differences in the definition of triple negative that had a hormone receptor (oestrogen receptor (ER)/progesterone receptor (PR)) expression cut‐off other than less than 1% or was not defined; </p> </li> <li> <p>potentially confounding extra treatments (e.g. the intervention contained a platinum as well as an additional anticancer agent) on the primary outcomes; </p> </li> <li> <p>a high or unclear risk of bias;</p> </li> <li> <p>considerable heterogeneity (i.e. I<sup>2</sup> statistic between 75% and 100%). In this case, a random‐effects approach was additionally conducted. </p> </li> </ul> </p> </section> <section id="CD014805-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Teams of two review authors (from SM, MW, AG and SE) assessed the certainty of the evidence for critical outcomes using the GRADE approach. This approach uses five considerations, bias, inconsistency, indirectness, imprecision and publication bias, to provide rationale for downgrading or upgrading the evidence (<a href="./references#CD014805-bbs2-0084" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). We assessed each outcome, and presented the information in summary of findings tables, using GRADEpro GDT software (<a href="./references#CD014805-bbs2-0066" title="GRADEpro GDT. Version accessed prior to 4 September 2023. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). The key outcomes assessed were: </p> <p> <ul id="CD014805-list-0010"> <li> <p>DFS;</p> </li> <li> <p>OS;</p> </li> <li> <p>pCR after neoadjuvant therapy;</p> </li> <li> <p>completion of regimens:</p> <ul id="CD014805-list-0011"> <li> <p>dose intensity, number of cycles completed, treatment delays;</p> </li> </ul> </li> <li> <p>any grade III/IV toxicity related to chemotherapy (stratified by haematological or non‐haematological toxicity): </p> <ul id="CD014805-list-0012"> <li> <p>non‐haematological toxicity, specifically peripheral neuropathy, renal impairment;</p> </li> <li> <p>haematological toxicity, specifically febrile neutropenia, anaemia;</p> </li> </ul> </li> <li> <p>quality of life.</p> </li> </ul> </p> <p>We reported summary of findings for time‐to‐event outcomes (DFS and OS) at two and five years (with non‐platinum group risks estimated from the mean of non‐platinum group Kaplan‐Meier probabilities at two and five years). For all other outcomes, we reported when the outcome was measured (e.g. pCR measured after surgical intervention shortly after completing neoadjuvant chemotherapy). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014805-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014805-sec-0039"></div> <section id="CD014805-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD014805-sec-0041"> <h4 class="title">Results of the search</h4> <p>Database and trial registry searches yielded 3972 records, and we screened the titles and abstracts of 3644 records after removing duplicates. We excluded 3468 records at title and abstract screening stage, and screened 176 full‐text articles or ongoing trial records. Of these, 114 records related to 20 included studies involving 21 treatment comparisons, and 28 records related to 25 ongoing studies. We excluded 34 records and presented the reasons for exclusion for the five studies that one may expect to find in the review the <a href="./references#CD014805-sec-0120" title="">Characteristics of excluded studies</a> table. </p> <p>See PRISMA flowchart (<a href="#CD014805-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD014805-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD014805-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD014805-sec-0042"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD014805-sec-0119" title="">Characteristics of included studies</a> table. </p> <p>The 20 included studies, involving 4468 participants, contributed to 21 treatment comparisons outlined in <a href="#CD014805-tbl-0004">Table 1</a>. Notably, the BrighTNess study has more than one intervention that was split into two treatment comparisons (<a href="./references#CD014805-bbs2-0003" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;36(15 Suppl):519. ">BrighTNess comparison 1</a>; <a href="./references#CD014805-bbs2-0004" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;35(15 Suppl):519. ">BrighTNess comparison 2</a>), which is why the number of studies and treatment comparisons included in an analysis may differ. </p> <div class="table" id="CD014805-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of the included treatment comparisons</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Year recruitment started</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (platinum‐containing)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platinum agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Same backbone?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adjuvant or neoadjuvant</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hormone receptor IHC cut‐off</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0001" title='GluzO , LiedtkeC , PratA , ChristgenM , GebauerD , KatesRE , et al. Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): results of the randomized WSG ADAPT-TN trial. Journal of Clinical Oncology2017;35(15 Suppl):573. GluzO , NitzU , ChristgenM , GrischkeEM , ForstbauerH , BraunMW , et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Journal of Clinical Oncology2015;33(15 Suppl):1032. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. Journal of the National Cancer Institute2018;110(6):628-37. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: survival results of WSG-ADAPT-TN phase II trial. Journal of Clinical Oncology2018;36(15 Suppl):573. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology2018;29(Suppl 8):viii703. GluzO , NitzU , LiedtkeC , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG – ADAPT TN randomized phase II trial. Cancer Research2016;76(4 Suppl):S6-07. GluzO , NitzU , LiedtkeC , PratA , ChristgenM , FeuerhakeF , et al. No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial. Cancer Research2019;79(4 Suppl):GS5-06. HarbeckN , HofmannD , GluzO , KatesRE , KummelS , NudingB , et al. ADAPT: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):TPS655. LiedtkeC , GluzO , NitzU , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. Oncology Research and Treatment2016;1:53. NCT01815242. Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer - triple negative breast cancer (ADAPT). clinicaltrials.gov/show/NCT01815242 (first received 21 March 2013). NitzU , GluzO , Von SchumannR , HofmannD , KatesRE , KuemmelS , et al. ADAPT – Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Cancer Research.2015;75(9 Suppl):OT3-2-04. '>ADAPT‐TN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nab‐paclitaxel 125 mg/m<sup>2</sup> + carboplatin AUC2 days 1 and 8 every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nab‐paclitaxel 125 mg/m<sup>2</sup> + gemcitabine 1000 mg/m<sup>2</sup> days 1 and 8 every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC2 every week (days 1 and 8 every 21 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0002" title="AndoM , YamauchiH , AogiK , ShimizuS , IwataH , MasudaN , et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment2014;145(2):401-9. IwaseM , AndoM , AogiK , ArugaT , InoueK , ShimomuraA , et al. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment2020;180(3):687-94. TamuraK , HashimotoJ , TsudaH , YoshidaM , YamauchiH , AogiK , et al. Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. Journal of Clinical Oncology2014;32(15 Suppl):1017. UMIN000003355. Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer. Center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004074 (first received 22 March 2010). ">Ando 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks for 4 cycles + paclitaxel 80 mg/m<sup>2</sup> days 1, 8, 15 for 4 cycles, followed by 4 cycles of cyclophosphamide 500 mg/m<sup>2</sup>, epirubicin 100 mg/m<sup>2</sup> and fluorouracil 500 mg/m<sup>2</sup> every 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> days 1, 8, 15 for 4 cycles followed by 4 cycles of cyclophosphamide 500 mg/m<sup>2</sup>, epirubicin 100 mg/m<sup>2</sup> and fluorouracil 500 mg/m<sup>2</sup> every 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0003" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;36(15 Suppl):519. ">BrighTNess comparison 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly + carboplatin AUC6 every 3 weeks for 12 weeks + veliparib 50 mg twice a day, followed by doxorubicin 60 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly for 12 weeks, followed by doxorubicin 60 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0004" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;35(15 Suppl):519. ">BrighTNess comparison 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly + carboplatin AUC6 every 3 weeks for 12 weeks, followed by doxorubicin 60 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly for 12 weeks, followed by doxorubicin 60 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0005" title="GolshanM , CirrincioneCT , CareyLA , SikovWM , BerryDA , BursteinHJ , et al. Impact of neoadjuvant therapy on breast conservation rates in triple negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). Journal of Clinical Oncology2015;33(15 Suppl):1007. GolshanM , CirrincioneCT , SikovWM , BerryDA , JasinskiS , WeisbergTF , et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals of Surgery2015;262(3):434-9. NCT00861705. Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. clinicaltrials.gov/show/NCT00861705 (first received 13 March 2009). ShepherdJH , BallmanK , PolleyMC , CampbellJD , FanC , SelitskyS , et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. Journal of Clinical Oncology2022;40(12):1323-34. ShepherdJH , HyslopT , FanC , MartinezAF , ParkerJ , HoadleyK , et al. Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival. Cancer Research2021;81(4 Suppl):PD9-03. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneC , TolaneyS , et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research2013;73(24 Suppl):S5-01. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Cancer Research2016;76(4 Suppl):S2-05. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology2015;33(1):13-21. SikovWM , PerouCM , GolshanM , CollyarD , BerryDA , HahnOM , et al. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):TPS110. SikovWM , PolleyMY , TwohyE , PerouCM , SinghB , BerryDA , et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple negative breast cancer (TNBC). Journal of Clinical Oncology2019;37(15 Suppl):591. ">CALGB 40603</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly + carboplatin AUC6 every 3 weeks for 12 weeks followed by doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 weeks for 4 cycles ± bevacizumab 10 mg/kg every 2 weeks for 9 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly for 12 weeks followed by doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 weeks for 4 cycles ± bevacizumab 10 mg/kg every 2 weeks for 9 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0008" title="AlbaE , ChaconJI , LluchA , AntonA , EstevezL , CirauquiB , et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Research and Treatment2012;136(2):487-93. AlbaE , ChaconJI , LluchA , Garcia-EstevezL , AntonA , CirauquiB , et al. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03 – a multicenter, randomized phase II study. Journal of Clinical Oncology2011;29(15 Suppl):1015. NCT00432172. Selective neoadjuvant treatment according to immunohistochemical subtype for HER2 negative breast cancer patients. clinicaltrials.gov/show/NCT00432172 (first received 7 February 2007). SantonjaA , AlbanellJ , ChaconJI , LluchA , Sanchez-MunozA , RojoF , et al. Triple-negative breast cancer subtypes and pathologic complete-response rate to neoadjuvant chemotherapy: results from the GEICAM/2006-2003 study. Journal of Clinical Oncology2014;32(15 Suppl):1024. ">GEICAM 2006‐03</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles followed by docetaxel 75 mg/m<sup>2</sup> + carboplatin AUC6 every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles followed by docetaxel 75 mg/m<sup>2</sup> every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0009" title="NCT02125344. A phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). clinicaltrials.gov/show/NCT02125344. (first received 29 April 2014). PohlE , SchneeweissA , HaukeJ , MoebusV , FurlanettoJ , DenkertC , et al. Germline mutation status and therapy response in patients with triple negative breast cancer (TNBC): results of the GeparOcto study. Annals of Oncology2018;29(8 Suppl):viii77. Pohl-RescignoE , HaukeJ , LoiblS , MobusV , DenkertC , FaschingPA , et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncology2020;6(5):744-8. SchneeweissA , MobusV , TeschH , HanuschC , DenkertC , LubbeK , et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. European Journal of Cancer2019;106:181-92. SchneeweissA , MobusV , TeschH , KlareP , DenkertC , KastK , et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology2020;31(4 Suppl):S303. SchneeweissA , MoebusV , BlohmerJU , Dan CostaS , DenkertC , EidtmannH , et al. A randomized phase III trial comparing two dose-dense dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Journal of Clinical Oncology2015;33(15 Suppl):TPS1101. SchneeweissA , MoebusV , TeschH , HanuschC , DenkertC , LuebbeK , et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high risk early breast cancer (GeparOcto). Journal of Clinical Oncology2017;35(15 Suppl):518. ">GeparOcto</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> + non‐pegylated liposomal doxorubicin 20 mg/m<sup>2</sup> + carboplatin AUC1.5 weekly for 18 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 150 mg/m<sup>2</sup> + paclitaxel 225 mg/m<sup>2</sup> + cyclophosphamide 2000 mg/m<sup>2</sup> every 2 weeks for 3 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC1.5 every week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0010" title="EUDRACT2015-003509-41-DE. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD) (GeparOla). clinicaltrialsregister.eu/ctr-search/search?query=2015-003509-41 (first received 1 August 2016). FaschingPA , BlohmerJU , BurchardiN , CostaSD , DenkertC , HanuschC , et al. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. Journal of Clinical Oncology2016;34(15 Suppl):TPS1096. FaschingPA , JackischC , RhiemK , SchneeweissA , KlareP , HanuschC , et al. GeparOLA: a randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer. Journal of Clinical Oncology2019;37(15 Suppl):506. FaschingPA , LinkT , HaukeJ , SeitherF , JackischC , KlareP , et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Annals of Oncology2021;32(1):49-57. HaukeJ , ErnstC , FaschingPA , JackischC , SeitherF , KlareP , et al. Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: results of the GeparOLA study (NCT02789332). Annals of Oncology2020;31(4 Suppl):S313. NCT02789332. Assessing the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency. clinicaltrials.gov/show/NCT02789332 (first received 3 June 2016). ">GeparOLA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> + carboplatin AUC2 weekly for 12 weeks followed by epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly + olaparib 100 mg twice a day for 12 weeks followed by epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC2 every week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0011" title="Darb-EsfahaniS , WeichertW , DenkertC , vonMinckwitzG , NekljudovaV , LindnerJ , et al. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – a translational subproject of the GeparSixto trial. Annals of Oncology2015;26(Suppl 3):III15. DenkertC , LoiblS , SalatC , SinnBV , SchemC , EndrisV , et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Research2013;73(24 Suppl):S1-06. DenkertC , vonMinckwitzG , BraseJC , Darb-EsfahaniS , GadeS , KronenwettR , et al. Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: prediction of response to carboplatin-based chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):510. DenkertC , vonMinckwitzG , BraseJC , SinnBV , GadeS , KronenwettR , et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology2015;33(9):983-91. EUDRAC2011-000553-23-DE. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer – GeparSixto. clinicaltrialsregister.eu/ctr-search/search?query=2011-000553-23 (first received 29 September 2011). GuoS , LoiblS , vonMinckwitzG , Darb-EsfahaniS , LedererB , DenkertC . PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Research2020;52(3):689-96. HahnenE , LedererB , HaukeJ , LoiblS , KroberS , SchneeweissA , et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology2017;3(10):1378-85. Llop-GuevaraA , LoiblS , VillacampaG , VladimirovaV , SchneeweissA , KarnT , et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Annals of Oncology2021;32(12):1590-6. LoiblS , DenkertC , LoiS , AndreF , MuellerB , SchneeweissA , et al. PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):11061. LoiblS , DenkertC , SchneeweisA , PaepkeS , LehmannA , RezaiM , et al. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer-prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Research2013;73(24 Suppl):S4-06. LoiblS , WeberKE , TimmsKM , ElkinEP , HahnenE , FaschingPA , et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Annals of Oncology2018;29(12):2341-7. NCT01426880. Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). clinicaltrials.gov/show/NCT01426880 (first received 1 September 2001). StevicI , MullerV , WeberK , FaschingPA , KarnT , MarmeF , et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine2018;16(1):179. UntchM , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Annals of Oncology2017;28(Suppl 5):V49. vonMinckwitzG , HahnenE , FaschingPA , HaukeJ , SchneeweisA , SalatC , et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. Journal of Clinical Oncology2014;32(15 Suppl):1005. vonMinckwitzG , LoiblS , SchneeweissA , SalatCT , RezaiM , ZahmDM , et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Research2016;76(4 Suppl):S2-04. vonMinckwitzG , O'ShaughnessyJ , WinerEP , WolmarkN , GeyerCE , HuoberJB , et al. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). Journal of Clinical Oncology2014;32(15 Suppl):TPS1149. vonMinckwitzG , SchneeweissA , LoiblS , SalatC , DenkertC , RezaiM , et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology2014;15(7):747-56. vonMinckwitzG , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Journal of Clinical Oncology2013;31(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , FaschingPA , SchneeweissA , et al. Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. Journal of Clinical Oncology2015;33(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , HahnenE , FaschingPA , et al. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Research2017;77(4 Suppl):P1-09-02. ">GeparSixto</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC2 or 1.5 + paclitaxel 80 mg/m<sup>2</sup> + non‐pegylated liposomal doxorubicin 20 mg/m<sup>2</sup> + bevacizumab 15 mg/kg every 3 weeks for 18 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> + non‐pegylated liposomal doxorubicin 20 mg/m<sup>2</sup> weekly + bevacizumab 15 mg/kg every 3 weeks for 18 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC1.5 or 2 every week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0012" title="GigolaevaL , KrivorotkoP , ZhiltsovaE , DashyanG , ChadjimatovaS , PesotckiyR , et al. Neoadjuvant chemotherapy regimens for triple negative breast cancer patients. Breast2019;44(Suppl 1):S70. ">Gigolaeva 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles followed by carboplatin AUC2 weekly + eribulin 1.4 mg/m<sup>2</sup> or paclitaxel 175 mg/m<sup>2</sup> every 3 weeks for 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles followed by paclitaxel 80 mg/m<sup>2</sup> for 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC2 every week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0013" title="NCT01670500. Cisplatin vs. doxorubicin/cyclophosphamide in BRCA. clinicaltrials.gov/show/NCT01670500 (first received 22 August 2012). TungN , ArunB , HackerMR , HofstatterE , ToppmeyerDL , IsakoffSJ , et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). Journal of Clinical Oncology2020;38(14):1539-48. TungN , ArunB , HofstatterE , HackerMR , ToppmeyerDL , IsakoffSJ , et al. Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: results from the INFORM trial (TBCRC 031). Cancer Research2019;80(4 Suppl):GS6-03. ">INFORM</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin 75 mg/m<sup>2</sup> every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2–3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin 75 mg/m<sup>2</sup> every 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly + veliparib 50 mg twice daily + carboplatin AUC6 every 3 weeks for 12 weeks followed by doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly for 12 weeks followed by doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0015" title="LiQ , WangJ , MuY , ZhangT , HanY , LuoY , et al. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chinese Journal of Cancer Research2020;32(4):485-96. MuY , ZhangT , HanY , WangJ , LiQ , LuoY , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple negative breast cancer patients with high recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. NCT01378533. The trial comparing dose-dense AC-T with PC as adjuvant therapy for TNBC. clinicaltrials.gov/show/NCT01378533 (first received 22 June 2011). WangJ , LiQ , MuY , ZhangT , HanY , WangJ , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. ">Li 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 150 mg/m<sup>2</sup> + carboplatin AUC3 every 2 weeks for 8 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 80 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 weeks for 4 cycles followed by paclitaxel 175 mg/m<sup>2</sup> every 2 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC3 every 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐fluorouracil 500 mg/m<sup>2</sup> + epirubicin 100 mg/m<sup>2</sup> + cyclophosphamide 500 mg/m<sup>2</sup> every 3 weeks for 3 cycles then docetaxel 80 mg/m<sup>2</sup> + carboplatin AUC5 every 3 weeks for 3 cycles, followed by postoperative radiotherapy, followed by cyclophosphamide 50 mg daily and methotrexate 2.5 mg twice daily on days 1, 2 of each week for 1 year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐fluorouracil 500 mg/m<sup>2</sup> + epirubicin 100 mg/m<sup>2</sup> + cyclophosphamide 500 mg/m<sup>2</sup> every 3 weeks for 3 cycles then docetaxel 80 mg/m<sup>2</sup> every 3 weeks for 3 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0017" title="NCT03154749. TC (docetaxel/carboplatin) versus EC-T (epirubicin/cyclophosphamide followed by docetaxe) as neoadjuvant chemotherapy for triple-negative breast cancer. clinicaltrials.gov/show/NCT03154749 (first received 16 May 2017). ZhangL , WuZ , LinY , LiJ , LiuZ , CaoY , et al. Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label, phase II trial. Journal of Clinical Oncology2022;38(15 Suppl):586. ZhangL , WuZY , LiJ , LinY , LiuZ , CaoY , et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial. International Journal of Cancer2022;150(4):654-62. ">NeoCART</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel 75 mg/m<sup>2</sup> + carboplatin AUC6 every 3 weeks for 6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles followed by docetaxel 100 mg/m<sup>2</sup> every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0018" title="NCT01216111. Comparison study of adjuvant chemotherapy for Chinese triple negative breast cancer. clinicaltrials.gov/show/NCT01216111 (first received 7 October 2010). NCT04031703. Study comparing paclitaxel plus carboplatin versus anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer (PATTERN). clinicaltrials.gov/show/NCT04031703 (first received 24 July 2019). YuKD , YeFG , HeM , FanL , MaD , MoM , et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncology2020;6(9):1390-6. ">PATTERN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> + carboplatin AUC2 days 1, 8, 15, every 28 days for 6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide 500 mg/m<sup>2</sup> + epirubicin 100 mg/m<sup>2</sup> + fluorouracil 500 mg/m<sup>2</sup> every 3 weeks for 3 cycles followed by docetaxel 100 mg/m<sup>2</sup> every 3 weeks for 3 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC2 every week (days 1, 8, 15 every 28 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0019" title="MayerEL , AbramsonV , JankowitzR , FalksonC , MarcomPK , TrainaT , et al. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Annals of Oncology2020;31(11):1518-25. MayerEL , AbramsonVG , JankowitzRC , FalksonCI , MarcomPK , TrainaTA , et al. TBCRC 030: a randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC- evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2019;37(15 Suppl):507. MayerEL , Vaz-LuisI , RichardsonAL , PerouCM , TungNM , AbramsonVG , et al. TBCRC030: a randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC) – evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2014;32(15 Suppl):TPS1145. NCT01982448. Cisplatin vs paclitaxel for triple negative breast cancer. clinicaltrials.gov/show/NCT01982448 (first received 13 November 2013). ">TBCRC 030</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin 75 mg/m<sup>2</sup> every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin 75 mg/m<sup>2</sup> every 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lobaplatin 30 mg/m<sup>2</sup> for 4 cycles + epirubicin 80 mg/m<sup>2</sup> + docetaxel 75 mg/m<sup>2</sup> every 3 weeks presurgery and 2 cycles postsurgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 80 mg/m<sup>2</sup> for 4 cycles + docetaxel 75 mg/m<sup>2</sup> every 3 weeks presurgery and 2 cycles postsurgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lobaplatin 30 mg/m<sup>2</sup> every 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0021" title="NCT01276769. Comparison study of neoadjuvant paclitaxel plus carboplatin/epirubicin treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01276769 (first received 13 January 2011). ZhangP , YinY , MoH , ZhangB , WangX , LiQ , et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget2016;7(37):60647-56. ZhangP , YinY , XuB , WangX , ZhangB , LiQ , et al. Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer – a phase II clinical trial. Cancer Research2013;73(24 Suppl):P3-14-07. ">Zhang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 175 mg/m<sup>2</sup> + carboplatin AUC5 every 3 weeks for 4–6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 75 mg/m<sup>2</sup> + paclitaxel 175 mg/m<sup>2</sup> every 3 weeks for 4–6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided in translation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 175 mg/m<sup>2</sup> day 1, carboplatin AUC5 day 2, every 3 weeks for 2 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 75 mg/m2 day 1, paclitaxel 175 mg/m<sup>2</sup> day 2, every 3 weeks for 2 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided in translation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0023" title="DuF , WangW , WangY , LiM , ZhuA , WangJ , et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Research and Treatment2020;182(1):67-77. NCT01150513. Docetaxel+carboplatin vs epirubicin+cyclophosphamide followed by docetaxel as adjuvant treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01150513 (first received 25 June 2010). YuanP , DuF , WangJ , MaF , FanY , XuB . Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer. Journal of Clinical Oncology2016;34(Suppl 15):1068. YuanP , XuB . A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients. Journal of Clinical Oncology2012;30(15 Suppl):TPS1135. YuanP , XuBH , WangJY , MaF , LiQ , ZhangP , et al. Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial. Chung Hua Chung Liu Tsa Chih 2012;34(6):465-8. ZhengF , DuF , WangW , WangY , LiM , ZhaoJ , et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Research and Treatment2022;191(1):97-105. ">Zheng 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel 75 mg/m<sup>2</sup> or paclitaxel 175 mg/m<sup>2</sup> + carboplatin AUC5 every 3 weeks for 6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles, followed by docetaxel 75 mg/m<sup>2</sup> or paclitaxel 175 mg/m<sup>2</sup> every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AUC: area under the curve; IHC: immunohistochemistry.</p> </div> </div> <p><a href="#CD014805-tbl-0005">Table 2</a> details the number of treatment comparisons by subgroup and efficacy outcome. </p> <div class="table" id="CD014805-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Number of treatment comparisons by subgroup and efficacy outcomes</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="2" valign="top"></td> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Treatment comparisons n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>DFS n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>OS n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>pCR n (%)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (76%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Treatment setting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (76%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (5%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Subgroups</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BRCA mutation subgroup reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HRD status subgroup reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node positive reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (14%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (14%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (14%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Type of platinum agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (62%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (10%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lobaplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Type of regimen</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Different backbone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (67%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (33%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (33%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same backbone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (33%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (24%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Anthracycline content in intervention arm</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anthracycline present</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (33%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (47%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anthracycline free</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Schedule of platinum agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (67%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (57%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (24%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (14%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (24%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Hormone receptor IHC cut‐off</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1% or not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (24%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (43%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (47%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (33%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>DFS: disease‐free survival; HRD: homologous recombination deficiency; IHC: immunohistochemistry; n: number; OS: overall survival; pCR: pathological complete response. </p> </div> </div> <p> <ul id="CD014805-list-0013"> <li> <p>15 studies (16 treatment comparisons) involved neoadjuvant chemotherapy with one study combining neoadjuvant and adjuvant therapy, and four studies involved adjuvant chemotherapy </p> </li> <li> <p>17 studies (18 treatment comparisons) used carboplatin, two studies used cisplatin and one study used lobaplatin </p> </li> <li> <p>nine studies had an anthracycline‐free intervention arm</p> </li> <li> <p>six studies stratified results for BRCA mutations, one trial for HRD status, and three by lymph node status </p> </li> <li> <p>six studies (seven treatment comparisons) used the same chemotherapy backbone (i.e. platinum agent plus regimen A versus regimen A) and 14 trials used a different backbone (i.e. regimen A versus regimen B) </p> </li> </ul> </p> <p>We included studies that examined other subtypes of breast cancer, provided the outcome of DFS, OS or pCR was described for the TNBC subgroup. For such studies, only efficacy analyses are reported for the TNBC group (<a href="./references#CD014805-bbs2-0002" title="AndoM , YamauchiH , AogiK , ShimizuS , IwataH , MasudaN , et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment2014;145(2):401-9. IwaseM , AndoM , AogiK , ArugaT , InoueK , ShimomuraA , et al. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment2020;180(3):687-94. TamuraK , HashimotoJ , TsudaH , YoshidaM , YamauchiH , AogiK , et al. Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. Journal of Clinical Oncology2014;32(15 Suppl):1017. UMIN000003355. Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer. Center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004074 (first received 22 March 2010). ">Ando 2014</a>; <a href="./references#CD014805-bbs2-0008" title="AlbaE , ChaconJI , LluchA , AntonA , EstevezL , CirauquiB , et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Research and Treatment2012;136(2):487-93. AlbaE , ChaconJI , LluchA , Garcia-EstevezL , AntonA , CirauquiB , et al. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03 – a multicenter, randomized phase II study. Journal of Clinical Oncology2011;29(15 Suppl):1015. NCT00432172. Selective neoadjuvant treatment according to immunohistochemical subtype for HER2 negative breast cancer patients. clinicaltrials.gov/show/NCT00432172 (first received 7 February 2007). SantonjaA , AlbanellJ , ChaconJI , LluchA , Sanchez-MunozA , RojoF , et al. Triple-negative breast cancer subtypes and pathologic complete-response rate to neoadjuvant chemotherapy: results from the GEICAM/2006-2003 study. Journal of Clinical Oncology2014;32(15 Suppl):1024. ">GEICAM 2006‐03</a>; <a href="./references#CD014805-bbs2-0009" title="NCT02125344. A phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). clinicaltrials.gov/show/NCT02125344. (first received 29 April 2014). PohlE , SchneeweissA , HaukeJ , MoebusV , FurlanettoJ , DenkertC , et al. Germline mutation status and therapy response in patients with triple negative breast cancer (TNBC): results of the GeparOcto study. Annals of Oncology2018;29(8 Suppl):viii77. Pohl-RescignoE , HaukeJ , LoiblS , MobusV , DenkertC , FaschingPA , et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncology2020;6(5):744-8. SchneeweissA , MobusV , TeschH , HanuschC , DenkertC , LubbeK , et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. European Journal of Cancer2019;106:181-92. SchneeweissA , MobusV , TeschH , KlareP , DenkertC , KastK , et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology2020;31(4 Suppl):S303. SchneeweissA , MoebusV , BlohmerJU , Dan CostaS , DenkertC , EidtmannH , et al. A randomized phase III trial comparing two dose-dense dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Journal of Clinical Oncology2015;33(15 Suppl):TPS1101. SchneeweissA , MoebusV , TeschH , HanuschC , DenkertC , LuebbeK , et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high risk early breast cancer (GeparOcto). Journal of Clinical Oncology2017;35(15 Suppl):518. ">GeparOcto</a>; <a href="./references#CD014805-bbs2-0010" title="EUDRACT2015-003509-41-DE. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD) (GeparOla). clinicaltrialsregister.eu/ctr-search/search?query=2015-003509-41 (first received 1 August 2016). FaschingPA , BlohmerJU , BurchardiN , CostaSD , DenkertC , HanuschC , et al. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. Journal of Clinical Oncology2016;34(15 Suppl):TPS1096. FaschingPA , JackischC , RhiemK , SchneeweissA , KlareP , HanuschC , et al. GeparOLA: a randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer. Journal of Clinical Oncology2019;37(15 Suppl):506. FaschingPA , LinkT , HaukeJ , SeitherF , JackischC , KlareP , et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Annals of Oncology2021;32(1):49-57. HaukeJ , ErnstC , FaschingPA , JackischC , SeitherF , KlareP , et al. Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: results of the GeparOLA study (NCT02789332). Annals of Oncology2020;31(4 Suppl):S313. NCT02789332. Assessing the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency. clinicaltrials.gov/show/NCT02789332 (first received 3 June 2016). ">GeparOLA</a>; <a href="./references#CD014805-bbs2-0011" title="Darb-EsfahaniS , WeichertW , DenkertC , vonMinckwitzG , NekljudovaV , LindnerJ , et al. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – a translational subproject of the GeparSixto trial. Annals of Oncology2015;26(Suppl 3):III15. DenkertC , LoiblS , SalatC , SinnBV , SchemC , EndrisV , et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Research2013;73(24 Suppl):S1-06. DenkertC , vonMinckwitzG , BraseJC , Darb-EsfahaniS , GadeS , KronenwettR , et al. Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: prediction of response to carboplatin-based chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):510. DenkertC , vonMinckwitzG , BraseJC , SinnBV , GadeS , KronenwettR , et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology2015;33(9):983-91. EUDRAC2011-000553-23-DE. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer – GeparSixto. clinicaltrialsregister.eu/ctr-search/search?query=2011-000553-23 (first received 29 September 2011). GuoS , LoiblS , vonMinckwitzG , Darb-EsfahaniS , LedererB , DenkertC . PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Research2020;52(3):689-96. HahnenE , LedererB , HaukeJ , LoiblS , KroberS , SchneeweissA , et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology2017;3(10):1378-85. Llop-GuevaraA , LoiblS , VillacampaG , VladimirovaV , SchneeweissA , KarnT , et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Annals of Oncology2021;32(12):1590-6. LoiblS , DenkertC , LoiS , AndreF , MuellerB , SchneeweissA , et al. PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):11061. LoiblS , DenkertC , SchneeweisA , PaepkeS , LehmannA , RezaiM , et al. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer-prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Research2013;73(24 Suppl):S4-06. LoiblS , WeberKE , TimmsKM , ElkinEP , HahnenE , FaschingPA , et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Annals of Oncology2018;29(12):2341-7. NCT01426880. Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). clinicaltrials.gov/show/NCT01426880 (first received 1 September 2001). StevicI , MullerV , WeberK , FaschingPA , KarnT , MarmeF , et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine2018;16(1):179. UntchM , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Annals of Oncology2017;28(Suppl 5):V49. vonMinckwitzG , HahnenE , FaschingPA , HaukeJ , SchneeweisA , SalatC , et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. Journal of Clinical Oncology2014;32(15 Suppl):1005. vonMinckwitzG , LoiblS , SchneeweissA , SalatCT , RezaiM , ZahmDM , et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Research2016;76(4 Suppl):S2-04. vonMinckwitzG , O'ShaughnessyJ , WinerEP , WolmarkN , GeyerCE , HuoberJB , et al. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). Journal of Clinical Oncology2014;32(15 Suppl):TPS1149. vonMinckwitzG , SchneeweissA , LoiblS , SalatC , DenkertC , RezaiM , et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology2014;15(7):747-56. vonMinckwitzG , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Journal of Clinical Oncology2013;31(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , FaschingPA , SchneeweissA , et al. Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. Journal of Clinical Oncology2015;33(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , HahnenE , FaschingPA , et al. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Research2017;77(4 Suppl):P1-09-02. ">GeparSixto</a>; <a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a>; <a href="./references#CD014805-bbs2-0019" title="MayerEL , AbramsonV , JankowitzR , FalksonC , MarcomPK , TrainaT , et al. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Annals of Oncology2020;31(11):1518-25. MayerEL , AbramsonVG , JankowitzRC , FalksonCI , MarcomPK , TrainaTA , et al. TBCRC 030: a randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC- evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2019;37(15 Suppl):507. MayerEL , Vaz-LuisI , RichardsonAL , PerouCM , TungNM , AbramsonVG , et al. TBCRC030: a randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC) – evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2014;32(15 Suppl):TPS1145. NCT01982448. Cisplatin vs paclitaxel for triple negative breast cancer. clinicaltrials.gov/show/NCT01982448 (first received 13 November 2013). ">TBCRC 030</a>). Other outcomes including toxicity and the completion of chemotherapy regimens may be reported for the whole cohort if subgroup data were not published. This is not considered a significant change from the protocol because participants with TNBC are unlikely to have substantially different chemotherapy adverse effects compared to participants with other subtypes of breast cancer. </p> <p>Notably, there were studies where participants in the intervention group received platinum agents as well as other experimental interventions. In <a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a>, participants randomised to the intervention received platinum chemotherapy as well as a further year of metronomic oral chemotherapy. Trialists in <a href="./references#CD014805-bbs2-0057" title="LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509.">BrighTNess</a> examined the effects of both carboplatin and veliparib. To compare all participants in this trial receiving platinum chemotherapy, we split this study into two analysis groups, or 'treatment comparisons' (<a href="./references#CD014805-bbs2-0003" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;36(15 Suppl):519. ">BrighTNess comparison 1</a> intervention: paclitaxel, veliparib and carboplatin followed by doxorubicin and cyclophosphamide (AC), and <a href="./references#CD014805-bbs2-0004" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;35(15 Suppl):519. ">BrighTNess comparison 2</a> intervention: paclitaxel and carboplatin followed by AC). Both were compared to the control group of paclitaxel alone followed by AC. </p> </section> <section id="CD014805-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded 34 records on full‐text review owing to:</p> <p> <ul id="CD014805-list-0014"> <li> <p>incorrect study population (12 records). We excluded studies where the population included people with TNBC with residual disease after chemotherapy and surgery; studies on unresectable or metastatic TNBC; studies which included hormone receptor‐positive or HER2‐positive subtypes of breast cancer, and did not separately report outcomes for TNBC; and studies where HER‐2 status was not determined or reported; </p> </li> <li> <p>incorrect intervention (12 records). We excluded studies employing high‐dose chemotherapy requiring autologous stem cell transplant; </p> </li> <li> <p>incorrect study design (three records). We excluded retrospective or non‐randomised study designs; </p> </li> <li> <p>studies not reporting critical outcomes (one study). We excluded one study that did not measure DFS, OS or pCR; such studies often reported other outcomes including breast‐conserving surgery rate. </p> </li> <li> <p>meta‐analyses (six papers). We checked meta‐analyses for eligible references, and whether our results were concordant. </p> </li> </ul> </p> <p>The reasons for excluding five studies that may be expected in this review are provided in the <a href="./references#CD014805-sec-0120" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD014805-sec-0044"> <h4 class="title">Ongoing studies</h4> <p>We identified 25 eligible ongoing studies from trial records and abstract publications based on the available information (see <a href="./references#CD014805-sec-0121" title="">Characteristics of ongoing studies</a> table). </p> <p> <ul id="CD014805-list-0015"> <li> <p>15 studies examined neoadjuvant chemotherapy, eight studies examined adjuvant therapy and two studies included both neoadjuvant and adjuvant therapy </p> </li> <li> <p>18 studies used carboplatin, six studies used cisplatin, and one study used lobaplatin</p> </li> <li> <p>Nine studies reported DFS or OS as a primary outcome and 18 reported DFS or OS as a secondary outcome </p> </li> </ul> </p> <p>The results of the more recent studies are pending; however, it is considered that the inactive older trial records are unlikely to produce results despite emails requesting outcome data from the trialists (<a href="./references#CD014805-bbs2-0045" title="NCT03168880. A randomized controlled trial of neoadjuvant weekly paclitaxel versus weekly paclitaxel plus weekly carboplatin in women with large operable or locally advanced, triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT03168880 (first received 30 May 2017). ">NCT03168880</a>; <a href="./references#CD014805-bbs2-0037" title="NCT00919880. Comparison of neo-adjuvant weekly paclitaxel with or without carboplatin in early breast cancer. clinicaltrials.gov/show/NCT00919880 (first received 12 June 2009). ">NCT00919880</a>; <a href="./references#CD014805-bbs2-0038" title="NCT01752686. A phase III trial of carboplatin as adjuvant chemotherapy in triple negative breast cancer. clinicaltrials.gov/show/NCT01752686 (first received 19 December 2012). ">NCT01752686</a>). </p> </section> </section> <section id="CD014805-sec-0045"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD014805-fig-0002">Figure 2</a> for a summary of risk of bias judgements of the included studies. </p> <div class="figure" id="CD014805-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD014805-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD014805-sec-0046"> <h4 class="title">Allocation</h4> <p>Nine studies (10 treatment comparisons) were at low risk of bias for random sequence generation and 14 studies (15 treatment comparisons) for allocation concealment. Those deemed at unclear risk did not detail procedures for randomisation (<a href="./references#CD014805-bbs2-0001" title='GluzO , LiedtkeC , PratA , ChristgenM , GebauerD , KatesRE , et al. Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): results of the randomized WSG ADAPT-TN trial. Journal of Clinical Oncology2017;35(15 Suppl):573. GluzO , NitzU , ChristgenM , GrischkeEM , ForstbauerH , BraunMW , et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Journal of Clinical Oncology2015;33(15 Suppl):1032. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. Journal of the National Cancer Institute2018;110(6):628-37. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: survival results of WSG-ADAPT-TN phase II trial. Journal of Clinical Oncology2018;36(15 Suppl):573. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology2018;29(Suppl 8):viii703. GluzO , NitzU , LiedtkeC , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG – ADAPT TN randomized phase II trial. Cancer Research2016;76(4 Suppl):S6-07. GluzO , NitzU , LiedtkeC , PratA , ChristgenM , FeuerhakeF , et al. No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial. Cancer Research2019;79(4 Suppl):GS5-06. HarbeckN , HofmannD , GluzO , KatesRE , KummelS , NudingB , et al. ADAPT: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):TPS655. LiedtkeC , GluzO , NitzU , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. Oncology Research and Treatment2016;1:53. NCT01815242. Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer - triple negative breast cancer (ADAPT). clinicaltrials.gov/show/NCT01815242 (first received 21 March 2013). NitzU , GluzO , Von SchumannR , HofmannD , KatesRE , KuemmelS , et al. ADAPT – Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Cancer Research.2015;75(9 Suppl):OT3-2-04. '>ADAPT‐TN</a>; <a href="./references#CD014805-bbs2-0005" title="GolshanM , CirrincioneCT , CareyLA , SikovWM , BerryDA , BursteinHJ , et al. Impact of neoadjuvant therapy on breast conservation rates in triple negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). Journal of Clinical Oncology2015;33(15 Suppl):1007. GolshanM , CirrincioneCT , SikovWM , BerryDA , JasinskiS , WeisbergTF , et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals of Surgery2015;262(3):434-9. NCT00861705. Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. clinicaltrials.gov/show/NCT00861705 (first received 13 March 2009). ShepherdJH , BallmanK , PolleyMC , CampbellJD , FanC , SelitskyS , et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. Journal of Clinical Oncology2022;40(12):1323-34. ShepherdJH , HyslopT , FanC , MartinezAF , ParkerJ , HoadleyK , et al. Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival. Cancer Research2021;81(4 Suppl):PD9-03. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneC , TolaneyS , et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research2013;73(24 Suppl):S5-01. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Cancer Research2016;76(4 Suppl):S2-05. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology2015;33(1):13-21. SikovWM , PerouCM , GolshanM , CollyarD , BerryDA , HahnOM , et al. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):TPS110. SikovWM , PolleyMY , TwohyE , PerouCM , SinghB , BerryDA , et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple negative breast cancer (TNBC). Journal of Clinical Oncology2019;37(15 Suppl):591. ">CALGB 40603</a>; <a href="./references#CD014805-bbs2-0013" title="NCT01670500. Cisplatin vs. doxorubicin/cyclophosphamide in BRCA. clinicaltrials.gov/show/NCT01670500 (first received 22 August 2012). TungN , ArunB , HackerMR , HofstatterE , ToppmeyerDL , IsakoffSJ , et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). Journal of Clinical Oncology2020;38(14):1539-48. TungN , ArunB , HofstatterE , HackerMR , ToppmeyerDL , IsakoffSJ , et al. Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: results from the INFORM trial (TBCRC 031). Cancer Research2019;80(4 Suppl):GS6-03. ">INFORM</a>; <a href="./references#CD014805-bbs2-0008" title="AlbaE , ChaconJI , LluchA , AntonA , EstevezL , CirauquiB , et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Research and Treatment2012;136(2):487-93. AlbaE , ChaconJI , LluchA , Garcia-EstevezL , AntonA , CirauquiB , et al. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03 – a multicenter, randomized phase II study. Journal of Clinical Oncology2011;29(15 Suppl):1015. NCT00432172. Selective neoadjuvant treatment according to immunohistochemical subtype for HER2 negative breast cancer patients. clinicaltrials.gov/show/NCT00432172 (first received 7 February 2007). SantonjaA , AlbanellJ , ChaconJI , LluchA , Sanchez-MunozA , RojoF , et al. Triple-negative breast cancer subtypes and pathologic complete-response rate to neoadjuvant chemotherapy: results from the GEICAM/2006-2003 study. Journal of Clinical Oncology2014;32(15 Suppl):1024. ">GEICAM 2006‐03</a>; <a href="./references#CD014805-bbs2-0012" title="GigolaevaL , KrivorotkoP , ZhiltsovaE , DashyanG , ChadjimatovaS , PesotckiyR , et al. Neoadjuvant chemotherapy regimens for triple negative breast cancer patients. Breast2019;44(Suppl 1):S70. ">Gigolaeva 2019</a>; <a href="./references#CD014805-bbs2-0015" title="LiQ , WangJ , MuY , ZhangT , HanY , LuoY , et al. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chinese Journal of Cancer Research2020;32(4):485-96. MuY , ZhangT , HanY , WangJ , LiQ , LuoY , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple negative breast cancer patients with high recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. NCT01378533. The trial comparing dose-dense AC-T with PC as adjuvant therapy for TNBC. clinicaltrials.gov/show/NCT01378533 (first received 22 June 2011). WangJ , LiQ , MuY , ZhangT , HanY , WangJ , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. ">Li 2020</a>; <a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a>; <a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a>; <a href="./references#CD014805-bbs2-0021" title="NCT01276769. Comparison study of neoadjuvant paclitaxel plus carboplatin/epirubicin treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01276769 (first received 13 January 2011). ZhangP , YinY , MoH , ZhangB , WangX , LiQ , et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget2016;7(37):60647-56. ZhangP , YinY , XuB , WangX , ZhangB , LiQ , et al. Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer – a phase II clinical trial. Cancer Research2013;73(24 Suppl):P3-14-07. ">Zhang 2016</a>; <a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a>; <a href="./references#CD014805-bbs2-0023" title="DuF , WangW , WangY , LiM , ZhuA , WangJ , et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Research and Treatment2020;182(1):67-77. NCT01150513. Docetaxel+carboplatin vs epirubicin+cyclophosphamide followed by docetaxel as adjuvant treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01150513 (first received 25 June 2010). YuanP , DuF , WangJ , MaF , FanY , XuB . Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer. Journal of Clinical Oncology2016;34(Suppl 15):1068. YuanP , XuB . A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients. Journal of Clinical Oncology2012;30(15 Suppl):TPS1135. YuanP , XuBH , WangJY , MaF , LiQ , ZhangP , et al. Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial. Chung Hua Chung Liu Tsa Chih 2012;34(6):465-8. ZhengF , DuF , WangW , WangY , LiM , ZhaoJ , et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Research and Treatment2022;191(1):97-105. ">Zheng 2022</a>), or whether allocation was performed centrally (<a href="./references#CD014805-bbs2-0012" title="GigolaevaL , KrivorotkoP , ZhiltsovaE , DashyanG , ChadjimatovaS , PesotckiyR , et al. Neoadjuvant chemotherapy regimens for triple negative breast cancer patients. Breast2019;44(Suppl 1):S70. ">Gigolaeva 2019</a>; <a href="./references#CD014805-bbs2-0015" title="LiQ , WangJ , MuY , ZhangT , HanY , LuoY , et al. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chinese Journal of Cancer Research2020;32(4):485-96. MuY , ZhangT , HanY , WangJ , LiQ , LuoY , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple negative breast cancer patients with high recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. NCT01378533. The trial comparing dose-dense AC-T with PC as adjuvant therapy for TNBC. clinicaltrials.gov/show/NCT01378533 (first received 22 June 2011). WangJ , LiQ , MuY , ZhangT , HanY , WangJ , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. ">Li 2020</a>; <a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a>; <a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a>; <a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a>; <a href="./references#CD014805-bbs2-0021" title="NCT01276769. Comparison study of neoadjuvant paclitaxel plus carboplatin/epirubicin treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01276769 (first received 13 January 2011). ZhangP , YinY , MoH , ZhangB , WangX , LiQ , et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget2016;7(37):60647-56. ZhangP , YinY , XuB , WangX , ZhangB , LiQ , et al. Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer – a phase II clinical trial. Cancer Research2013;73(24 Suppl):P3-14-07. ">Zhang 2016</a>). </p> </section> <section id="CD014805-sec-0047"> <h4 class="title">Blinding</h4> <p>Nineteen studies were described as open‐label. Performance bias due to lack of blinding of participants and personnel was not considered to be a serious concern given the objective nature of the efficacy outcomes and most toxicity outcomes. As such, these studies were deemed at unclear risk of bias. One study was double blinded throughout the course of the trial (<a href="./references#CD014805-bbs2-0057" title="LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509.">BrighTNess</a>), and judged at low risk of bias for all outcomes. </p> <p>We assessed detection bias by outcome. For DFS, OS, pCR and toxicity, lack of blinding was perceived as unlikely to have an impact given the nature or method in which each outcome is assessed (i.e. through imaging, biochemical tests, reviewed by independent panels, or a combination of these). All studies reporting DFS or OS were perceived to be at low risk of bias. All studies reporting pCR were deemed to be at low risk of bias except for two studies at unclear risk because the papers did not provide any information on tests used or process to evaluate tumour response (<a href="./references#CD014805-bbs2-0012" title="GigolaevaL , KrivorotkoP , ZhiltsovaE , DashyanG , ChadjimatovaS , PesotckiyR , et al. Neoadjuvant chemotherapy regimens for triple negative breast cancer patients. Breast2019;44(Suppl 1):S70. ">Gigolaeva 2019</a>; <a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a>). Similarly, studies reporting toxicities were at low risk of bias except for one study as no information was provided on how toxicity was assessed (<a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a>). None of the studies that collected quality of life measures reported data and no risk of bias assessment was possible. </p> </section> <section id="CD014805-sec-0048"> <h4 class="title">Incomplete outcome data</h4> <p>Most studies did not complete a true intention‐to‐treat analysis, in that participants who were randomised but did not receive treatment were excluded from the efficacy and safety analysis. Notably, only a very small number of participants were excluded in each study after randomisation. Nine studies were at unclear risk of bias. We judged six studies at unclear risk of bias because the reasons for excluding participants were not detailed (<a href="./references#CD014805-bbs2-0005" title="GolshanM , CirrincioneCT , CareyLA , SikovWM , BerryDA , BursteinHJ , et al. Impact of neoadjuvant therapy on breast conservation rates in triple negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). Journal of Clinical Oncology2015;33(15 Suppl):1007. GolshanM , CirrincioneCT , SikovWM , BerryDA , JasinskiS , WeisbergTF , et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals of Surgery2015;262(3):434-9. NCT00861705. Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. clinicaltrials.gov/show/NCT00861705 (first received 13 March 2009). ShepherdJH , BallmanK , PolleyMC , CampbellJD , FanC , SelitskyS , et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. Journal of Clinical Oncology2022;40(12):1323-34. ShepherdJH , HyslopT , FanC , MartinezAF , ParkerJ , HoadleyK , et al. Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival. Cancer Research2021;81(4 Suppl):PD9-03. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneC , TolaneyS , et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research2013;73(24 Suppl):S5-01. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Cancer Research2016;76(4 Suppl):S2-05. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology2015;33(1):13-21. SikovWM , PerouCM , GolshanM , CollyarD , BerryDA , HahnOM , et al. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):TPS110. SikovWM , PolleyMY , TwohyE , PerouCM , SinghB , BerryDA , et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple negative breast cancer (TNBC). Journal of Clinical Oncology2019;37(15 Suppl):591. ">CALGB 40603</a>; <a href="./references#CD014805-bbs2-0009" title="NCT02125344. A phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). clinicaltrials.gov/show/NCT02125344. (first received 29 April 2014). PohlE , SchneeweissA , HaukeJ , MoebusV , FurlanettoJ , DenkertC , et al. Germline mutation status and therapy response in patients with triple negative breast cancer (TNBC): results of the GeparOcto study. Annals of Oncology2018;29(8 Suppl):viii77. Pohl-RescignoE , HaukeJ , LoiblS , MobusV , DenkertC , FaschingPA , et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncology2020;6(5):744-8. SchneeweissA , MobusV , TeschH , HanuschC , DenkertC , LubbeK , et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. European Journal of Cancer2019;106:181-92. SchneeweissA , MobusV , TeschH , KlareP , DenkertC , KastK , et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology2020;31(4 Suppl):S303. SchneeweissA , MoebusV , BlohmerJU , Dan CostaS , DenkertC , EidtmannH , et al. A randomized phase III trial comparing two dose-dense dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Journal of Clinical Oncology2015;33(15 Suppl):TPS1101. SchneeweissA , MoebusV , TeschH , HanuschC , DenkertC , LuebbeK , et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high risk early breast cancer (GeparOcto). Journal of Clinical Oncology2017;35(15 Suppl):518. ">GeparOcto</a>; <a href="./references#CD014805-bbs2-0011" title="Darb-EsfahaniS , WeichertW , DenkertC , vonMinckwitzG , NekljudovaV , LindnerJ , et al. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – a translational subproject of the GeparSixto trial. Annals of Oncology2015;26(Suppl 3):III15. DenkertC , LoiblS , SalatC , SinnBV , SchemC , EndrisV , et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Research2013;73(24 Suppl):S1-06. DenkertC , vonMinckwitzG , BraseJC , Darb-EsfahaniS , GadeS , KronenwettR , et al. Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: prediction of response to carboplatin-based chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):510. DenkertC , vonMinckwitzG , BraseJC , SinnBV , GadeS , KronenwettR , et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology2015;33(9):983-91. EUDRAC2011-000553-23-DE. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer – GeparSixto. clinicaltrialsregister.eu/ctr-search/search?query=2011-000553-23 (first received 29 September 2011). GuoS , LoiblS , vonMinckwitzG , Darb-EsfahaniS , LedererB , DenkertC . PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Research2020;52(3):689-96. HahnenE , LedererB , HaukeJ , LoiblS , KroberS , SchneeweissA , et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology2017;3(10):1378-85. Llop-GuevaraA , LoiblS , VillacampaG , VladimirovaV , SchneeweissA , KarnT , et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Annals of Oncology2021;32(12):1590-6. LoiblS , DenkertC , LoiS , AndreF , MuellerB , SchneeweissA , et al. PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):11061. LoiblS , DenkertC , SchneeweisA , PaepkeS , LehmannA , RezaiM , et al. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer-prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Research2013;73(24 Suppl):S4-06. LoiblS , WeberKE , TimmsKM , ElkinEP , HahnenE , FaschingPA , et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Annals of Oncology2018;29(12):2341-7. NCT01426880. Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). clinicaltrials.gov/show/NCT01426880 (first received 1 September 2001). StevicI , MullerV , WeberK , FaschingPA , KarnT , MarmeF , et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine2018;16(1):179. UntchM , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Annals of Oncology2017;28(Suppl 5):V49. vonMinckwitzG , HahnenE , FaschingPA , HaukeJ , SchneeweisA , SalatC , et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. Journal of Clinical Oncology2014;32(15 Suppl):1005. vonMinckwitzG , LoiblS , SchneeweissA , SalatCT , RezaiM , ZahmDM , et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Research2016;76(4 Suppl):S2-04. vonMinckwitzG , O'ShaughnessyJ , WinerEP , WolmarkN , GeyerCE , HuoberJB , et al. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). Journal of Clinical Oncology2014;32(15 Suppl):TPS1149. vonMinckwitzG , SchneeweissA , LoiblS , SalatC , DenkertC , RezaiM , et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology2014;15(7):747-56. vonMinckwitzG , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Journal of Clinical Oncology2013;31(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , FaschingPA , SchneeweissA , et al. Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. Journal of Clinical Oncology2015;33(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , HahnenE , FaschingPA , et al. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Research2017;77(4 Suppl):P1-09-02. ">GeparSixto</a>; <a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a>; <a href="./references#CD014805-bbs2-0021" title="NCT01276769. Comparison study of neoadjuvant paclitaxel plus carboplatin/epirubicin treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01276769 (first received 13 January 2011). ZhangP , YinY , MoH , ZhangB , WangX , LiQ , et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget2016;7(37):60647-56. ZhangP , YinY , XuB , WangX , ZhangB , LiQ , et al. Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer – a phase II clinical trial. Cancer Research2013;73(24 Suppl):P3-14-07. ">Zhang 2016</a>; <a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a>). One study was at unclear risk of attrition bias as there were several randomised people with missing pCR data that could not be accounted for (<a href="./references#CD014805-bbs2-0001" title='GluzO , LiedtkeC , PratA , ChristgenM , GebauerD , KatesRE , et al. Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): results of the randomized WSG ADAPT-TN trial. Journal of Clinical Oncology2017;35(15 Suppl):573. GluzO , NitzU , ChristgenM , GrischkeEM , ForstbauerH , BraunMW , et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Journal of Clinical Oncology2015;33(15 Suppl):1032. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. Journal of the National Cancer Institute2018;110(6):628-37. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: survival results of WSG-ADAPT-TN phase II trial. Journal of Clinical Oncology2018;36(15 Suppl):573. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology2018;29(Suppl 8):viii703. GluzO , NitzU , LiedtkeC , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG – ADAPT TN randomized phase II trial. Cancer Research2016;76(4 Suppl):S6-07. GluzO , NitzU , LiedtkeC , PratA , ChristgenM , FeuerhakeF , et al. No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial. Cancer Research2019;79(4 Suppl):GS5-06. HarbeckN , HofmannD , GluzO , KatesRE , KummelS , NudingB , et al. ADAPT: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):TPS655. LiedtkeC , GluzO , NitzU , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. Oncology Research and Treatment2016;1:53. NCT01815242. Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer - triple negative breast cancer (ADAPT). clinicaltrials.gov/show/NCT01815242 (first received 21 March 2013). NitzU , GluzO , Von SchumannR , HofmannD , KatesRE , KuemmelS , et al. ADAPT – Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Cancer Research.2015;75(9 Suppl):OT3-2-04. '>ADAPT‐TN</a>). Two studies did not provide a CONSORT diagram or associated information and were classified at unclear risk of bias (<a href="./references#CD014805-bbs2-0012" title="GigolaevaL , KrivorotkoP , ZhiltsovaE , DashyanG , ChadjimatovaS , PesotckiyR , et al. Neoadjuvant chemotherapy regimens for triple negative breast cancer patients. Breast2019;44(Suppl 1):S70. ">Gigolaeva 2019</a>; <a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a>). </p> </section> <section id="CD014805-sec-0049"> <h4 class="title">Selective reporting</h4> <p>One study was at high risk of bias as it did not report DFS or OS, despite these outcomes being listed in the trial registry records (<a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a>). As pCR data were reported in 2016, these important long‐term efficacy outcomes would have been expected to be reported by 2022. Four studies with more recent publications which have not yet published results on critical outcomes were at unclear risk (<a href="./references#CD014805-bbs2-0010" title="EUDRACT2015-003509-41-DE. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD) (GeparOla). clinicaltrialsregister.eu/ctr-search/search?query=2015-003509-41 (first received 1 August 2016). FaschingPA , BlohmerJU , BurchardiN , CostaSD , DenkertC , HanuschC , et al. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. Journal of Clinical Oncology2016;34(15 Suppl):TPS1096. FaschingPA , JackischC , RhiemK , SchneeweissA , KlareP , HanuschC , et al. GeparOLA: a randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer. Journal of Clinical Oncology2019;37(15 Suppl):506. FaschingPA , LinkT , HaukeJ , SeitherF , JackischC , KlareP , et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Annals of Oncology2021;32(1):49-57. HaukeJ , ErnstC , FaschingPA , JackischC , SeitherF , KlareP , et al. Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: results of the GeparOLA study (NCT02789332). Annals of Oncology2020;31(4 Suppl):S313. NCT02789332. Assessing the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency. clinicaltrials.gov/show/NCT02789332 (first received 3 June 2016). ">GeparOLA</a>; <a href="./references#CD014805-bbs2-0009" title="NCT02125344. A phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). clinicaltrials.gov/show/NCT02125344. (first received 29 April 2014). PohlE , SchneeweissA , HaukeJ , MoebusV , FurlanettoJ , DenkertC , et al. Germline mutation status and therapy response in patients with triple negative breast cancer (TNBC): results of the GeparOcto study. Annals of Oncology2018;29(8 Suppl):viii77. Pohl-RescignoE , HaukeJ , LoiblS , MobusV , DenkertC , FaschingPA , et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncology2020;6(5):744-8. SchneeweissA , MobusV , TeschH , HanuschC , DenkertC , LubbeK , et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. European Journal of Cancer2019;106:181-92. SchneeweissA , MobusV , TeschH , KlareP , DenkertC , KastK , et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology2020;31(4 Suppl):S303. SchneeweissA , MoebusV , BlohmerJU , Dan CostaS , DenkertC , EidtmannH , et al. A randomized phase III trial comparing two dose-dense dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Journal of Clinical Oncology2015;33(15 Suppl):TPS1101. SchneeweissA , MoebusV , TeschH , HanuschC , DenkertC , LuebbeK , et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high risk early breast cancer (GeparOcto). Journal of Clinical Oncology2017;35(15 Suppl):518. ">GeparOcto</a>; <a href="./references#CD014805-bbs2-0013" title="NCT01670500. Cisplatin vs. doxorubicin/cyclophosphamide in BRCA. clinicaltrials.gov/show/NCT01670500 (first received 22 August 2012). TungN , ArunB , HackerMR , HofstatterE , ToppmeyerDL , IsakoffSJ , et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). Journal of Clinical Oncology2020;38(14):1539-48. TungN , ArunB , HofstatterE , HackerMR , ToppmeyerDL , IsakoffSJ , et al. Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: results from the INFORM trial (TBCRC 031). Cancer Research2019;80(4 Suppl):GS6-03. ">INFORM</a>; <a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a>). Two additional studies did not provide sufficient information for an assessment and were judged at unclear risk of bias (e.g. abstract only; <a href="./references#CD014805-bbs2-0012" title="GigolaevaL , KrivorotkoP , ZhiltsovaE , DashyanG , ChadjimatovaS , PesotckiyR , et al. Neoadjuvant chemotherapy regimens for triple negative breast cancer patients. Breast2019;44(Suppl 1):S70. ">Gigolaeva 2019</a>; <a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a>). </p> <p>Four studies identified quality of life as an outcome in their trial registry records or publications (<a href="./references#CD014805-bbs2-0057" title="LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509.">BrighTNess</a>; <a href="./references#CD014805-bbs2-0009" title="NCT02125344. A phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). clinicaltrials.gov/show/NCT02125344. (first received 29 April 2014). PohlE , SchneeweissA , HaukeJ , MoebusV , FurlanettoJ , DenkertC , et al. Germline mutation status and therapy response in patients with triple negative breast cancer (TNBC): results of the GeparOcto study. Annals of Oncology2018;29(8 Suppl):viii77. Pohl-RescignoE , HaukeJ , LoiblS , MobusV , DenkertC , FaschingPA , et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncology2020;6(5):744-8. SchneeweissA , MobusV , TeschH , HanuschC , DenkertC , LubbeK , et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. European Journal of Cancer2019;106:181-92. SchneeweissA , MobusV , TeschH , KlareP , DenkertC , KastK , et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology2020;31(4 Suppl):S303. SchneeweissA , MoebusV , BlohmerJU , Dan CostaS , DenkertC , EidtmannH , et al. A randomized phase III trial comparing two dose-dense dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Journal of Clinical Oncology2015;33(15 Suppl):TPS1101. SchneeweissA , MoebusV , TeschH , HanuschC , DenkertC , LuebbeK , et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high risk early breast cancer (GeparOcto). Journal of Clinical Oncology2017;35(15 Suppl):518. ">GeparOcto</a>; <a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a>; <a href="./references#CD014805-bbs2-0023" title="DuF , WangW , WangY , LiM , ZhuA , WangJ , et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Research and Treatment2020;182(1):67-77. NCT01150513. Docetaxel+carboplatin vs epirubicin+cyclophosphamide followed by docetaxel as adjuvant treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01150513 (first received 25 June 2010). YuanP , DuF , WangJ , MaF , FanY , XuB . Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer. Journal of Clinical Oncology2016;34(Suppl 15):1068. YuanP , XuB . A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients. Journal of Clinical Oncology2012;30(15 Suppl):TPS1135. YuanP , XuBH , WangJY , MaF , LiQ , ZhangP , et al. Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial. Chung Hua Chung Liu Tsa Chih 2012;34(6):465-8. ZhengF , DuF , WangW , WangY , LiM , ZhaoJ , et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Research and Treatment2022;191(1):97-105. ">Zheng 2022</a>); however, there were no published reports of quality of life measures from these studies. </p> </section> <section id="CD014805-sec-0050"> <h4 class="title">Other potential sources of bias</h4> <p>One study was published in abstract form only and did not have an identifiable trial registration record (<a href="./references#CD014805-bbs2-0012" title="GigolaevaL , KrivorotkoP , ZhiltsovaE , DashyanG , ChadjimatovaS , PesotckiyR , et al. Neoadjuvant chemotherapy regimens for triple negative breast cancer patients. Breast2019;44(Suppl 1):S70. ">Gigolaeva 2019</a>). As such, the risk of bias assessment was limited and assessed as unclear. Another study required translation (<a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a>). While outcome measures were provided in the translation, we did not have sufficient translated information to make risk of bias assessments for this domain and most others. </p> </section> </section> <section id="CD014805-sec-0051"> <h3 class="title" id="CD014805-sec-0051">Effects of interventions</h3> <p>See: <a href="./full#CD014805-tbl-0001"><b>Summary of findings 1</b> Platinum‐containing chemotherapy compared to chemotherapy without platinum in neoadjuvant therapy for early triple‐negative breast cancer</a>; <a href="./full#CD014805-tbl-0002"><b>Summary of findings 2</b> Platinum‐containing chemotherapy compared to chemotherapy without platinum in adjuvant therapy for early triple‐negative breast cancer</a>; <a href="./full#CD014805-tbl-0003"><b>Summary of findings 3</b> Platinum‐containing chemotherapy compared to chemotherapy without platinum for early triple‐negative breast cancer</a> </p> <section id="CD014805-sec-0052"> <h4 class="title">Neoadjuvant therapy</h4> <p>See <a href="./full#CD014805-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD014805-sec-0053"> <h5 class="title">Disease‐free survival</h5> <p>Ten of the 16 neoadjuvant studies collected data on DFS; however, two studies did not report data (<a href="./references#CD014805-bbs2-0009" title="NCT02125344. A phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). clinicaltrials.gov/show/NCT02125344. (first received 29 April 2014). PohlE , SchneeweissA , HaukeJ , MoebusV , FurlanettoJ , DenkertC , et al. Germline mutation status and therapy response in patients with triple negative breast cancer (TNBC): results of the GeparOcto study. Annals of Oncology2018;29(8 Suppl):viii77. Pohl-RescignoE , HaukeJ , LoiblS , MobusV , DenkertC , FaschingPA , et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncology2020;6(5):744-8. SchneeweissA , MobusV , TeschH , HanuschC , DenkertC , LubbeK , et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. European Journal of Cancer2019;106:181-92. SchneeweissA , MobusV , TeschH , KlareP , DenkertC , KastK , et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology2020;31(4 Suppl):S303. SchneeweissA , MoebusV , BlohmerJU , Dan CostaS , DenkertC , EidtmannH , et al. A randomized phase III trial comparing two dose-dense dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Journal of Clinical Oncology2015;33(15 Suppl):TPS1101. SchneeweissA , MoebusV , TeschH , HanuschC , DenkertC , LuebbeK , et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high risk early breast cancer (GeparOcto). Journal of Clinical Oncology2017;35(15 Suppl):518. ">GeparOcto</a>; <a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a>). Median follow‐up ranged from 36 to 94.8 months. Platinum‐based chemotherapy improved DFS compared to non‐platinum‐containing chemotherapy (HR 0.63, 95% CI 0.53 to 0.75; P &lt; 0.001, I<sup>2</sup> = 30%; 7 studies, 8 treatment comparisons; high‐certainty evidence; <a href="./references#CD014805-fig-0007" title="">Analysis 1.1</a>; <a href="#CD014805-fig-0003">Figure 3</a>). A total of 1966 people were included in the analysis with an estimated 500 DFS events. </p> <div class="figure" id="CD014805-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="original image" data-id="CD014805-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>One other study reported on DFS following neoadjuvant and adjuvant treatment, but results could not be separated for neoadjuvant therapy alone (<a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a>). Based on this one study, the results suggested an improvement in DFS in the platinum‐based chemotherapy group (HR 0.21, 95% CI 0.05 to 0.97; 1 study, 125 participants). </p> </section> <section id="CD014805-sec-0054"> <h5 class="title">Overall survival</h5> <p>Ten of the 16 neoadjuvant studies collected data on OS; however, two studies collected data but did not report them (<a href="./references#CD014805-bbs2-0009" title="NCT02125344. A phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). clinicaltrials.gov/show/NCT02125344. (first received 29 April 2014). PohlE , SchneeweissA , HaukeJ , MoebusV , FurlanettoJ , DenkertC , et al. Germline mutation status and therapy response in patients with triple negative breast cancer (TNBC): results of the GeparOcto study. Annals of Oncology2018;29(8 Suppl):viii77. Pohl-RescignoE , HaukeJ , LoiblS , MobusV , DenkertC , FaschingPA , et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncology2020;6(5):744-8. SchneeweissA , MobusV , TeschH , HanuschC , DenkertC , LubbeK , et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. European Journal of Cancer2019;106:181-92. SchneeweissA , MobusV , TeschH , KlareP , DenkertC , KastK , et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology2020;31(4 Suppl):S303. SchneeweissA , MoebusV , BlohmerJU , Dan CostaS , DenkertC , EidtmannH , et al. A randomized phase III trial comparing two dose-dense dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Journal of Clinical Oncology2015;33(15 Suppl):TPS1101. SchneeweissA , MoebusV , TeschH , HanuschC , DenkertC , LuebbeK , et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high risk early breast cancer (GeparOcto). Journal of Clinical Oncology2017;35(15 Suppl):518. ">GeparOcto</a>; <a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a>). Median follow‐up ranged from 36 to 94.8 months. Platinum chemotherapy reduced mortality (HR 0.69, 95% CI 0.55 to 0.86; P = 0.001, I<sup>2</sup> = 29%; 7 studies, 8 treatment comparisons; high‐certainty evidence; <a href="./references#CD014805-fig-0008" title="">Analysis 1.2</a>; <a href="#CD014805-fig-0004">Figure 4</a>). A total of 1973 participants were involved in these studies, with an estimated 307 deaths. </p> <div class="figure" id="CD014805-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD014805-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>One other study collected "all‐cause mortality" and reported no deaths in either group and an HR was not provided or estimable (<a href="./references#CD014805-bbs2-0013" title="NCT01670500. Cisplatin vs. doxorubicin/cyclophosphamide in BRCA. clinicaltrials.gov/show/NCT01670500 (first received 22 August 2012). TungN , ArunB , HackerMR , HofstatterE , ToppmeyerDL , IsakoffSJ , et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). Journal of Clinical Oncology2020;38(14):1539-48. TungN , ArunB , HofstatterE , HackerMR , ToppmeyerDL , IsakoffSJ , et al. Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: results from the INFORM trial (TBCRC 031). Cancer Research2019;80(4 Suppl):GS6-03. ">INFORM</a>). Follow‐up time statistics for these data are unknown. </p> </section> <section id="CD014805-sec-0055"> <h5 class="title">Pathological complete response</h5> <p>Fifteen trials (16 treatment comparisons) involving only neoadjuvant treatment reported pCR outcome data. Platinum chemotherapy was associated with a large improvement in the rate of pCR (RR 1.44, 95% CI 1.31 to 1.59, P = 0.009, I<sup>2</sup> = 52%; 15 studies, 16 treatment comparisons, 3083 participants; high‐certainty evidence; <a href="./references#CD014805-fig-0009" title="">Analysis 1.3</a>.1; <a href="#CD014805-fig-0005">Figure 5</a>). One study reported adjusted probabilities of pCR rather than discrete numbers and a sensitivity analysis (removing the adjusted values) gave a very similar result for pCR (RR 1.43, 95% CI 1.30 to 1.58; 3023 participants) (<a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a>). </p> <div class="figure" id="CD014805-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="original image" data-id="CD014805-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>One other study that combined neoadjuvant and adjuvant therapy also showed an improvement in tumour response (RR 3.05, 95% CI 1.48 to 6.26; 125 participants) (<a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a>). </p> </section> </section> <section id="CD014805-sec-0056"> <h4 class="title">Adjuvant therapy</h4> <p>See <a href="./full#CD014805-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD014805-sec-0057"> <h5 class="title">Disease‐free survival</h5> <p>All four studies of adjuvant chemotherapy collected and reported DFS with median follow‐up ranging from 52 to 97.6 months. Platinum chemotherapy improved DFS (HR 0.69, 95% CI 0.54 to 0.88; P = 0.003, I<sup>2</sup> = 38%; high‐certainty evidence; <a href="./references#CD014805-fig-0010" title="">Analysis 2.1</a>; <a href="#CD014805-fig-0003">Figure 3</a>). These studies included 1256 participants, with an estimated 262 DFS events. </p> </section> <section id="CD014805-sec-0058"> <h5 class="title">Overall survival</h5> <p>All four studies collected and reported OS with follow‐up ranging from 52 to 97.6 months. Adjuvant platinum chemotherapy extended OS (HR 0.70, 95% CI 0.50 to 0.96; P = 0.03, I<sup>2</sup> = 53%; high‐certainty evidence; <a href="./references#CD014805-fig-0011" title="">Analysis 2.2</a>; <a href="#CD014805-fig-0004">Figure 4</a>). A total of 1256 participants were included in this analysis, with an estimated 153 deaths. </p> </section> </section> <section id="CD014805-sec-0059"> <h4 class="title">All studies</h4> <p>To assess the effect of platinum agents on treatment adherence and toxicity overall, we combined data from neoadjuvant and adjuvant studies. See <a href="./full#CD014805-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD014805-sec-0060"> <h5 class="title">Completion of regimens</h5> <p>Participants receiving platinum chemotherapy were more than twice as likely to have delay in starting the next cycle of chemotherapy (RR 2.23, 95% CI 1.70 to 2.94; P &lt; 0.001, I<sup>2</sup> = 70%; 4 studies, 5 treatment comparisons; moderate‐certainty evidence; <a href="./references#CD014805-fig-0013" title="">Analysis 3.1</a>). </p> <p>Participants receiving platinum chemotherapy were also more likely to require dose reductions (RR 1.77, 95% CI 1.56 to 2.02; P &lt; 0.001; I<sup>2</sup> = 91%; 7 studies, 8 treatment comparisons; moderate‐certainty evidence; <a href="./references#CD014805-fig-0014" title="">Analysis 3.2</a>). </p> <p>Participants receiving platinum chemotherapy were 20% more likely to require early cessation of treatment (RR 1.20, 95% CI 1.04 to 1.38; P = 0.01; I<sup>2</sup> = 15%; 16 studies, 17 treatment comparisons; high‐certainty evidence; <a href="./references#CD014805-fig-0015" title="">Analysis 3.3</a>; <a href="#CD014805-fig-0006">Figure 6</a>). This was not always due to toxicity, as indicated by some studies that provided reasons for early cessation (early cessation due to toxicity: <a href="./references#CD014805-bbs2-0001" title='GluzO , LiedtkeC , PratA , ChristgenM , GebauerD , KatesRE , et al. Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): results of the randomized WSG ADAPT-TN trial. Journal of Clinical Oncology2017;35(15 Suppl):573. GluzO , NitzU , ChristgenM , GrischkeEM , ForstbauerH , BraunMW , et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Journal of Clinical Oncology2015;33(15 Suppl):1032. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. Journal of the National Cancer Institute2018;110(6):628-37. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: survival results of WSG-ADAPT-TN phase II trial. Journal of Clinical Oncology2018;36(15 Suppl):573. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology2018;29(Suppl 8):viii703. GluzO , NitzU , LiedtkeC , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG – ADAPT TN randomized phase II trial. Cancer Research2016;76(4 Suppl):S6-07. GluzO , NitzU , LiedtkeC , PratA , ChristgenM , FeuerhakeF , et al. No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial. Cancer Research2019;79(4 Suppl):GS5-06. HarbeckN , HofmannD , GluzO , KatesRE , KummelS , NudingB , et al. ADAPT: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):TPS655. LiedtkeC , GluzO , NitzU , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. Oncology Research and Treatment2016;1:53. NCT01815242. Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer - triple negative breast cancer (ADAPT). clinicaltrials.gov/show/NCT01815242 (first received 21 March 2013). NitzU , GluzO , Von SchumannR , HofmannD , KatesRE , KuemmelS , et al. ADAPT – Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Cancer Research.2015;75(9 Suppl):OT3-2-04. '>ADAPT‐TN</a>: 45% in intervention group versus 45% in control group; <a href="./references#CD014805-bbs2-0005" title="GolshanM , CirrincioneCT , CareyLA , SikovWM , BerryDA , BursteinHJ , et al. Impact of neoadjuvant therapy on breast conservation rates in triple negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). Journal of Clinical Oncology2015;33(15 Suppl):1007. GolshanM , CirrincioneCT , SikovWM , BerryDA , JasinskiS , WeisbergTF , et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals of Surgery2015;262(3):434-9. NCT00861705. Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. clinicaltrials.gov/show/NCT00861705 (first received 13 March 2009). ShepherdJH , BallmanK , PolleyMC , CampbellJD , FanC , SelitskyS , et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. Journal of Clinical Oncology2022;40(12):1323-34. ShepherdJH , HyslopT , FanC , MartinezAF , ParkerJ , HoadleyK , et al. Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival. Cancer Research2021;81(4 Suppl):PD9-03. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneC , TolaneyS , et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research2013;73(24 Suppl):S5-01. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Cancer Research2016;76(4 Suppl):S2-05. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology2015;33(1):13-21. SikovWM , PerouCM , GolshanM , CollyarD , BerryDA , HahnOM , et al. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):TPS110. SikovWM , PolleyMY , TwohyE , PerouCM , SinghB , BerryDA , et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple negative breast cancer (TNBC). Journal of Clinical Oncology2019;37(15 Suppl):591. ">CALGB 40603</a>: 40% in intervention group versus 32% in control group; <a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a>: 77% in intervention group versus 50% in control group). Other reasons included progression of disease, withdrawal of consent/refusal of treatment or other/unknown. </p> <div class="figure" id="CD014805-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="original image" data-id="CD014805-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD014805-sec-0061"> <h5 class="title">Any grade III/IV toxicity</h5> <p>We collected data for grade III/IV haematological toxicity, neuropathy, nausea, renal impairment and treatment‐related death. </p> <section id="CD014805-sec-0062"> <h6 class="title">Haematological toxicity</h6> <p>Participants receiving platinum‐based chemotherapy were more likely to have grade III/IV neutropenia (RR 1.53, 95% CI 1.43 to 1.63; P &lt; 0.001; I<sup>2</sup> = 97%; 19 studies, 20 treatment comparisons; moderate‐certainty evidence; <a href="./references#CD014805-fig-0016" title="">Analysis 3.4</a>). Participants receiving platinum‐based chemotherapy were unlikely to have higher rates of grade III/IV febrile neutropenia (RR 1.16, 95% CI 0.89 to 1.49; P = 0.27, I<sup>2</sup> = 69%; 11 studies, 12 treatment comparisons; moderate‐certainty evidence; <a href="./references#CD014805-fig-0017" title="">Analysis 3.5</a>). </p> <p>For platinum recipients, there were considerably higher risks of anaemia (RR 8.20, 95% CI 5.66 to 11.89; P &lt; 0.001; I<sup>2</sup> = 42%; 18 studies, 19 treatment comparisons; moderate‐certainty evidence; <a href="./references#CD014805-fig-0018" title="">Analysis 3.6</a>). There is likely to be a much higher risk of thrombocytopenia in participants receiving platinum chemotherapy (RR 7.59, 95% CI 5.10 to 11.29; P &lt; 0.001, I<sup>2</sup> = 44%; 18 studies, 19 treatment comparisons; moderate‐certainty evidence; <a href="./references#CD014805-fig-0019" title="">Analysis 3.7</a>). </p> </section> <section id="CD014805-sec-0063"> <h6 class="title">Non‐haematological toxicity</h6> <p>There is likely little to no difference in rates of grade III/IV neuropathy associated with platinum chemotherapy (RR 1.22, 95% CI 0.95 to 1.57; P = 0.12, I<sup>2</sup> = 0; 14 studies, 15 treatment comparisons; moderate‐certainty evidence; <a href="./references#CD014805-fig-0020" title="">Analysis 3.8</a>). </p> <p>Participants receiving platinum chemotherapy had a higher rate of grade III/IV nausea (RR 1.89, 95% CI 1.30 to 2.74; P &lt; 0.001; I<sup>2</sup> = 0; 16 studies, 17 treatment comparisons; high‐certainty evidence; <a href="./references#CD014805-fig-0021" title="">Analysis 3.9</a>). </p> <p>Four studies reported data on renal impairment (<a href="./references#CD014805-bbs2-0013" title="NCT01670500. Cisplatin vs. doxorubicin/cyclophosphamide in BRCA. clinicaltrials.gov/show/NCT01670500 (first received 22 August 2012). TungN , ArunB , HackerMR , HofstatterE , ToppmeyerDL , IsakoffSJ , et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). Journal of Clinical Oncology2020;38(14):1539-48. TungN , ArunB , HofstatterE , HackerMR , ToppmeyerDL , IsakoffSJ , et al. Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: results from the INFORM trial (TBCRC 031). Cancer Research2019;80(4 Suppl):GS6-03. ">INFORM</a>; <a href="./references#CD014805-bbs2-0015" title="LiQ , WangJ , MuY , ZhangT , HanY , LuoY , et al. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chinese Journal of Cancer Research2020;32(4):485-96. MuY , ZhangT , HanY , WangJ , LiQ , LuoY , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple negative breast cancer patients with high recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. NCT01378533. The trial comparing dose-dense AC-T with PC as adjuvant therapy for TNBC. clinicaltrials.gov/show/NCT01378533 (first received 22 June 2011). WangJ , LiQ , MuY , ZhangT , HanY , WangJ , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. ">Li 2020</a>; <a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a>; <a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a>). One study reported two events in 60 people in the platinum arm (3%) and no events in 57 people in the non‐platinum arm. None of the other studies reported any grade III/IV renal impairment (<a href="./references#CD014805-fig-0022" title="">Analysis 3.10</a>). </p> </section> <section id="CD014805-sec-0064"> <h6 class="title">Treatment‐related death</h6> <p>Treatment‐related death was a very rare event, with seven events in 3094 participants. This outcome was not different between platinum and non‐platinum intervention arms (RR 0.58, 95% CI 0.14 to 2.33; P = 0.44, I<sup>2</sup> = 0; 10 studies, 11 treatment comparisons; note 8 studies reported treatment‐related deaths but recorded 0 events in both groups. Thus, the RR and CIs were calculated from 3 studies rather than 11; high‐certainty evidence; <a href="./references#CD014805-fig-0023" title="">Analysis 3.11</a>). </p> </section> </section> <section id="CD014805-sec-0065"> <h5 class="title">Quality of life</h5> <p>Although a prespecified outcome of four studies (1198 participants), there were no published quality of life data in the eligible studies available for this review. </p> </section> <section id="CD014805-sec-0066"> <h5 class="title">Subgroup analysis</h5> <section id="CD014805-sec-0067"> <h6 class="title">Disease‐free survival</h6> <section id="CD014805-sec-0068"> <p><b><i>BRCA</i> mutation status</b></p> <p>Four studies, with 1452 participants, reported DFS outcomes stratified by <i>BRCA</i> mutation status (<a href="./references#CD014805-bbs2-0057" title="LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509.">BrighTNess</a>; <a href="./references#CD014805-bbs2-0011" title="Darb-EsfahaniS , WeichertW , DenkertC , vonMinckwitzG , NekljudovaV , LindnerJ , et al. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – a translational subproject of the GeparSixto trial. Annals of Oncology2015;26(Suppl 3):III15. DenkertC , LoiblS , SalatC , SinnBV , SchemC , EndrisV , et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Research2013;73(24 Suppl):S1-06. DenkertC , vonMinckwitzG , BraseJC , Darb-EsfahaniS , GadeS , KronenwettR , et al. Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: prediction of response to carboplatin-based chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):510. DenkertC , vonMinckwitzG , BraseJC , SinnBV , GadeS , KronenwettR , et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology2015;33(9):983-91. EUDRAC2011-000553-23-DE. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer – GeparSixto. clinicaltrialsregister.eu/ctr-search/search?query=2011-000553-23 (first received 29 September 2011). GuoS , LoiblS , vonMinckwitzG , Darb-EsfahaniS , LedererB , DenkertC . PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Research2020;52(3):689-96. HahnenE , LedererB , HaukeJ , LoiblS , KroberS , SchneeweissA , et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology2017;3(10):1378-85. Llop-GuevaraA , LoiblS , VillacampaG , VladimirovaV , SchneeweissA , KarnT , et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Annals of Oncology2021;32(12):1590-6. LoiblS , DenkertC , LoiS , AndreF , MuellerB , SchneeweissA , et al. PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):11061. LoiblS , DenkertC , SchneeweisA , PaepkeS , LehmannA , RezaiM , et al. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer-prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Research2013;73(24 Suppl):S4-06. LoiblS , WeberKE , TimmsKM , ElkinEP , HahnenE , FaschingPA , et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Annals of Oncology2018;29(12):2341-7. NCT01426880. Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). clinicaltrials.gov/show/NCT01426880 (first received 1 September 2001). StevicI , MullerV , WeberK , FaschingPA , KarnT , MarmeF , et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine2018;16(1):179. UntchM , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Annals of Oncology2017;28(Suppl 5):V49. vonMinckwitzG , HahnenE , FaschingPA , HaukeJ , SchneeweisA , SalatC , et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. Journal of Clinical Oncology2014;32(15 Suppl):1005. vonMinckwitzG , LoiblS , SchneeweissA , SalatCT , RezaiM , ZahmDM , et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Research2016;76(4 Suppl):S2-04. vonMinckwitzG , O'ShaughnessyJ , WinerEP , WolmarkN , GeyerCE , HuoberJB , et al. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). Journal of Clinical Oncology2014;32(15 Suppl):TPS1149. vonMinckwitzG , SchneeweissA , LoiblS , SalatC , DenkertC , RezaiM , et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology2014;15(7):747-56. vonMinckwitzG , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Journal of Clinical Oncology2013;31(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , FaschingPA , SchneeweissA , et al. Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. Journal of Clinical Oncology2015;33(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , HahnenE , FaschingPA , et al. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Research2017;77(4 Suppl):P1-09-02. ">GeparSixto</a>; <a href="./references#CD014805-bbs2-0018" title="NCT01216111. Comparison study of adjuvant chemotherapy for Chinese triple negative breast cancer. clinicaltrials.gov/show/NCT01216111 (first received 7 October 2010). NCT04031703. Study comparing paclitaxel plus carboplatin versus anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer (PATTERN). clinicaltrials.gov/show/NCT04031703 (first received 24 July 2019). YuKD , YeFG , HeM , FanL , MaD , MoM , et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncology2020;6(9):1390-6. ">PATTERN</a>; <a href="./references#CD014805-bbs2-0023" title="DuF , WangW , WangY , LiM , ZhuA , WangJ , et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Research and Treatment2020;182(1):67-77. NCT01150513. Docetaxel+carboplatin vs epirubicin+cyclophosphamide followed by docetaxel as adjuvant treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01150513 (first received 25 June 2010). YuanP , DuF , WangJ , MaF , FanY , XuB . Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer. Journal of Clinical Oncology2016;34(Suppl 15):1068. YuanP , XuB . A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients. Journal of Clinical Oncology2012;30(15 Suppl):TPS1135. YuanP , XuBH , WangJY , MaF , LiQ , ZhangP , et al. Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial. Chung Hua Chung Liu Tsa Chih 2012;34(6):465-8. ZhengF , DuF , WangW , WangY , LiM , ZhaoJ , et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Research and Treatment2022;191(1):97-105. ">Zheng 2022</a>). There was no evidence of a difference in DFS outcomes based on <i>BRCA</i> mutation status (<i>BRCA</i> wild‐type: HR 0.65, 95% CI 0.50 to 0.85; <i>BRCA</i> mutation: HR 0.72, 95% CI 0.41 to 1.25; P = 0.76; <a href="./references#CD014805-fig-0026" title="">Analysis 4.1</a>). The number of participants in these trials with a known <i>BRCA</i> mutation was small, with 222 pathogenic variant carriers, of whom 118 received platinum. </p> </section> <section id="CD014805-sec-0069"> <p><b>Homologous recombination deficiency status</b></p> <p>One study, with 521 participants, reported DFS according to HRD status, based on a multigene panel including 12 breast cancer homologous recombination repair (HRR) associated susceptibility genes (<i>ATM</i> , <i>ATR</i> , <i>BARD1</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>BRIP1</i> , <i>CHEK2</i> , <i>FANCM</i> , <i>PALB2</i> , <i>RAD51C</i> , <i>RAD51D</i> and <i>RECQL</i>) (<a href="./references#CD014805-bbs2-0018" title="NCT01216111. Comparison study of adjuvant chemotherapy for Chinese triple negative breast cancer. clinicaltrials.gov/show/NCT01216111 (first received 7 October 2010). NCT04031703. Study comparing paclitaxel plus carboplatin versus anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer (PATTERN). clinicaltrials.gov/show/NCT04031703 (first received 24 July 2019). YuKD , YeFG , HeM , FanL , MaD , MoM , et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncology2020;6(9):1390-6. ">PATTERN</a>). There was no evidence of a difference in outcomes between HRD‐positive and HRD‐negative participants (HRD‐positive: HR 0.39, 95% CI 0.15 to 1.00; HRD negative: HR 0.70, 95% CI 0.42 to 1.15; <a href="./references#CD014805-fig-0028" title="">Analysis 5.1</a>) with no subgroup difference (P = 0.28). As there was a small number of participants with HRD‐positive tumours (120 participants), this analysis may be underpowered. </p> </section> <section id="CD014805-sec-0070"> <p><b>Lymph node status</b></p> <p>Three studies, with 1097 participants, reported DFS according to lymph node status (<a href="./references#CD014805-bbs2-0015" title="LiQ , WangJ , MuY , ZhangT , HanY , LuoY , et al. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chinese Journal of Cancer Research2020;32(4):485-96. MuY , ZhangT , HanY , WangJ , LiQ , LuoY , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple negative breast cancer patients with high recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. NCT01378533. The trial comparing dose-dense AC-T with PC as adjuvant therapy for TNBC. clinicaltrials.gov/show/NCT01378533 (first received 22 June 2011). WangJ , LiQ , MuY , ZhangT , HanY , WangJ , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. ">Li 2020</a>; <a href="./references#CD014805-bbs2-0018" title="NCT01216111. Comparison study of adjuvant chemotherapy for Chinese triple negative breast cancer. clinicaltrials.gov/show/NCT01216111 (first received 7 October 2010). NCT04031703. Study comparing paclitaxel plus carboplatin versus anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer (PATTERN). clinicaltrials.gov/show/NCT04031703 (first received 24 July 2019). YuKD , YeFG , HeM , FanL , MaD , MoM , et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncology2020;6(9):1390-6. ">PATTERN</a>; <a href="./references#CD014805-bbs2-0023" title="DuF , WangW , WangY , LiM , ZhuA , WangJ , et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Research and Treatment2020;182(1):67-77. NCT01150513. Docetaxel+carboplatin vs epirubicin+cyclophosphamide followed by docetaxel as adjuvant treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01150513 (first received 25 June 2010). YuanP , DuF , WangJ , MaF , FanY , XuB . Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer. Journal of Clinical Oncology2016;34(Suppl 15):1068. YuanP , XuB . A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients. Journal of Clinical Oncology2012;30(15 Suppl):TPS1135. YuanP , XuBH , WangJY , MaF , LiQ , ZhangP , et al. Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial. Chung Hua Chung Liu Tsa Chih 2012;34(6):465-8. ZhengF , DuF , WangW , WangY , LiM , ZhaoJ , et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Research and Treatment2022;191(1):97-105. ">Zheng 2022</a>). Participants were 29% lymph node‐positive and 71% lymph node negative in this analysis. There was a trend towards benefit for the addition of platinum in both subgroups (lymph node‐positive: HR 0.86, 95% CI 0.54 to 1.37; lymph node‐negative: HR 0.82, 95% CI 0.55 to 1.22; <a href="./references#CD014805-fig-0030" title="">Analysis 6.1</a>); there was no subgroup difference (P = 0.85). </p> </section> <section id="CD014805-sec-0071"> <p><b>Type of platinum agent used</b></p> <p>Eleven of 12 studies reporting DFS used carboplatin, demonstrating a benefit (HR 0.65, 95% CI 0.57 to 0.75; <a href="./references#CD014805-fig-0032" title="">Analysis 7.1</a>). The remaining study reporting DFS assessed a novel platinum compound, lobaplatin, given both before and after surgery. This study also demonstrated DFS benefit albeit with wide CIs (HR 0.21, 95% CI 0.05 to 0.98). </p> </section> <section id="CD014805-sec-0072"> <p><b>Same chemotherapy backbone for intervention and control arm</b></p> <p>There was a benefit from the addition of platinum whether this was added to an anthracycline/taxane backbone, or as another combination. There was no subgroup difference in DFS benefit between the seven studies with a different backbone (HR 0.62, 95% CI 0.51 to 0.76) and in the five studies with the same backbone (HR 0.67, 95% CI 0.55 to 0.81) with a P value for subgroup difference of 0.63 (<a href="./references#CD014805-fig-0035" title="">Analysis 8.1</a>). </p> </section> <section id="CD014805-sec-0073"> <p><b>Anthracycline‐free platinum arm</b></p> <p>In the 12 studies (13 treatment comparisons) reporting DFS, seven had intervention arms combining platinum chemotherapy with anthracycline chemotherapy (including doxorubicin, epirubicin and non‐pegylated liposomal doxorubicin). Six treatment comparisons had anthracycline‐free platinum intervention arms. Both subgroups had a similar impact on DFS (anthracycline‐free intervention: HR 0.59, 95% CI 0.47 to 0.73; anthracycline‐containing intervention: HR 0.69, 95% CI 0.57 to 0.83; <a href="./references#CD014805-fig-0038" title="">Analysis 9.1</a>); there was little evidence of a subgroup difference (P = 0.27). </p> </section> <section id="CD014805-sec-0074"> <p><b>Schedule of platinum agent</b></p> <p>There was benefit across all schedules: three‐weekly (HR 0.71, 95% CI 0.59 to 0.85; 9 treatment comparisons), two‐weekly (HR 0.31, 95% CI 0.14 to 0.70; 1 study) and weekly groups (HR 0.58, 95% CI 0.45 to 0.74; 3 studies). </p> </section> </section> </section> <section id="CD014805-sec-0075"> <h5 class="title">Overall survival</h5> <section id="CD014805-sec-0076"> <h6 class="title">BRCA mutation, homologous recombination deficiency, lymph node status</h6> <p>No studies reported OS outcomes stratified for BRCA, HRD or lymph node status.</p> </section> <section id="CD014805-sec-0077"> <h6 class="title">Type of platinum agent used</h6> <p>All studies reporting OS used carboplatin. Therefore, there were insufficient data to assess OS benefit in agents other than carboplatin. </p> </section> <section id="CD014805-sec-0078"> <h6 class="title">Same backbone</h6> <p>There was improved OS in the seven studies with a different chemotherapy backbone in the platinum compared to the control arm (HR 0.62, 95% CI 0.47 to 0.81) and in the four studies with the same chemotherapy backbone (HR 0.75, 95% CI 0.57 to 0.99); there was little to no difference between groups (P = 0.85; <a href="./references#CD014805-fig-0036" title="">Analysis 8.2</a>). </p> </section> <section id="CD014805-sec-0079"> <h6 class="title">Anthracycline‐free platinum arm</h6> <p>Eleven studies reported OS, and of these five had intervention arms adding platinum chemotherapy to anthracycline chemotherapy, and six had anthracycline‐free intervention arms with a platinum‐taxane combination. There was a survival benefit in both subgroups (anthracycline‐free studies: HR 0.57, 95% CI 0.41 to 0.78; 1607 participants; anthracycline‐containing studies: HR 0.77, 95% CI 0.61 to 0.96; 1622 participants); there was no difference between groups (P = 0.14; <a href="./references#CD014805-fig-0039" title="">Analysis 9.2</a>). </p> </section> <section id="CD014805-sec-0080"> <h6 class="title">Schedule of platinum agent</h6> <p>There was benefit for OS across all treatment schedules: three‐weekly (HR 0.79, 95% CI 0.64 to 0.99; 8 treatment comparisons), two‐weekly (HR 0.14, 95% CI 0.04 to 0.52; 1 study) and weekly groups (HR 0.55, 95% CI 0.39 to 0.78; 3 studies) (<a href="./references#CD014805-fig-0042" title="">Analysis 10.2</a>). </p> </section> <section id="CD014805-sec-0081"> <h6 class="title">Pathological complete response</h6> <section id="CD014805-sec-0082"> <p><b>BRCA mutation status</b></p> <p>Five studies, with 1478 participants, were included in this analysis, including four studies (five treatment comparisons) that reported pCR stratified by BRCA mutation status (<a href="./references#CD014805-bbs2-0057" title="LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509.">BrighTNess</a>; <a href="./references#CD014805-bbs2-0009" title="NCT02125344. A phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). clinicaltrials.gov/show/NCT02125344. (first received 29 April 2014). PohlE , SchneeweissA , HaukeJ , MoebusV , FurlanettoJ , DenkertC , et al. Germline mutation status and therapy response in patients with triple negative breast cancer (TNBC): results of the GeparOcto study. Annals of Oncology2018;29(8 Suppl):viii77. Pohl-RescignoE , HaukeJ , LoiblS , MobusV , DenkertC , FaschingPA , et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncology2020;6(5):744-8. SchneeweissA , MobusV , TeschH , HanuschC , DenkertC , LubbeK , et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. European Journal of Cancer2019;106:181-92. SchneeweissA , MobusV , TeschH , KlareP , DenkertC , KastK , et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology2020;31(4 Suppl):S303. SchneeweissA , MoebusV , BlohmerJU , Dan CostaS , DenkertC , EidtmannH , et al. A randomized phase III trial comparing two dose-dense dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Journal of Clinical Oncology2015;33(15 Suppl):TPS1101. SchneeweissA , MoebusV , TeschH , HanuschC , DenkertC , LuebbeK , et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high risk early breast cancer (GeparOcto). Journal of Clinical Oncology2017;35(15 Suppl):518. ">GeparOcto</a>; <a href="./references#CD014805-bbs2-0010" title="EUDRACT2015-003509-41-DE. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD) (GeparOla). clinicaltrialsregister.eu/ctr-search/search?query=2015-003509-41 (first received 1 August 2016). FaschingPA , BlohmerJU , BurchardiN , CostaSD , DenkertC , HanuschC , et al. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. Journal of Clinical Oncology2016;34(15 Suppl):TPS1096. FaschingPA , JackischC , RhiemK , SchneeweissA , KlareP , HanuschC , et al. GeparOLA: a randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer. Journal of Clinical Oncology2019;37(15 Suppl):506. FaschingPA , LinkT , HaukeJ , SeitherF , JackischC , KlareP , et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Annals of Oncology2021;32(1):49-57. HaukeJ , ErnstC , FaschingPA , JackischC , SeitherF , KlareP , et al. Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: results of the GeparOLA study (NCT02789332). Annals of Oncology2020;31(4 Suppl):S313. NCT02789332. Assessing the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency. clinicaltrials.gov/show/NCT02789332 (first received 3 June 2016). ">GeparOLA</a>; <a href="./references#CD014805-bbs2-0011" title="Darb-EsfahaniS , WeichertW , DenkertC , vonMinckwitzG , NekljudovaV , LindnerJ , et al. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – a translational subproject of the GeparSixto trial. Annals of Oncology2015;26(Suppl 3):III15. DenkertC , LoiblS , SalatC , SinnBV , SchemC , EndrisV , et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Research2013;73(24 Suppl):S1-06. DenkertC , vonMinckwitzG , BraseJC , Darb-EsfahaniS , GadeS , KronenwettR , et al. Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: prediction of response to carboplatin-based chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):510. DenkertC , vonMinckwitzG , BraseJC , SinnBV , GadeS , KronenwettR , et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology2015;33(9):983-91. EUDRAC2011-000553-23-DE. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer – GeparSixto. clinicaltrialsregister.eu/ctr-search/search?query=2011-000553-23 (first received 29 September 2011). GuoS , LoiblS , vonMinckwitzG , Darb-EsfahaniS , LedererB , DenkertC . PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Research2020;52(3):689-96. HahnenE , LedererB , HaukeJ , LoiblS , KroberS , SchneeweissA , et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology2017;3(10):1378-85. Llop-GuevaraA , LoiblS , VillacampaG , VladimirovaV , SchneeweissA , KarnT , et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Annals of Oncology2021;32(12):1590-6. LoiblS , DenkertC , LoiS , AndreF , MuellerB , SchneeweissA , et al. PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):11061. LoiblS , DenkertC , SchneeweisA , PaepkeS , LehmannA , RezaiM , et al. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer-prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Research2013;73(24 Suppl):S4-06. LoiblS , WeberKE , TimmsKM , ElkinEP , HahnenE , FaschingPA , et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Annals of Oncology2018;29(12):2341-7. NCT01426880. Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). clinicaltrials.gov/show/NCT01426880 (first received 1 September 2001). StevicI , MullerV , WeberK , FaschingPA , KarnT , MarmeF , et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine2018;16(1):179. UntchM , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Annals of Oncology2017;28(Suppl 5):V49. vonMinckwitzG , HahnenE , FaschingPA , HaukeJ , SchneeweisA , SalatC , et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. Journal of Clinical Oncology2014;32(15 Suppl):1005. vonMinckwitzG , LoiblS , SchneeweissA , SalatCT , RezaiM , ZahmDM , et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Research2016;76(4 Suppl):S2-04. vonMinckwitzG , O'ShaughnessyJ , WinerEP , WolmarkN , GeyerCE , HuoberJB , et al. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). Journal of Clinical Oncology2014;32(15 Suppl):TPS1149. vonMinckwitzG , SchneeweissA , LoiblS , SalatC , DenkertC , RezaiM , et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology2014;15(7):747-56. vonMinckwitzG , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Journal of Clinical Oncology2013;31(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , FaschingPA , SchneeweissA , et al. Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. Journal of Clinical Oncology2015;33(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , HahnenE , FaschingPA , et al. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Research2017;77(4 Suppl):P1-09-02. ">GeparSixto</a>), and one study that contained only participants with a BRCA mutation (<a href="./references#CD014805-bbs2-0013" title="NCT01670500. Cisplatin vs. doxorubicin/cyclophosphamide in BRCA. clinicaltrials.gov/show/NCT01670500 (first received 22 August 2012). TungN , ArunB , HackerMR , HofstatterE , ToppmeyerDL , IsakoffSJ , et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). Journal of Clinical Oncology2020;38(14):1539-48. TungN , ArunB , HofstatterE , HackerMR , ToppmeyerDL , IsakoffSJ , et al. Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: results from the INFORM trial (TBCRC 031). Cancer Research2019;80(4 Suppl):GS6-03. ">INFORM</a>). There was no evidence of a difference between groups (BRCA wild‐type: RR 1.40, 95% CI 1.21 to 1.63; BRCA mutation: RR 1.11, 95% CI 0.91 to 1.36; P = 0.07; <a href="./references#CD014805-fig-0027" title="">Analysis 4.2</a>). </p> </section> <section id="CD014805-sec-0083"> <p><b>Homologous recombination deficiency status</b></p> <p>One study with 104 participants reported rates of pCR according to HRD status (<a href="./references#CD014805-bbs2-0019" title="MayerEL , AbramsonV , JankowitzR , FalksonC , MarcomPK , TrainaT , et al. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Annals of Oncology2020;31(11):1518-25. MayerEL , AbramsonVG , JankowitzRC , FalksonCI , MarcomPK , TrainaTA , et al. TBCRC 030: a randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC- evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2019;37(15 Suppl):507. MayerEL , Vaz-LuisI , RichardsonAL , PerouCM , TungNM , AbramsonVG , et al. TBCRC030: a randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC) – evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2014;32(15 Suppl):TPS1145. NCT01982448. Cisplatin vs paclitaxel for triple negative breast cancer. clinicaltrials.gov/show/NCT01982448 (first received 13 November 2013). ">TBCRC 030</a>). There was no evidence of a difference between subgroups (HRD‐positive: RR 0.90, 95% CI 0.28 to 2.84; HRD‐negative: RR 0.25, 95% CI 0.03 to 2.18; <a href="./references#CD014805-fig-0029" title="">Analysis 5.2</a>; P = 0.31). </p> </section> <section id="CD014805-sec-0084"> <p><b>Lymph node status</b></p> <p>Two studies, with 721 participants, reported pCR rates according to lymph node status. There was a similar pCR benefit from addition of platinum in both subgroups (lymph node‐positive: RR 1.89, 95% CI 1.31 to 2.73; lymph node‐negative: HR 1.83, 95% CI 1.35 to 2.50; <a href="./references#CD014805-fig-0031" title="">Analysis 6.2</a>) (P = 0.91 for subgroup differences). </p> </section> <section id="CD014805-sec-0085"> <p><b>Type of platinum agent used</b></p> <p>In the pCR analysis, there was a clear benefit in the studies using carboplatin (HR 1.45, 95% CI 1.32 to 1.60; 12 studies, 2801 participants) and lobaplatin (RR 3.05, 95% CI 1.48 to 6.26; 1 study, 125 participants), but not in the studies using cisplatin (RR 1.00, 95% CI 0.58 to 1.75; 2 studies, 222 participants; <a href="./references#CD014805-fig-0034" title="">Analysis 7.3</a>; <a href="./references#CD014805-bbs2-0013" title="NCT01670500. Cisplatin vs. doxorubicin/cyclophosphamide in BRCA. clinicaltrials.gov/show/NCT01670500 (first received 22 August 2012). TungN , ArunB , HackerMR , HofstatterE , ToppmeyerDL , IsakoffSJ , et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). Journal of Clinical Oncology2020;38(14):1539-48. TungN , ArunB , HofstatterE , HackerMR , ToppmeyerDL , IsakoffSJ , et al. Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: results from the INFORM trial (TBCRC 031). Cancer Research2019;80(4 Suppl):GS6-03. ">INFORM</a>; <a href="./references#CD014805-bbs2-0019" title="MayerEL , AbramsonV , JankowitzR , FalksonC , MarcomPK , TrainaT , et al. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Annals of Oncology2020;31(11):1518-25. MayerEL , AbramsonVG , JankowitzRC , FalksonCI , MarcomPK , TrainaTA , et al. TBCRC 030: a randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC- evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2019;37(15 Suppl):507. MayerEL , Vaz-LuisI , RichardsonAL , PerouCM , TungNM , AbramsonVG , et al. TBCRC030: a randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC) – evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2014;32(15 Suppl):TPS1145. NCT01982448. Cisplatin vs paclitaxel for triple negative breast cancer. clinicaltrials.gov/show/NCT01982448 (first received 13 November 2013). ">TBCRC 030</a>); there was weak evidence of a subgroup difference (P = 0.07). This supports the DFS and OS findings in that the clearest evidence for benefit in this meta‐analysis is for carboplatin, with a single study supporting the use of lobaplatin. </p> </section> <section id="CD014805-sec-0086"> <p><b>Same backbone</b></p> <p>There was weak evidence of a difference in pCR benefit between the subgroup of nine studies with a different backbone (RR 1.35, 95% CI 1.18 to 1.53; 1473 people) and in the subgroup of six studies with the same backbone (RR 1.59, 95% CI 1.38 to 1.84; 1675 people) with a P value for subgroup differences of 0.09 (<a href="./references#CD014805-fig-0037" title="">Analysis 8.3</a>). </p> </section> <section id="CD014805-sec-0087"> <p><b>Anthracycline‐free platinum arm</b></p> <p>Outcomes for pCR were similar amongst the 10 treatment comparisons with an anthracycline‐containing intervention (RR 1.44, 95% CI 1.29 to 1.61), and the six studies with anthracycline‐free intervention (RR 1.53, 95% CI 1.24 to 1.89) with a P value for subgroup differences of 0.61 (<a href="./references#CD014805-fig-0040" title="">Analysis 9.3</a>). </p> </section> <section id="CD014805-sec-0088"> <p><b>Schedule of platinum agent</b></p> <p>There was an increased likelihood of pCR across the three‐weekly (11 treatment comparisons, RR 1.61, 95% CI 1.38 to 1.87) and weekly groups (5 studies, RR 1.34, 95% CI 1.19 to 1.52) in <a href="./references#CD014805-fig-0043" title="">Analysis 10.3</a>, with minimal evidence of subgroup differences (P = 0.07). </p> </section> </section> </section> <section id="CD014805-sec-0089"> <h5 class="title">Sensitivity analyses</h5> <section id="CD014805-sec-0090"> <h6 class="title">Hormone receptor immunohistochemistry cut‐off other than less than 1%</h6> <p>The ideal hormone receptor IHC cut‐off varied between studies on this topic. Although less than 1% was the most commonly used definition, other cut‐offs included less than 5% and less than 10%. </p> <p> <ul id="CD014805-list-0016"> <li> <p>When stratified by hormone receptor IHC cut‐off, improved DFS was similar in studies that defined TNBC by less than 1% hormone receptor staining (HR 0.60, 95% CI 0.50 to 0.71; <a href="./references#CD014805-bbs2-0001" title='GluzO , LiedtkeC , PratA , ChristgenM , GebauerD , KatesRE , et al. Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): results of the randomized WSG ADAPT-TN trial. Journal of Clinical Oncology2017;35(15 Suppl):573. GluzO , NitzU , ChristgenM , GrischkeEM , ForstbauerH , BraunMW , et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Journal of Clinical Oncology2015;33(15 Suppl):1032. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. Journal of the National Cancer Institute2018;110(6):628-37. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: survival results of WSG-ADAPT-TN phase II trial. Journal of Clinical Oncology2018;36(15 Suppl):573. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology2018;29(Suppl 8):viii703. GluzO , NitzU , LiedtkeC , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG – ADAPT TN randomized phase II trial. Cancer Research2016;76(4 Suppl):S6-07. GluzO , NitzU , LiedtkeC , PratA , ChristgenM , FeuerhakeF , et al. No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial. Cancer Research2019;79(4 Suppl):GS5-06. HarbeckN , HofmannD , GluzO , KatesRE , KummelS , NudingB , et al. ADAPT: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):TPS655. LiedtkeC , GluzO , NitzU , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. Oncology Research and Treatment2016;1:53. NCT01815242. Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer - triple negative breast cancer (ADAPT). clinicaltrials.gov/show/NCT01815242 (first received 21 March 2013). NitzU , GluzO , Von SchumannR , HofmannD , KatesRE , KuemmelS , et al. ADAPT – Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Cancer Research.2015;75(9 Suppl):OT3-2-04. '>ADAPT‐TN</a>; <a href="./references#CD014805-bbs2-0057" title="LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509.">BrighTNess</a>; <a href="./references#CD014805-bbs2-0011" title="Darb-EsfahaniS , WeichertW , DenkertC , vonMinckwitzG , NekljudovaV , LindnerJ , et al. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – a translational subproject of the GeparSixto trial. Annals of Oncology2015;26(Suppl 3):III15. DenkertC , LoiblS , SalatC , SinnBV , SchemC , EndrisV , et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Research2013;73(24 Suppl):S1-06. DenkertC , vonMinckwitzG , BraseJC , Darb-EsfahaniS , GadeS , KronenwettR , et al. Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: prediction of response to carboplatin-based chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):510. DenkertC , vonMinckwitzG , BraseJC , SinnBV , GadeS , KronenwettR , et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology2015;33(9):983-91. EUDRAC2011-000553-23-DE. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer – GeparSixto. clinicaltrialsregister.eu/ctr-search/search?query=2011-000553-23 (first received 29 September 2011). GuoS , LoiblS , vonMinckwitzG , Darb-EsfahaniS , LedererB , DenkertC . PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Research2020;52(3):689-96. HahnenE , LedererB , HaukeJ , LoiblS , KroberS , SchneeweissA , et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology2017;3(10):1378-85. Llop-GuevaraA , LoiblS , VillacampaG , VladimirovaV , SchneeweissA , KarnT , et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Annals of Oncology2021;32(12):1590-6. LoiblS , DenkertC , LoiS , AndreF , MuellerB , SchneeweissA , et al. PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):11061. LoiblS , DenkertC , SchneeweisA , PaepkeS , LehmannA , RezaiM , et al. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer-prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Research2013;73(24 Suppl):S4-06. LoiblS , WeberKE , TimmsKM , ElkinEP , HahnenE , FaschingPA , et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Annals of Oncology2018;29(12):2341-7. NCT01426880. Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). clinicaltrials.gov/show/NCT01426880 (first received 1 September 2001). StevicI , MullerV , WeberK , FaschingPA , KarnT , MarmeF , et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine2018;16(1):179. UntchM , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Annals of Oncology2017;28(Suppl 5):V49. vonMinckwitzG , HahnenE , FaschingPA , HaukeJ , SchneeweisA , SalatC , et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. Journal of Clinical Oncology2014;32(15 Suppl):1005. vonMinckwitzG , LoiblS , SchneeweissA , SalatCT , RezaiM , ZahmDM , et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Research2016;76(4 Suppl):S2-04. vonMinckwitzG , O'ShaughnessyJ , WinerEP , WolmarkN , GeyerCE , HuoberJB , et al. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). Journal of Clinical Oncology2014;32(15 Suppl):TPS1149. vonMinckwitzG , SchneeweissA , LoiblS , SalatC , DenkertC , RezaiM , et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology2014;15(7):747-56. vonMinckwitzG , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Journal of Clinical Oncology2013;31(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , FaschingPA , SchneeweissA , et al. Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. Journal of Clinical Oncology2015;33(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , HahnenE , FaschingPA , et al. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Research2017;77(4 Suppl):P1-09-02. ">GeparSixto</a>; <a href="./references#CD014805-bbs2-0015" title="LiQ , WangJ , MuY , ZhangT , HanY , LuoY , et al. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chinese Journal of Cancer Research2020;32(4):485-96. MuY , ZhangT , HanY , WangJ , LiQ , LuoY , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple negative breast cancer patients with high recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. NCT01378533. The trial comparing dose-dense AC-T with PC as adjuvant therapy for TNBC. clinicaltrials.gov/show/NCT01378533 (first received 22 June 2011). WangJ , LiQ , MuY , ZhangT , HanY , WangJ , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. ">Li 2020</a>; <a href="./references#CD014805-bbs2-0017" title="NCT03154749. TC (docetaxel/carboplatin) versus EC-T (epirubicin/cyclophosphamide followed by docetaxe) as neoadjuvant chemotherapy for triple-negative breast cancer. clinicaltrials.gov/show/NCT03154749 (first received 16 May 2017). ZhangL , WuZ , LinY , LiJ , LiuZ , CaoY , et al. Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label, phase II trial. Journal of Clinical Oncology2022;38(15 Suppl):586. ZhangL , WuZY , LiJ , LinY , LiuZ , CaoY , et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial. International Journal of Cancer2022;150(4):654-62. ">NeoCART</a>; <a href="./references#CD014805-bbs2-0018" title="NCT01216111. Comparison study of adjuvant chemotherapy for Chinese triple negative breast cancer. clinicaltrials.gov/show/NCT01216111 (first received 7 October 2010). NCT04031703. Study comparing paclitaxel plus carboplatin versus anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer (PATTERN). clinicaltrials.gov/show/NCT04031703 (first received 24 July 2019). YuKD , YeFG , HeM , FanL , MaD , MoM , et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncology2020;6(9):1390-6. ">PATTERN</a>; <a href="./references#CD014805-bbs2-0023" title="DuF , WangW , WangY , LiM , ZhuA , WangJ , et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Research and Treatment2020;182(1):67-77. NCT01150513. Docetaxel+carboplatin vs epirubicin+cyclophosphamide followed by docetaxel as adjuvant treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01150513 (first received 25 June 2010). YuanP , DuF , WangJ , MaF , FanY , XuB . Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer. Journal of Clinical Oncology2016;34(Suppl 15):1068. YuanP , XuB . A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients. Journal of Clinical Oncology2012;30(15 Suppl):TPS1135. YuanP , XuBH , WangJY , MaF , LiQ , ZhangP , et al. Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial. Chung Hua Chung Liu Tsa Chih 2012;34(6):465-8. ZhengF , DuF , WangW , WangY , LiM , ZhaoJ , et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Research and Treatment2022;191(1):97-105. ">Zheng 2022</a>) compared to studies in this review where the cut‐off was less than 10% or not stated (HR 0.76, 95% CI 0.59 to 0.98; less than 10%: <a href="./references#CD014805-bbs2-0002" title="AndoM , YamauchiH , AogiK , ShimizuS , IwataH , MasudaN , et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment2014;145(2):401-9. IwaseM , AndoM , AogiK , ArugaT , InoueK , ShimomuraA , et al. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment2020;180(3):687-94. TamuraK , HashimotoJ , TsudaH , YoshidaM , YamauchiH , AogiK , et al. Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. Journal of Clinical Oncology2014;32(15 Suppl):1017. UMIN000003355. Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer. Center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004074 (first received 22 March 2010). ">Ando 2014</a>; <a href="./references#CD014805-bbs2-0005" title="GolshanM , CirrincioneCT , CareyLA , SikovWM , BerryDA , BursteinHJ , et al. Impact of neoadjuvant therapy on breast conservation rates in triple negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). Journal of Clinical Oncology2015;33(15 Suppl):1007. GolshanM , CirrincioneCT , SikovWM , BerryDA , JasinskiS , WeisbergTF , et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals of Surgery2015;262(3):434-9. NCT00861705. Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. clinicaltrials.gov/show/NCT00861705 (first received 13 March 2009). ShepherdJH , BallmanK , PolleyMC , CampbellJD , FanC , SelitskyS , et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. Journal of Clinical Oncology2022;40(12):1323-34. ShepherdJH , HyslopT , FanC , MartinezAF , ParkerJ , HoadleyK , et al. Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival. Cancer Research2021;81(4 Suppl):PD9-03. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneC , TolaneyS , et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research2013;73(24 Suppl):S5-01. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Cancer Research2016;76(4 Suppl):S2-05. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology2015;33(1):13-21. SikovWM , PerouCM , GolshanM , CollyarD , BerryDA , HahnOM , et al. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):TPS110. SikovWM , PolleyMY , TwohyE , PerouCM , SinghB , BerryDA , et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple negative breast cancer (TNBC). Journal of Clinical Oncology2019;37(15 Suppl):591. ">CALGB 40603</a>; <a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a>; <a href="./references#CD014805-bbs2-0021" title="NCT01276769. Comparison study of neoadjuvant paclitaxel plus carboplatin/epirubicin treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01276769 (first received 13 January 2011). ZhangP , YinY , MoH , ZhangB , WangX , LiQ , et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget2016;7(37):60647-56. ZhangP , YinY , XuB , WangX , ZhangB , LiQ , et al. Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer – a phase II clinical trial. Cancer Research2013;73(24 Suppl):P3-14-07. ">Zhang 2016</a>; not stated: <a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a>). There was no difference between subgroups (P = 0.11). </p> </li> <li> <p>There was improvement in OS in studies that defined TNBC by less than 1% hormone receptor staining (HR 0.62, 95% CI 0.49 to 0.79; 2468 participants; <a href="./references#CD014805-bbs2-0001" title='GluzO , LiedtkeC , PratA , ChristgenM , GebauerD , KatesRE , et al. Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): results of the randomized WSG ADAPT-TN trial. Journal of Clinical Oncology2017;35(15 Suppl):573. GluzO , NitzU , ChristgenM , GrischkeEM , ForstbauerH , BraunMW , et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Journal of Clinical Oncology2015;33(15 Suppl):1032. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. Journal of the National Cancer Institute2018;110(6):628-37. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: survival results of WSG-ADAPT-TN phase II trial. Journal of Clinical Oncology2018;36(15 Suppl):573. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology2018;29(Suppl 8):viii703. GluzO , NitzU , LiedtkeC , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG – ADAPT TN randomized phase II trial. Cancer Research2016;76(4 Suppl):S6-07. GluzO , NitzU , LiedtkeC , PratA , ChristgenM , FeuerhakeF , et al. No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial. Cancer Research2019;79(4 Suppl):GS5-06. HarbeckN , HofmannD , GluzO , KatesRE , KummelS , NudingB , et al. ADAPT: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):TPS655. LiedtkeC , GluzO , NitzU , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. Oncology Research and Treatment2016;1:53. NCT01815242. Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer - triple negative breast cancer (ADAPT). clinicaltrials.gov/show/NCT01815242 (first received 21 March 2013). NitzU , GluzO , Von SchumannR , HofmannD , KatesRE , KuemmelS , et al. ADAPT – Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Cancer Research.2015;75(9 Suppl):OT3-2-04. '>ADAPT‐TN</a>; <a href="./references#CD014805-bbs2-0057" title="LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509.">BrighTNess</a>; <a href="./references#CD014805-bbs2-0011" title="Darb-EsfahaniS , WeichertW , DenkertC , vonMinckwitzG , NekljudovaV , LindnerJ , et al. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – a translational subproject of the GeparSixto trial. Annals of Oncology2015;26(Suppl 3):III15. DenkertC , LoiblS , SalatC , SinnBV , SchemC , EndrisV , et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Research2013;73(24 Suppl):S1-06. DenkertC , vonMinckwitzG , BraseJC , Darb-EsfahaniS , GadeS , KronenwettR , et al. Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: prediction of response to carboplatin-based chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):510. DenkertC , vonMinckwitzG , BraseJC , SinnBV , GadeS , KronenwettR , et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology2015;33(9):983-91. EUDRAC2011-000553-23-DE. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer – GeparSixto. clinicaltrialsregister.eu/ctr-search/search?query=2011-000553-23 (first received 29 September 2011). GuoS , LoiblS , vonMinckwitzG , Darb-EsfahaniS , LedererB , DenkertC . PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Research2020;52(3):689-96. HahnenE , LedererB , HaukeJ , LoiblS , KroberS , SchneeweissA , et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology2017;3(10):1378-85. Llop-GuevaraA , LoiblS , VillacampaG , VladimirovaV , SchneeweissA , KarnT , et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Annals of Oncology2021;32(12):1590-6. LoiblS , DenkertC , LoiS , AndreF , MuellerB , SchneeweissA , et al. PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):11061. LoiblS , DenkertC , SchneeweisA , PaepkeS , LehmannA , RezaiM , et al. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer-prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Research2013;73(24 Suppl):S4-06. LoiblS , WeberKE , TimmsKM , ElkinEP , HahnenE , FaschingPA , et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Annals of Oncology2018;29(12):2341-7. NCT01426880. Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). clinicaltrials.gov/show/NCT01426880 (first received 1 September 2001). StevicI , MullerV , WeberK , FaschingPA , KarnT , MarmeF , et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine2018;16(1):179. UntchM , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Annals of Oncology2017;28(Suppl 5):V49. vonMinckwitzG , HahnenE , FaschingPA , HaukeJ , SchneeweisA , SalatC , et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. Journal of Clinical Oncology2014;32(15 Suppl):1005. vonMinckwitzG , LoiblS , SchneeweissA , SalatCT , RezaiM , ZahmDM , et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Research2016;76(4 Suppl):S2-04. vonMinckwitzG , O'ShaughnessyJ , WinerEP , WolmarkN , GeyerCE , HuoberJB , et al. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). Journal of Clinical Oncology2014;32(15 Suppl):TPS1149. vonMinckwitzG , SchneeweissA , LoiblS , SalatC , DenkertC , RezaiM , et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology2014;15(7):747-56. vonMinckwitzG , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Journal of Clinical Oncology2013;31(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , FaschingPA , SchneeweissA , et al. Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. Journal of Clinical Oncology2015;33(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , HahnenE , FaschingPA , et al. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Research2017;77(4 Suppl):P1-09-02. ">GeparSixto</a>; <a href="./references#CD014805-bbs2-0015" title="LiQ , WangJ , MuY , ZhangT , HanY , LuoY , et al. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chinese Journal of Cancer Research2020;32(4):485-96. MuY , ZhangT , HanY , WangJ , LiQ , LuoY , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple negative breast cancer patients with high recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. NCT01378533. The trial comparing dose-dense AC-T with PC as adjuvant therapy for TNBC. clinicaltrials.gov/show/NCT01378533 (first received 22 June 2011). WangJ , LiQ , MuY , ZhangT , HanY , WangJ , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. ">Li 2020</a>; <a href="./references#CD014805-bbs2-0017" title="NCT03154749. TC (docetaxel/carboplatin) versus EC-T (epirubicin/cyclophosphamide followed by docetaxe) as neoadjuvant chemotherapy for triple-negative breast cancer. clinicaltrials.gov/show/NCT03154749 (first received 16 May 2017). ZhangL , WuZ , LinY , LiJ , LiuZ , CaoY , et al. Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label, phase II trial. Journal of Clinical Oncology2022;38(15 Suppl):586. ZhangL , WuZY , LiJ , LinY , LiuZ , CaoY , et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial. International Journal of Cancer2022;150(4):654-62. ">NeoCART</a>; <a href="./references#CD014805-bbs2-0018" title="NCT01216111. Comparison study of adjuvant chemotherapy for Chinese triple negative breast cancer. clinicaltrials.gov/show/NCT01216111 (first received 7 October 2010). NCT04031703. Study comparing paclitaxel plus carboplatin versus anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer (PATTERN). clinicaltrials.gov/show/NCT04031703 (first received 24 July 2019). YuKD , YeFG , HeM , FanL , MaD , MoM , et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncology2020;6(9):1390-6. ">PATTERN</a>; <a href="./references#CD014805-bbs2-0023" title="DuF , WangW , WangY , LiM , ZhuA , WangJ , et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Research and Treatment2020;182(1):67-77. NCT01150513. Docetaxel+carboplatin vs epirubicin+cyclophosphamide followed by docetaxel as adjuvant treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01150513 (first received 25 June 2010). YuanP , DuF , WangJ , MaF , FanY , XuB . Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer. Journal of Clinical Oncology2016;34(Suppl 15):1068. YuanP , XuB . A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients. Journal of Clinical Oncology2012;30(15 Suppl):TPS1135. YuanP , XuBH , WangJY , MaF , LiQ , ZhangP , et al. Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial. Chung Hua Chung Liu Tsa Chih 2012;34(6):465-8. ZhengF , DuF , WangW , WangY , LiM , ZhaoJ , et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Research and Treatment2022;191(1):97-105. ">Zheng 2022</a>), and in the group of studies where the cut‐off was less than 10% or not stated (HR 0.81, 95% CI 0.60 to 1.07; 761 participants; less than 10%: <a href="./references#CD014805-bbs2-0002" title="AndoM , YamauchiH , AogiK , ShimizuS , IwataH , MasudaN , et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment2014;145(2):401-9. IwaseM , AndoM , AogiK , ArugaT , InoueK , ShimomuraA , et al. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment2020;180(3):687-94. TamuraK , HashimotoJ , TsudaH , YoshidaM , YamauchiH , AogiK , et al. Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. Journal of Clinical Oncology2014;32(15 Suppl):1017. UMIN000003355. Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer. Center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004074 (first received 22 March 2010). ">Ando 2014</a>; <a href="./references#CD014805-bbs2-0005" title="GolshanM , CirrincioneCT , CareyLA , SikovWM , BerryDA , BursteinHJ , et al. Impact of neoadjuvant therapy on breast conservation rates in triple negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). Journal of Clinical Oncology2015;33(15 Suppl):1007. GolshanM , CirrincioneCT , SikovWM , BerryDA , JasinskiS , WeisbergTF , et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals of Surgery2015;262(3):434-9. NCT00861705. Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. clinicaltrials.gov/show/NCT00861705 (first received 13 March 2009). ShepherdJH , BallmanK , PolleyMC , CampbellJD , FanC , SelitskyS , et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. Journal of Clinical Oncology2022;40(12):1323-34. ShepherdJH , HyslopT , FanC , MartinezAF , ParkerJ , HoadleyK , et al. Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival. Cancer Research2021;81(4 Suppl):PD9-03. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneC , TolaneyS , et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research2013;73(24 Suppl):S5-01. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Cancer Research2016;76(4 Suppl):S2-05. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology2015;33(1):13-21. SikovWM , PerouCM , GolshanM , CollyarD , BerryDA , HahnOM , et al. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):TPS110. SikovWM , PolleyMY , TwohyE , PerouCM , SinghB , BerryDA , et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple negative breast cancer (TNBC). Journal of Clinical Oncology2019;37(15 Suppl):591. ">CALGB 40603</a>; <a href="./references#CD014805-bbs2-0021" title="NCT01276769. Comparison study of neoadjuvant paclitaxel plus carboplatin/epirubicin treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01276769 (first received 13 January 2011). ZhangP , YinY , MoH , ZhangB , WangX , LiQ , et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget2016;7(37):60647-56. ZhangP , YinY , XuB , WangX , ZhangB , LiQ , et al. Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer – a phase II clinical trial. Cancer Research2013;73(24 Suppl):P3-14-07. ">Zhang 2016</a>; not stated: <a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a>). There was no difference between subgroups (P = 0.18). </p> </li> <li> <p>An association between platinum chemotherapy and likelihood of pCR was similar in the less than 1% cut‐off subgroup (RR 1.42, 95% CI 1.26 to 1.58; <a href="./references#CD014805-bbs2-0001" title='GluzO , LiedtkeC , PratA , ChristgenM , GebauerD , KatesRE , et al. Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): results of the randomized WSG ADAPT-TN trial. Journal of Clinical Oncology2017;35(15 Suppl):573. GluzO , NitzU , ChristgenM , GrischkeEM , ForstbauerH , BraunMW , et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Journal of Clinical Oncology2015;33(15 Suppl):1032. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. Journal of the National Cancer Institute2018;110(6):628-37. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: survival results of WSG-ADAPT-TN phase II trial. Journal of Clinical Oncology2018;36(15 Suppl):573. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology2018;29(Suppl 8):viii703. GluzO , NitzU , LiedtkeC , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG – ADAPT TN randomized phase II trial. Cancer Research2016;76(4 Suppl):S6-07. GluzO , NitzU , LiedtkeC , PratA , ChristgenM , FeuerhakeF , et al. No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial. Cancer Research2019;79(4 Suppl):GS5-06. HarbeckN , HofmannD , GluzO , KatesRE , KummelS , NudingB , et al. ADAPT: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):TPS655. LiedtkeC , GluzO , NitzU , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. Oncology Research and Treatment2016;1:53. NCT01815242. Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer - triple negative breast cancer (ADAPT). clinicaltrials.gov/show/NCT01815242 (first received 21 March 2013). NitzU , GluzO , Von SchumannR , HofmannD , KatesRE , KuemmelS , et al. ADAPT – Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Cancer Research.2015;75(9 Suppl):OT3-2-04. '>ADAPT‐TN</a>; <a href="./references#CD014805-bbs2-0057" title="LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509.">BrighTNess</a>; <a href="./references#CD014805-bbs2-0009" title="NCT02125344. A phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). clinicaltrials.gov/show/NCT02125344. (first received 29 April 2014). PohlE , SchneeweissA , HaukeJ , MoebusV , FurlanettoJ , DenkertC , et al. Germline mutation status and therapy response in patients with triple negative breast cancer (TNBC): results of the GeparOcto study. Annals of Oncology2018;29(8 Suppl):viii77. Pohl-RescignoE , HaukeJ , LoiblS , MobusV , DenkertC , FaschingPA , et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncology2020;6(5):744-8. SchneeweissA , MobusV , TeschH , HanuschC , DenkertC , LubbeK , et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. European Journal of Cancer2019;106:181-92. SchneeweissA , MobusV , TeschH , KlareP , DenkertC , KastK , et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology2020;31(4 Suppl):S303. SchneeweissA , MoebusV , BlohmerJU , Dan CostaS , DenkertC , EidtmannH , et al. A randomized phase III trial comparing two dose-dense dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Journal of Clinical Oncology2015;33(15 Suppl):TPS1101. SchneeweissA , MoebusV , TeschH , HanuschC , DenkertC , LuebbeK , et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high risk early breast cancer (GeparOcto). Journal of Clinical Oncology2017;35(15 Suppl):518. ">GeparOcto</a>; <a href="./references#CD014805-bbs2-0010" title="EUDRACT2015-003509-41-DE. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD) (GeparOla). clinicaltrialsregister.eu/ctr-search/search?query=2015-003509-41 (first received 1 August 2016). FaschingPA , BlohmerJU , BurchardiN , CostaSD , DenkertC , HanuschC , et al. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. Journal of Clinical Oncology2016;34(15 Suppl):TPS1096. FaschingPA , JackischC , RhiemK , SchneeweissA , KlareP , HanuschC , et al. GeparOLA: a randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer. Journal of Clinical Oncology2019;37(15 Suppl):506. FaschingPA , LinkT , HaukeJ , SeitherF , JackischC , KlareP , et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Annals of Oncology2021;32(1):49-57. HaukeJ , ErnstC , FaschingPA , JackischC , SeitherF , KlareP , et al. Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: results of the GeparOLA study (NCT02789332). Annals of Oncology2020;31(4 Suppl):S313. NCT02789332. Assessing the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency. clinicaltrials.gov/show/NCT02789332 (first received 3 June 2016). ">GeparOLA</a>; <a href="./references#CD014805-bbs2-0011" title="Darb-EsfahaniS , WeichertW , DenkertC , vonMinckwitzG , NekljudovaV , LindnerJ , et al. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – a translational subproject of the GeparSixto trial. Annals of Oncology2015;26(Suppl 3):III15. DenkertC , LoiblS , SalatC , SinnBV , SchemC , EndrisV , et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Research2013;73(24 Suppl):S1-06. DenkertC , vonMinckwitzG , BraseJC , Darb-EsfahaniS , GadeS , KronenwettR , et al. Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: prediction of response to carboplatin-based chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):510. DenkertC , vonMinckwitzG , BraseJC , SinnBV , GadeS , KronenwettR , et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology2015;33(9):983-91. EUDRAC2011-000553-23-DE. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer – GeparSixto. clinicaltrialsregister.eu/ctr-search/search?query=2011-000553-23 (first received 29 September 2011). GuoS , LoiblS , vonMinckwitzG , Darb-EsfahaniS , LedererB , DenkertC . PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Research2020;52(3):689-96. HahnenE , LedererB , HaukeJ , LoiblS , KroberS , SchneeweissA , et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology2017;3(10):1378-85. Llop-GuevaraA , LoiblS , VillacampaG , VladimirovaV , SchneeweissA , KarnT , et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Annals of Oncology2021;32(12):1590-6. LoiblS , DenkertC , LoiS , AndreF , MuellerB , SchneeweissA , et al. PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):11061. LoiblS , DenkertC , SchneeweisA , PaepkeS , LehmannA , RezaiM , et al. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer-prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Research2013;73(24 Suppl):S4-06. LoiblS , WeberKE , TimmsKM , ElkinEP , HahnenE , FaschingPA , et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Annals of Oncology2018;29(12):2341-7. NCT01426880. Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). clinicaltrials.gov/show/NCT01426880 (first received 1 September 2001). StevicI , MullerV , WeberK , FaschingPA , KarnT , MarmeF , et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine2018;16(1):179. UntchM , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Annals of Oncology2017;28(Suppl 5):V49. vonMinckwitzG , HahnenE , FaschingPA , HaukeJ , SchneeweisA , SalatC , et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. Journal of Clinical Oncology2014;32(15 Suppl):1005. vonMinckwitzG , LoiblS , SchneeweissA , SalatCT , RezaiM , ZahmDM , et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Research2016;76(4 Suppl):S2-04. vonMinckwitzG , O'ShaughnessyJ , WinerEP , WolmarkN , GeyerCE , HuoberJB , et al. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). Journal of Clinical Oncology2014;32(15 Suppl):TPS1149. vonMinckwitzG , SchneeweissA , LoiblS , SalatC , DenkertC , RezaiM , et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology2014;15(7):747-56. vonMinckwitzG , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Journal of Clinical Oncology2013;31(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , FaschingPA , SchneeweissA , et al. Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. Journal of Clinical Oncology2015;33(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , HahnenE , FaschingPA , et al. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Research2017;77(4 Suppl):P1-09-02. ">GeparSixto</a>; <a href="./references#CD014805-bbs2-0017" title="NCT03154749. TC (docetaxel/carboplatin) versus EC-T (epirubicin/cyclophosphamide followed by docetaxe) as neoadjuvant chemotherapy for triple-negative breast cancer. clinicaltrials.gov/show/NCT03154749 (first received 16 May 2017). ZhangL , WuZ , LinY , LiJ , LiuZ , CaoY , et al. Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label, phase II trial. Journal of Clinical Oncology2022;38(15 Suppl):586. ZhangL , WuZY , LiJ , LinY , LiuZ , CaoY , et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial. International Journal of Cancer2022;150(4):654-62. ">NeoCART</a>), and the subgroup of studies with a cut‐off of less than 5%, 10% or not stated (RR of 1.57, 95% CI 1.30 to 1.90; less than 5%: <a href="./references#CD014805-bbs2-0019" title="MayerEL , AbramsonV , JankowitzR , FalksonC , MarcomPK , TrainaT , et al. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Annals of Oncology2020;31(11):1518-25. MayerEL , AbramsonVG , JankowitzRC , FalksonCI , MarcomPK , TrainaTA , et al. TBCRC 030: a randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC- evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2019;37(15 Suppl):507. MayerEL , Vaz-LuisI , RichardsonAL , PerouCM , TungNM , AbramsonVG , et al. TBCRC030: a randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC) – evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2014;32(15 Suppl):TPS1145. NCT01982448. Cisplatin vs paclitaxel for triple negative breast cancer. clinicaltrials.gov/show/NCT01982448 (first received 13 November 2013). ">TBCRC 030</a>, less than 10%: <a href="./references#CD014805-bbs2-0002" title="AndoM , YamauchiH , AogiK , ShimizuS , IwataH , MasudaN , et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment2014;145(2):401-9. IwaseM , AndoM , AogiK , ArugaT , InoueK , ShimomuraA , et al. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment2020;180(3):687-94. TamuraK , HashimotoJ , TsudaH , YoshidaM , YamauchiH , AogiK , et al. Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. Journal of Clinical Oncology2014;32(15 Suppl):1017. UMIN000003355. Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer. Center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004074 (first received 22 March 2010). ">Ando 2014</a>; <a href="./references#CD014805-bbs2-0005" title="GolshanM , CirrincioneCT , CareyLA , SikovWM , BerryDA , BursteinHJ , et al. Impact of neoadjuvant therapy on breast conservation rates in triple negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). Journal of Clinical Oncology2015;33(15 Suppl):1007. GolshanM , CirrincioneCT , SikovWM , BerryDA , JasinskiS , WeisbergTF , et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals of Surgery2015;262(3):434-9. NCT00861705. Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. clinicaltrials.gov/show/NCT00861705 (first received 13 March 2009). ShepherdJH , BallmanK , PolleyMC , CampbellJD , FanC , SelitskyS , et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. Journal of Clinical Oncology2022;40(12):1323-34. ShepherdJH , HyslopT , FanC , MartinezAF , ParkerJ , HoadleyK , et al. Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival. Cancer Research2021;81(4 Suppl):PD9-03. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneC , TolaneyS , et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research2013;73(24 Suppl):S5-01. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Cancer Research2016;76(4 Suppl):S2-05. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology2015;33(1):13-21. SikovWM , PerouCM , GolshanM , CollyarD , BerryDA , HahnOM , et al. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):TPS110. SikovWM , PolleyMY , TwohyE , PerouCM , SinghB , BerryDA , et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple negative breast cancer (TNBC). Journal of Clinical Oncology2019;37(15 Suppl):591. ">CALGB 40603</a>; <a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a>; <a href="./references#CD014805-bbs2-0021" title="NCT01276769. Comparison study of neoadjuvant paclitaxel plus carboplatin/epirubicin treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01276769 (first received 13 January 2011). ZhangP , YinY , MoH , ZhangB , WangX , LiQ , et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget2016;7(37):60647-56. ZhangP , YinY , XuB , WangX , ZhangB , LiQ , et al. Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer – a phase II clinical trial. Cancer Research2013;73(24 Suppl):P3-14-07. ">Zhang 2016</a>; not stated: <a href="./references#CD014805-bbs2-0008" title="AlbaE , ChaconJI , LluchA , AntonA , EstevezL , CirauquiB , et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Research and Treatment2012;136(2):487-93. AlbaE , ChaconJI , LluchA , Garcia-EstevezL , AntonA , CirauquiB , et al. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03 – a multicenter, randomized phase II study. Journal of Clinical Oncology2011;29(15 Suppl):1015. NCT00432172. Selective neoadjuvant treatment according to immunohistochemical subtype for HER2 negative breast cancer patients. clinicaltrials.gov/show/NCT00432172 (first received 7 February 2007). SantonjaA , AlbanellJ , ChaconJI , LluchA , Sanchez-MunozA , RojoF , et al. Triple-negative breast cancer subtypes and pathologic complete-response rate to neoadjuvant chemotherapy: results from the GEICAM/2006-2003 study. Journal of Clinical Oncology2014;32(15 Suppl):1024. ">GEICAM 2006‐03</a>; <a href="./references#CD014805-bbs2-0012" title="GigolaevaL , KrivorotkoP , ZhiltsovaE , DashyanG , ChadjimatovaS , PesotckiyR , et al. Neoadjuvant chemotherapy regimens for triple negative breast cancer patients. Breast2019;44(Suppl 1):S70. ">Gigolaeva 2019</a>; <a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a>). There was no difference between subgroups (P = 0.35). </p> </li> </ul> </p> </section> <section id="CD014805-sec-0091"> <h6 class="title">Potentially confounding treatments in intervention arm</h6> <p>Multiple studies tested interventions combined with platinum chemotherapy. These treatments were viewed as potentially confounding in this sensitivity analysis. However, notably, all of these extra treatments have subsequently been found to be ineffective (<a href="./references#CD014805-bbs2-0055" title="Banys-PaluchowskiM , RuckhäberleE , SchützF , KrawczykN , FehmT . Metronomic chemotherapy for primary non-metastatic breast cancer – a systematic review of the literature. Geburtshilfe Frauenheilkd2017;77(2):142-8.">Banys‐Paluchowski 2017</a>; <a href="./references#CD014805-bbs2-0057" title="LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509.">BrighTNess</a>; <a href="./references#CD014805-bbs2-0085" title="ShepherdJH , BallmanK , PolleyMC , CampbellJD , FanC , SelitskyS , et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. Journal of Clinical Oncology2022;40(12):1323-34.">Shepherd 2022</a>). The studies of note included <a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a>, which provided the intervention group with a further 12 months of metronomic chemotherapy; <a href="./references#CD014805-bbs2-0003" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;36(15 Suppl):519. ">BrighTNess comparison 1</a>, which included veliparib; and <a href="./references#CD014805-bbs2-0005" title="GolshanM , CirrincioneCT , CareyLA , SikovWM , BerryDA , BursteinHJ , et al. Impact of neoadjuvant therapy on breast conservation rates in triple negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). Journal of Clinical Oncology2015;33(15 Suppl):1007. GolshanM , CirrincioneCT , SikovWM , BerryDA , JasinskiS , WeisbergTF , et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals of Surgery2015;262(3):434-9. NCT00861705. Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. clinicaltrials.gov/show/NCT00861705 (first received 13 March 2009). ShepherdJH , BallmanK , PolleyMC , CampbellJD , FanC , SelitskyS , et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. Journal of Clinical Oncology2022;40(12):1323-34. ShepherdJH , HyslopT , FanC , MartinezAF , ParkerJ , HoadleyK , et al. Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival. Cancer Research2021;81(4 Suppl):PD9-03. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneC , TolaneyS , et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research2013;73(24 Suppl):S5-01. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Cancer Research2016;76(4 Suppl):S2-05. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology2015;33(1):13-21. SikovWM , PerouCM , GolshanM , CollyarD , BerryDA , HahnOM , et al. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):TPS110. SikovWM , PolleyMY , TwohyE , PerouCM , SinghB , BerryDA , et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple negative breast cancer (TNBC). Journal of Clinical Oncology2019;37(15 Suppl):591. ">CALGB 40603</a>, which provided one group with bevacizumab. </p> <p>The sensitivity analysis for outcome measures revealed the following.</p> <p> <ul id="CD014805-list-0017"> <li> <p>The DFS effect was similar when studies with potentially confounding extra treatments were removed (HR 0.60, 95% CI 0.50 to 0.71). This was done by removing <a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a> and <a href="./references#CD014805-bbs2-0003" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;36(15 Suppl):519. ">BrighTNess comparison 1</a>, and using only the bevacizumab‐free arm of CALGB‐40603. </p> </li> <li> <p>This OS effect was similar when two studies with potentially confounding extra treatments (<a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a>; <a href="./references#CD014805-bbs2-0003" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;36(15 Suppl):519. ">BrighTNess comparison 1</a>) were removed (HR 0.64, 95% CI 0.52 to 0.79). </p> </li> <li> <p>The likelihood of pCR was similar when one study with potentially confounding extra treatment (<a href="./references#CD014805-bbs2-0003" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;36(15 Suppl):519. ">BrighTNess comparison 1</a>) was removed (HR 1.49, 95% CI 1.35 to 1.63). </p> </li> </ul> </p> </section> <section id="CD014805-sec-0092"> <h6 class="title">High or unclear risk of bias</h6> <p> <ul id="CD014805-list-0018"> <li> <p>All studies reporting DFS or OS had an overall low risk of bias so a sensitivity analysis was not performed for these outcomes. </p> </li> <li> <p>For pCR, the effect of removing two studies with most or all domains at unclear risk (<a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a>; <a href="./references#CD014805-bbs2-0012" title="GigolaevaL , KrivorotkoP , ZhiltsovaE , DashyanG , ChadjimatovaS , PesotckiyR , et al. Neoadjuvant chemotherapy regimens for triple negative breast cancer patients. Breast2019;44(Suppl 1):S70. ">Gigolaeva 2019</a>) was minimal on the likelihood of pCR (RR 1.44, 95% CI 1.30 to 1.59). </p> </li> </ul> </p> </section> <section id="CD014805-sec-0093"> <h6 class="title">Outcomes with considerably heterogeneity</h6> <p>We applied a random‐effects model to the two outcomes with considerable heterogeneity (i.e. an I<sup>2</sup> value of 75% to 100%). Both of these analyses resulted in a similar magnitude RR, but with wider CIs. </p> <p> <ul id="CD014805-list-0019"> <li> <p>Participants requiring a dose reduction: RR 2.18, 95% CI 1.08 to 4.41 compared to RR 1.77, 95% CI 1.56 to 2.02 with a fixed‐effect model. </p> </li> <li> <p>Neutropenia: RR 1.68, 95% CI 1.12 to 2.52 compared to RR 1.53, 95% CI 1.43 to 1.63 with a fixed‐effect model. </p> </li> </ul> </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014805-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014805-sec-0094"></div> <section id="CD014805-sec-0095"> <h3 class="title" id="CD014805-sec-0095">Summary of main results</h3> <p>Platinum‐based chemotherapy using carboplatin in the adjuvant or neoadjuvant setting improved long‐term outcomes of DFS and OS in early TNBC, regardless of the examined subgroups. This was at the cost of more frequent chemotherapy delays and dose reductions, and greater haematological toxicity as presented in <a href="./full#CD014805-tbl-0003">summary of findings Table 3</a>. There was benefit from platinum when platinum agents were added to both anthracycline‐containing regimens and in anthracycline‐free regimens. </p> <p>Though there are certainly increased haematological toxicities associated with platinum chemotherapy, permanent toxicity such as grade III/IV neuropathy and treatment‐related death were not different between groups. These trials did not report important quality‐of‐life measures. </p> <p>Attempts in this review to refine subgroups of triple‐negative biology, such as those with BRCA mutations or altered HRD status, have higher benefit from platinum therapy found no predictive role. The certainty of this evidence was low since numbers were low. Only one study assessed the role of HRD status on efficacy outcomes in our analysis. It remains unclear if more modern and focused HRD testing may offer better biomarkers for participants who will benefit from platinum chemotherapy. We were also unable to identify if there may be a subgroup of participants who might not benefit, and for whom de‐escalation therapy might be appropriate. </p> </section> <section id="CD014805-sec-0096"> <h3 class="title" id="CD014805-sec-0096">Overall completeness and applicability of evidence</h3> <p>These results were generally applicable to people with early TNBC, allowing for the trial to define hormone receptor cut‐offs which ranged from 1% to 10%. The range of ages captured in these trials was from 19 to 82 years. Outcomes based on age were not available. Information on participant gender was not collected. </p> <p>While racial background of participants was not captured in our analysis, these trials took place in several countries in Europe, Asia and the US. Black and African participants are likely to be a notable ethnic gap in this meta‐analysis given the dearth of trials occurring on the African continent and the low participation rates of Black Americans in cancer clinical trials (<a href="./references#CD014805-bbs2-0054" title="AwidiM , Al HadidiS . Participation of Black Americans in cancer clinical trials: current challenges and proposed solutions. JCO Oncology Practice2021;17(5):265-71.">Awidi 2021</a>). </p> <p>Recruitment of the included trials started between six and 16 years ago, and as such the standard therapy arms may not reflect current international standards. This is a shifting target, and the advent of new treatments used in early TNBC such as immunotherapy and PARP inhibitors, as well as the clinical heterogeneity of chemotherapy used in these studies, means the best regimen and timing of platinum chemotherapy remains unclear. This review also does not provide insight into the use of post‐neoadjuvant capecitabine, which is currently part of standard care for people with residual disease after neoadjuvant chemotherapy for TNBC. <a href="./references#CD014805-bbs2-0024" title="MayerIA , ZhaoF , ArteagaCL , SymmansWF , ParkBH , BurnetteBL , et al. A randomized phase III postoperative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131. Journal of Clinical Oncology2021;39(15 Suppl):605. MayerIA , ZhaoF , ArteagaCL , SymmansWF , ParkBH , BurnetteBL , et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. Journal of Clinical Oncology2021;39(23):2539-51. NCT02445391. Platinum based chemotherapy or capecitabine in treating patients with residual triple-negative basal-like breast cancer following neoadjuvant chemotherapy. clinicaltrials.gov/show/NCT02445391 (first received 15 May 2015). ">ECOG‐ACRIN EA1131</a> assessed whether platinum chemotherapy can replace capecitabine, but this study was excluded from this review given the study population included only those with residual disease. Further research into this area is warranted, particularly given the increasing number of drugs used in TNBC and increasing interest in biomarker‐directed treatment rationalisation. </p> <p>Many of the studies examining neoadjuvant chemotherapy only report pCR, which is a surrogate marker for long‐term benefit. Several studies did not report on certain important toxicity outcomes such as febrile neutropenia, renal impairment and treatment‐related death. The number of participants in subgroups of BRCA mutation status, HRD status and lymph node status were relatively small and may not have provided sufficient power to sufficiently address whether there are different outcomes for these groups. Recent data suggest that a DFS and OS benefit only exists for people aged less than 50 years (<a href="./references#CD014805-bbs2-0068" title="GuptaS , NairNS , HawaldarRW , VanmaliV , ParmarV , GuliaS , et al. Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: a phase III randomized controlled trial. San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, Texas.">Gupta 2022</a>); however, we did not include age as a subgroup analysis, neither were there outcome data reported stratified based on age in the studies analysed. </p> <p>No quality of life outcomes were reported. This is an important measure particularly when assessing outcomes which are more accurately reported by participants, such as fatigue and effects on cognition. As such, we may be missing important impacts of the addition of platinum chemotherapy on participants of these clinical trials both acutely and in the longer term. </p> <p>Use of platinum chemotherapy is variable, and at the time of writing is still not routinely recommended in NCCN or European Society for Medical Oncology guidelines. A lack of DFS and OS benefit is often cited as a reservation to the routine use of platinum chemotherapy. This review presents relevant, adequately powered outcome data to support the use of platinum chemotherapy in early TNBC, acknowledging the increased rate of haematological toxicity. </p> </section> <section id="CD014805-sec-0097"> <h3 class="title" id="CD014805-sec-0097">Quality of the evidence</h3> <p>This systematic review provides evidence from 20 studies, with 4468 participants, and provides high‐certainty evidence supporting the addition of platinum chemotherapy in the neoadjuvant and adjuvant settings with an increase in DFS and OS. </p> <p>An important methodological limitation in this meta‐analysis is that all but one of the included trials adopted an open‐label design. It is considered that the efficacy outcomes of DFS, OS and pCR are unlikely to be affected by a lack of blinding. However, the risk of bias may be increased for more subjective toxicity assessments such as nausea and neuropathy. </p> <p>Clinical heterogeneity was present in the chemotherapy regimens, and in the type, timing and duration of the platinum agent. Some trials used platinum in addition to an existing regimen (e.g. adding carboplatin to doxorubicin‐cyclophosphamide followed by paclitaxel), while others used platinum in place of other agents (e.g. comparing carboplatin‐docetaxel to doxorubicin‐cyclophosphamide followed by paclitaxel) or used as a single agent. In other trials, extra treatments such as veliparib, bevacizumab and metronomic chemotherapy were also added. </p> <p>Despite the clinical heterogeneity, this meta‐analysis demonstrated generally high‐certainty, consistent evidence for the primary outcome measures of DFS and OS. However, there was a significant degree of heterogeneity in many of the treatment delivery and toxicity outcome categories, including chemotherapy delays, dose reductions, neutropenia and febrile neutropenia. This resulted in downgrading of the certainty of evidence, as demonstrated in <a href="./full#CD014805-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD014805-sec-0098"> <h3 class="title" id="CD014805-sec-0098">Potential biases in the review process</h3> <p>Using standard Cochrane search methods, we identified numerous trial records. Our final 20 trials were consistent with previous reviews and studies cited in local and international guidelines. There is a high likelihood that all relevant trials were identified. </p> <p>Unfortunately, not all relevant data could be obtained. Notably, multiple studies listed outcomes including DFS, OS and quality of life which were never published. The lack of DFS and OS data reported in particular for cisplatin could indicate publication bias, given its failure to produce a benefit in pCR. </p> <p>In this review, we included studies with intervention treatments in addition to carboplatin, such as veliparib, bevacizumab and metronomic chemotherapy. While these trials were potentially confounding, a sensitivity analysis showed that removing these trials had a minimal impact on the pooled outcome analysis. </p> <p>Several studies recruited subgroups other than TNBC. These trials were only included if outcome measures were reported separately or only included less than 20% of participants with non‐TNBC. However, treatment completion and toxicity information were not always reported for each breast cancer subtype. As such, we presented these measures for the whole group who were receiving the same treatment, which may be a potential source of bias. </p> </section> <section id="CD014805-sec-0099"> <h3 class="title" id="CD014805-sec-0099">Agreements and disagreements with other studies or reviews</h3> <p>Early meta‐analyses of randomised, retrospective and prospective studies by <a href="./references#CD014805-bbs2-0079" title="PetrelliF , CoinuA , BorgonovoK , CabidduM , GhilardiM , LonatiV , et al. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Research and Treatment2014;144(2):223-32.">Petrelli 2014</a>, <a href="./references#CD014805-bbs2-0080" title="PoggioF , BruzzoneM , CeppiM , PondeNF , La ValleG , Del MastroL , et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Annals of Oncology2018;29(7):1497-508.">Poggio 2018</a>, <a href="./references#CD014805-bbs2-0089" title="WangLY , XieH , ZhouH , YaoWX , ZhaoX , WangY . Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials. Saudi Medical Journal2017;38(1):18-23.">Wang 2017</a>, and <a href="./references#CD014805-bbs2-0076" title="PandyJG , Balolong-GarciaJC , Cruz-OrdinarioMV , QueFV . Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer2019;19(1):1065.">Pandy 2019</a> showed an improvement in pCR associated with the use of platinum chemotherapy. None of the listed studies that examined DFS or OS were able to demonstrate a difference from the addition of platinum, likely due to a lack of reporting of these outcome measures and immature follow‐up. </p> <p>More recently, <a href="./references#CD014805-bbs2-0082" title="SalehRR , NadlerMB , DesnoyersA , MetiN , FazelzadR , AmirE . Platinum-based chemotherapy in early-stage triple negative breast cancer: a meta-analysis. Cancer Treatment Reviews2021;100:102283.">Saleh 2021</a> performed a meta‐analysis of 14 randomised or retrospective trials of platinum‐based perioperative chemotherapy. They found platinum chemotherapy was associated with an improvement in DFS but not OS. The inclusion of retrospective trials may have been a confounder in this analysis. </p> <p>Our findings have aligned with those of <a href="./references#CD014805-bbs2-0056" title="BianL , YuP , WenJ , LiN , HuangW , XieX , et al. Survival benefit of platinum-based regimen in early stage triple negative breast cancer: a meta-analysis of randomized controlled trials. NPJ Breast Cancer2021;7(1):157.">Bian 2021</a>, who found in seven randomised controlled trials that platinum‐based perioperative chemotherapy improved both DFS and OS for people with early TNBC. They explored subgroups including the setting of chemotherapy (adjuvant versus neoadjuvant) and lymph node status. This was the first meta‐analysis to demonstrate an OS benefit. Our review builds on the findings of this study, including more trials and adding additional subgroup analyses including BRCA, HRD, hormone receptor IHC % positive thresholds, chemotherapy content and timing. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014805-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD014805-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD014805-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-FIG-03" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD014805-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD014805-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-FIG-05" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD014805-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-FIG-06" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD014805-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Neoadjuvant, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Neoadjuvant, Outcome 1: Disease‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Neoadjuvant, Outcome 2: Overall survival" data-id="CD014805-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Neoadjuvant, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Neoadjuvant, Outcome 3: Pathological complete response" data-id="CD014805-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Neoadjuvant, Outcome 3: Pathological complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Adjuvant, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Adjuvant, Outcome 1: Disease‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Adjuvant, Outcome 2: Overall survival" data-id="CD014805-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Adjuvant, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Adjuvant, Outcome 3: Disease‐free survival without Wu 2018" data-id="CD014805-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Adjuvant, Outcome 3: Disease‐free survival without Wu 2018</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 1: Participants requiring chemotherapy delays" data-id="CD014805-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 1: Participants requiring chemotherapy delays </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 2: Participants requiring dose reduction" data-id="CD014805-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 2: Participants requiring dose reduction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 3: Early cessation of treatment" data-id="CD014805-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 3: Early cessation of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 4: Neutropenia" data-id="CD014805-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 4: Neutropenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 5: Febrile neutropenia" data-id="CD014805-fig-0017" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 5: Febrile neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 6: Anaemia" data-id="CD014805-fig-0018" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 6: Anaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 7: Thrombocytopenia" data-id="CD014805-fig-0019" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 7: Thrombocytopenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 8: Neuropathy" data-id="CD014805-fig-0020" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 8: Neuropathy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 9: Nausea" data-id="CD014805-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 9: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 10: Renal impairment" data-id="CD014805-fig-0022" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 10: Renal impairment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 11: Treatment‐related death" data-id="CD014805-fig-0023" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 11: Treatment‐related death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 12: Participants requiring dose reduction – random effects" data-id="CD014805-fig-0024" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 12: Participants requiring dose reduction – random effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: All studies: treatment adherence and toxicities, Outcome 13: Neutropenia – random effects" data-id="CD014805-fig-0025" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: All studies: treatment adherence and toxicities, Outcome 13: Neutropenia – random effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: BRCA mutation status, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0026" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: BRCA mutation status, Outcome 1: Disease‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: BRCA mutation status, Outcome 2: Pathological complete response" data-id="CD014805-fig-0027" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: BRCA mutation status, Outcome 2: Pathological complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Homologous recombination deficiency (HRD) status, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0028" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Homologous recombination deficiency (HRD) status, Outcome 1: Disease‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Homologous recombination deficiency (HRD) status, Outcome 2: Pathological complete response" data-id="CD014805-fig-0029" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Homologous recombination deficiency (HRD) status, Outcome 2: Pathological complete response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Lymph node status, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0030" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Lymph node status, Outcome 1: Disease‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Lymph node status, Outcome 2: Pathological complete response" data-id="CD014805-fig-0031" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Lymph node status, Outcome 2: Pathological complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Type of platinum agent, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0032" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Type of platinum agent, Outcome 1: Disease‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Type of platinum agent, Outcome 2: Overall survival" data-id="CD014805-fig-0033" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Type of platinum agent, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Type of platinum agent, Outcome 3: Pathological complete response" data-id="CD014805-fig-0034" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Type of platinum agent, Outcome 3: Pathological complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Same backbone chemotherapy with or without platinum, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0035" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Same backbone chemotherapy with or without platinum, Outcome 1: Disease‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Same backbone chemotherapy with or without platinum, Outcome 2: Overall survival" data-id="CD014805-fig-0036" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Same backbone chemotherapy with or without platinum, Outcome 2: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Same backbone chemotherapy with or without platinum, Outcome 3: Pathological complete response" data-id="CD014805-fig-0037" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Same backbone chemotherapy with or without platinum, Outcome 3: Pathological complete response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anthracycline content of chemotherapy, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0038" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Anthracycline content of chemotherapy, Outcome 1: Disease‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anthracycline content of chemotherapy, Outcome 2: Overall survival" data-id="CD014805-fig-0039" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Anthracycline content of chemotherapy, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anthracycline content of chemotherapy, Outcome 3: Pathological complete response" data-id="CD014805-fig-0040" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Anthracycline content of chemotherapy, Outcome 3: Pathological complete response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Schedule of platinum agent, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0041" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Schedule of platinum agent, Outcome 1: Disease‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Schedule of platinum agent, Outcome 2: Overall survival" data-id="CD014805-fig-0042" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Schedule of platinum agent, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Schedule of platinum agent, Outcome 3: Pathological complete response" data-id="CD014805-fig-0043" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Schedule of platinum agent, Outcome 3: Pathological complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Triple negative definition – hormone receptor immunohistochemistry cut‐off, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0044" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Triple negative definition – hormone receptor immunohistochemistry cut‐off, Outcome 1: Disease‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Triple negative definition – hormone receptor immunohistochemistry cut‐off, Outcome 2: Overall survival" data-id="CD014805-fig-0045" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Triple negative definition – hormone receptor immunohistochemistry cut‐off, Outcome 2: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Triple negative definition – hormone receptor immunohistochemistry cut‐off, Outcome 3: Pathological complete response" data-id="CD014805-fig-0046" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Triple negative definition – hormone receptor immunohistochemistry cut‐off, Outcome 3: Pathological complete response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Platinum‐based chemotherapy versus platinum free chemotherapy without Nasr 2015 or BrigTNess comparison 1, and using bevacizumab‐free CALGB, Outcome 1: Disease‐free survival" data-id="CD014805-fig-0047" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Platinum‐based chemotherapy versus platinum free chemotherapy without Nasr 2015 or BrigTNess comparison 1, and using bevacizumab‐free CALGB, Outcome 1: Disease‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Platinum‐based chemotherapy versus platinum free chemotherapy without Nasr 2015 or BrigTNess comparison 1, and using bevacizumab‐free CALGB, Outcome 2: Overall survival" data-id="CD014805-fig-0048" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Platinum‐based chemotherapy versus platinum free chemotherapy without Nasr 2015 or BrigTNess comparison 1, and using bevacizumab‐free CALGB, Outcome 2: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014805-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/urn:x-wiley:14651858:media:CD014805:CD014805-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Platinum‐based chemotherapy versus platinum free chemotherapy without Nasr 2015 or BrigTNess comparison 1, and using bevacizumab‐free CALGB, Outcome 3: Pathological complete response" data-id="CD014805-fig-0049" src="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_t/tCD014805-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Platinum‐based chemotherapy versus platinum free chemotherapy without Nasr 2015 or BrigTNess comparison 1, and using bevacizumab‐free CALGB, Outcome 3: Pathological complete response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/media/CDSR/CD014805/image_n/nCD014805-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014805-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Platinum‐containing chemotherapy compared to chemotherapy without platinum in neoadjuvant therapy for early triple‐negative breast cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐containing chemotherapy compared to chemotherapy without platinum in neoadjuvant therapy for early triple‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neoadjuvant therapy for early triple‐negative breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> platinum‐containing chemotherapy<br/><b>Comparison:</b> chemotherapy without platinum </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with chemotherapy without platinum</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with platinum‐containing chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DFS at 2 years</b><br/>assessed with: risk of recurrence<br/>follow‐up: range 3 years to 7.9 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.63</b><br/>(0.53 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1966<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b><br/>(117 to 162) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DFS at 5 years</b> </p> <p>follow‐up: range 3 years to 7.9 years</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.63</b><br/>(0.53 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1966<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>301 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b><br/>(173 to 235) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OS at 2 years</b><br/>assessed with: risk of death<br/>follow‐up: range 1.7 years to 7.9 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.69</b><br/>(0.55 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1973<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(27 to 41) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OS at 5 years</b><br/>follow‐up: range 1.7 years to 7.9 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.69</b><br/>(0.55 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1973<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b><br/>(110 to 166) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pathological complete response</b><br/>follow‐up: range 6 weeks to 9.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>305 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>440 per 1000</b><br/>(400 to 485) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.44</b><br/>(1.31 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3083<br/>(15 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>DFS:</b> disease‐free survival; <b>HR:</b> hazard ratio; <b>OS:</b> overall survival; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434916258784592377" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434916258784592377</a>. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Platinum‐containing chemotherapy compared to chemotherapy without platinum in neoadjuvant therapy for early triple‐negative breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014805-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Platinum‐containing chemotherapy compared to chemotherapy without platinum in adjuvant therapy for early triple‐negative breast cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐containing chemotherapy compared to chemotherapy without platinum in adjuvant therapy for early triple‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adjuvant therapy for early triple‐negative breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> platinum‐containing chemotherapy<br/><b>Comparison:</b> chemotherapy without platinum </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with chemotherapy without platinum</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with platinum‐containing chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DFS at 2 years</b> </p> <p>assessed with: risk of recurrence<br/>follow‐up: range 4.3 years to 8 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.69</b><br/>(0.54 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1256<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b><br/>(83 to 131) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DFS at 5 years</b> <br/>follow‐up: range 4.3 years to 8 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.69</b><br/>(0.54 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1256<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b><br/>(95 to 150) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OS at 2 years</b><br/>assessed with: risk of death<br/>follow‐up: range 4.3 years to 8 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.70</b><br/>(0.50 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1256<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b><br/>(27 to 50) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OS at 5 years</b><br/>follow‐up: range 4.3 years to 8 years </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.70</b><br/>(0.50 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1256<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/>(41 to 78) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>DFS:</b> disease‐free survival; <b>HR:</b> hazard ratio; <b>OS:</b> overall survival; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434981690495911791" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434981690495911791</a>. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Platinum‐containing chemotherapy compared to chemotherapy without platinum in adjuvant therapy for early triple‐negative breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014805-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Platinum‐containing chemotherapy compared to chemotherapy without platinum for early triple‐negative breast cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐containing chemotherapy compared to chemotherapy without platinum for early triple‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> early triple‐negative breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> platinum‐containing chemotherapy<br/><b>Comparison:</b> chemotherapy without platinum </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with chemotherapy without platinum</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with platinum‐containing chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants requiring chemotherapy delays</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>154 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1000</b><br/>(263 to 454) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.23</b><br/>(1.70 to 2.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1053<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants requiring dose reduction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>278 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b><br/>(433 to 561) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.77</b><br/>(1.56 to 2.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2055<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anaemia (grade III/IV)</b><br/>follow‐up: range 6 weeks to 38 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b><br/>(72 to 152) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.20</b><br/>(5.66 to 11.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4757<br/>(19 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile neutropenia (grade III/IV)</b><br/>follow‐up: range 12 weeks to 38 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><br/>(50 to 83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b><br/>(0.89 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3771<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Renal impairment (grade III/IV)</b><br/>follow‐up: range 6 weeks to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>4 studies reported renal impairment. 1 study reported 2 events in 60 people in the platinum arm (3%) and 0 events in 57 people in the non‐platinum arm. None of the other studies reported any grade III/IV events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>4 studies collected quality of life information using validated questionnaires but none of these reported data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434915765589228984" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_434915765589228984</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for inconsistency due to marked variability between trials, demonstrated by a wide range of hazard ratios and confidence intervals with minimal overlap. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Platinum‐containing chemotherapy compared to chemotherapy without platinum for early triple‐negative breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014805-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of the included treatment comparisons</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Year recruitment started</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (platinum‐containing)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platinum agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Same backbone?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adjuvant or neoadjuvant</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hormone receptor IHC cut‐off</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0001" title='GluzO , LiedtkeC , PratA , ChristgenM , GebauerD , KatesRE , et al. Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): results of the randomized WSG ADAPT-TN trial. Journal of Clinical Oncology2017;35(15 Suppl):573. GluzO , NitzU , ChristgenM , GrischkeEM , ForstbauerH , BraunMW , et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Journal of Clinical Oncology2015;33(15 Suppl):1032. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. Journal of the National Cancer Institute2018;110(6):628-37. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: survival results of WSG-ADAPT-TN phase II trial. Journal of Clinical Oncology2018;36(15 Suppl):573. GluzO , NitzU , LiedtkeC , ChristgenM , GrischkeEM , ForstbauerH , et al. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology2018;29(Suppl 8):viii703. GluzO , NitzU , LiedtkeC , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG – ADAPT TN randomized phase II trial. Cancer Research2016;76(4 Suppl):S6-07. GluzO , NitzU , LiedtkeC , PratA , ChristgenM , FeuerhakeF , et al. No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial. Cancer Research2019;79(4 Suppl):GS5-06. HarbeckN , HofmannD , GluzO , KatesRE , KummelS , NudingB , et al. ADAPT: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):TPS655. LiedtkeC , GluzO , NitzU , ChristgenM , SotlarK , GrischkeEM , et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. Oncology Research and Treatment2016;1:53. NCT01815242. Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer - triple negative breast cancer (ADAPT). clinicaltrials.gov/show/NCT01815242 (first received 21 March 2013). NitzU , GluzO , Von SchumannR , HofmannD , KatesRE , KuemmelS , et al. ADAPT – Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Cancer Research.2015;75(9 Suppl):OT3-2-04. '>ADAPT‐TN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nab‐paclitaxel 125 mg/m<sup>2</sup> + carboplatin AUC2 days 1 and 8 every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nab‐paclitaxel 125 mg/m<sup>2</sup> + gemcitabine 1000 mg/m<sup>2</sup> days 1 and 8 every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC2 every week (days 1 and 8 every 21 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0002" title="AndoM , YamauchiH , AogiK , ShimizuS , IwataH , MasudaN , et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment2014;145(2):401-9. IwaseM , AndoM , AogiK , ArugaT , InoueK , ShimomuraA , et al. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment2020;180(3):687-94. TamuraK , HashimotoJ , TsudaH , YoshidaM , YamauchiH , AogiK , et al. Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. Journal of Clinical Oncology2014;32(15 Suppl):1017. UMIN000003355. Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer. Center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004074 (first received 22 March 2010). ">Ando 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks for 4 cycles + paclitaxel 80 mg/m<sup>2</sup> days 1, 8, 15 for 4 cycles, followed by 4 cycles of cyclophosphamide 500 mg/m<sup>2</sup>, epirubicin 100 mg/m<sup>2</sup> and fluorouracil 500 mg/m<sup>2</sup> every 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> days 1, 8, 15 for 4 cycles followed by 4 cycles of cyclophosphamide 500 mg/m<sup>2</sup>, epirubicin 100 mg/m<sup>2</sup> and fluorouracil 500 mg/m<sup>2</sup> every 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0003" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;36(15 Suppl):519. ">BrighTNess comparison 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly + carboplatin AUC6 every 3 weeks for 12 weeks + veliparib 50 mg twice a day, followed by doxorubicin 60 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly for 12 weeks, followed by doxorubicin 60 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0004" title="EudraCT2013-002377-21. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21 (first received 17 November 2014). FilhoOM , StoverDG , AsadS , AnsellPJ , WatsonM , LoiblS , et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncology2021;7(4):603-8. GeyerCE , SikovWM , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology2022;33(4):384-94. GolshanM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , WolmarkN , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from an international randomized trial (BrighTNess). Journal of Clinical Oncology2017;35(15 Suppl):514. GolshanM , LoiblS , WongSM , HouberJB , O'ShaughnessyJ , RugoHS , et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surgery2020;155(3):e195410. GolshanM , WongSM , LoiblS , HuoberJB , O'ShaughnessyJ , RugoHS , et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: results from the phase III BrighTNess trial. European Journal of Surgical Oncology2020;46(2):223-8. LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. LoiblS , SikovW , HuoberJ , RugoHS , WolmarkN , O'ShaughnessyJ , et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after &gt;=4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology2021;32(Suppl 5):S408. Metzger-FilhoO , CollierK , AsadS , AnsellPJ , WatsonM , BaeJ , et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. NPJ Breast Cancer2021;7(1):142. NCT02032277. A study evaluating safety and efficacy of the addition of ABT-888 plus carboplatin versus the addition of carboplatin to standard chemotherapy versus standard chemotherapy in subjects with early stage triple negative breast cancer. clinicaltrials.gov/show/NCT02032277 (first received 10 January 2014). TelliML , MetzgerO , TimmsK , EvansB , VogelD , WeiH , et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal of Clinical Oncology2018;35(15 Suppl):519. ">BrighTNess comparison 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly + carboplatin AUC6 every 3 weeks for 12 weeks, followed by doxorubicin 60 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly for 12 weeks, followed by doxorubicin 60 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0005" title="GolshanM , CirrincioneCT , CareyLA , SikovWM , BerryDA , BursteinHJ , et al. Impact of neoadjuvant therapy on breast conservation rates in triple negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). Journal of Clinical Oncology2015;33(15 Suppl):1007. GolshanM , CirrincioneCT , SikovWM , BerryDA , JasinskiS , WeisbergTF , et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals of Surgery2015;262(3):434-9. NCT00861705. Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. clinicaltrials.gov/show/NCT00861705 (first received 13 March 2009). ShepherdJH , BallmanK , PolleyMC , CampbellJD , FanC , SelitskyS , et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. Journal of Clinical Oncology2022;40(12):1323-34. ShepherdJH , HyslopT , FanC , MartinezAF , ParkerJ , HoadleyK , et al. Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival. Cancer Research2021;81(4 Suppl):PD9-03. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneC , TolaneyS , et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research2013;73(24 Suppl):S5-01. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Cancer Research2016;76(4 Suppl):S2-05. SikovWM , BerryDA , PerouCM , SinghB , CirrincioneCT , TolaneySM , et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology2015;33(1):13-21. SikovWM , PerouCM , GolshanM , CollyarD , BerryDA , HahnOM , et al. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):TPS110. SikovWM , PolleyMY , TwohyE , PerouCM , SinghB , BerryDA , et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple negative breast cancer (TNBC). Journal of Clinical Oncology2019;37(15 Suppl):591. ">CALGB 40603</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly + carboplatin AUC6 every 3 weeks for 12 weeks followed by doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 weeks for 4 cycles ± bevacizumab 10 mg/kg every 2 weeks for 9 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly for 12 weeks followed by doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 weeks for 4 cycles ± bevacizumab 10 mg/kg every 2 weeks for 9 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0008" title="AlbaE , ChaconJI , LluchA , AntonA , EstevezL , CirauquiB , et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Research and Treatment2012;136(2):487-93. AlbaE , ChaconJI , LluchA , Garcia-EstevezL , AntonA , CirauquiB , et al. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03 – a multicenter, randomized phase II study. Journal of Clinical Oncology2011;29(15 Suppl):1015. NCT00432172. Selective neoadjuvant treatment according to immunohistochemical subtype for HER2 negative breast cancer patients. clinicaltrials.gov/show/NCT00432172 (first received 7 February 2007). SantonjaA , AlbanellJ , ChaconJI , LluchA , Sanchez-MunozA , RojoF , et al. Triple-negative breast cancer subtypes and pathologic complete-response rate to neoadjuvant chemotherapy: results from the GEICAM/2006-2003 study. Journal of Clinical Oncology2014;32(15 Suppl):1024. ">GEICAM 2006‐03</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles followed by docetaxel 75 mg/m<sup>2</sup> + carboplatin AUC6 every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles followed by docetaxel 75 mg/m<sup>2</sup> every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0009" title="NCT02125344. A phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). clinicaltrials.gov/show/NCT02125344. (first received 29 April 2014). PohlE , SchneeweissA , HaukeJ , MoebusV , FurlanettoJ , DenkertC , et al. Germline mutation status and therapy response in patients with triple negative breast cancer (TNBC): results of the GeparOcto study. Annals of Oncology2018;29(8 Suppl):viii77. Pohl-RescignoE , HaukeJ , LoiblS , MobusV , DenkertC , FaschingPA , et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncology2020;6(5):744-8. SchneeweissA , MobusV , TeschH , HanuschC , DenkertC , LubbeK , et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. European Journal of Cancer2019;106:181-92. SchneeweissA , MobusV , TeschH , KlareP , DenkertC , KastK , et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology2020;31(4 Suppl):S303. SchneeweissA , MoebusV , BlohmerJU , Dan CostaS , DenkertC , EidtmannH , et al. A randomized phase III trial comparing two dose-dense dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Journal of Clinical Oncology2015;33(15 Suppl):TPS1101. SchneeweissA , MoebusV , TeschH , HanuschC , DenkertC , LuebbeK , et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high risk early breast cancer (GeparOcto). Journal of Clinical Oncology2017;35(15 Suppl):518. ">GeparOcto</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> + non‐pegylated liposomal doxorubicin 20 mg/m<sup>2</sup> + carboplatin AUC1.5 weekly for 18 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 150 mg/m<sup>2</sup> + paclitaxel 225 mg/m<sup>2</sup> + cyclophosphamide 2000 mg/m<sup>2</sup> every 2 weeks for 3 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC1.5 every week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0010" title="EUDRACT2015-003509-41-DE. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD) (GeparOla). clinicaltrialsregister.eu/ctr-search/search?query=2015-003509-41 (first received 1 August 2016). FaschingPA , BlohmerJU , BurchardiN , CostaSD , DenkertC , HanuschC , et al. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. Journal of Clinical Oncology2016;34(15 Suppl):TPS1096. FaschingPA , JackischC , RhiemK , SchneeweissA , KlareP , HanuschC , et al. GeparOLA: a randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer. Journal of Clinical Oncology2019;37(15 Suppl):506. FaschingPA , LinkT , HaukeJ , SeitherF , JackischC , KlareP , et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Annals of Oncology2021;32(1):49-57. HaukeJ , ErnstC , FaschingPA , JackischC , SeitherF , KlareP , et al. Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: results of the GeparOLA study (NCT02789332). Annals of Oncology2020;31(4 Suppl):S313. NCT02789332. Assessing the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency. clinicaltrials.gov/show/NCT02789332 (first received 3 June 2016). ">GeparOLA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> + carboplatin AUC2 weekly for 12 weeks followed by epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly + olaparib 100 mg twice a day for 12 weeks followed by epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC2 every week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0011" title="Darb-EsfahaniS , WeichertW , DenkertC , vonMinckwitzG , NekljudovaV , LindnerJ , et al. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – a translational subproject of the GeparSixto trial. Annals of Oncology2015;26(Suppl 3):III15. DenkertC , LoiblS , SalatC , SinnBV , SchemC , EndrisV , et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Research2013;73(24 Suppl):S1-06. DenkertC , vonMinckwitzG , BraseJC , Darb-EsfahaniS , GadeS , KronenwettR , et al. Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: prediction of response to carboplatin-based chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):510. DenkertC , vonMinckwitzG , BraseJC , SinnBV , GadeS , KronenwettR , et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology2015;33(9):983-91. EUDRAC2011-000553-23-DE. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer – GeparSixto. clinicaltrialsregister.eu/ctr-search/search?query=2011-000553-23 (first received 29 September 2011). GuoS , LoiblS , vonMinckwitzG , Darb-EsfahaniS , LedererB , DenkertC . PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Research2020;52(3):689-96. HahnenE , LedererB , HaukeJ , LoiblS , KroberS , SchneeweissA , et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology2017;3(10):1378-85. Llop-GuevaraA , LoiblS , VillacampaG , VladimirovaV , SchneeweissA , KarnT , et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Annals of Oncology2021;32(12):1590-6. LoiblS , DenkertC , LoiS , AndreF , MuellerB , SchneeweissA , et al. PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):11061. LoiblS , DenkertC , SchneeweisA , PaepkeS , LehmannA , RezaiM , et al. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer-prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Research2013;73(24 Suppl):S4-06. LoiblS , WeberKE , TimmsKM , ElkinEP , HahnenE , FaschingPA , et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Annals of Oncology2018;29(12):2341-7. NCT01426880. Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). clinicaltrials.gov/show/NCT01426880 (first received 1 September 2001). StevicI , MullerV , WeberK , FaschingPA , KarnT , MarmeF , et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine2018;16(1):179. UntchM , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Annals of Oncology2017;28(Suppl 5):V49. vonMinckwitzG , HahnenE , FaschingPA , HaukeJ , SchneeweisA , SalatC , et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. Journal of Clinical Oncology2014;32(15 Suppl):1005. vonMinckwitzG , LoiblS , SchneeweissA , SalatCT , RezaiM , ZahmDM , et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Research2016;76(4 Suppl):S2-04. vonMinckwitzG , O'ShaughnessyJ , WinerEP , WolmarkN , GeyerCE , HuoberJB , et al. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). Journal of Clinical Oncology2014;32(15 Suppl):TPS1149. vonMinckwitzG , SchneeweissA , LoiblS , SalatC , DenkertC , RezaiM , et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology2014;15(7):747-56. vonMinckwitzG , SchneeweissA , SalatC , RezaiM , ZahmDM , KlareP , et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Journal of Clinical Oncology2013;31(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , FaschingPA , SchneeweissA , et al. Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. Journal of Clinical Oncology2015;33(15 Suppl):1004. vonMinckwitzG , TimmsK , UntchM , ElkinEP , HahnenE , FaschingPA , et al. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Research2017;77(4 Suppl):P1-09-02. ">GeparSixto</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC2 or 1.5 + paclitaxel 80 mg/m<sup>2</sup> + non‐pegylated liposomal doxorubicin 20 mg/m<sup>2</sup> + bevacizumab 15 mg/kg every 3 weeks for 18 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> + non‐pegylated liposomal doxorubicin 20 mg/m<sup>2</sup> weekly + bevacizumab 15 mg/kg every 3 weeks for 18 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC1.5 or 2 every week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0012" title="GigolaevaL , KrivorotkoP , ZhiltsovaE , DashyanG , ChadjimatovaS , PesotckiyR , et al. Neoadjuvant chemotherapy regimens for triple negative breast cancer patients. Breast2019;44(Suppl 1):S70. ">Gigolaeva 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles followed by carboplatin AUC2 weekly + eribulin 1.4 mg/m<sup>2</sup> or paclitaxel 175 mg/m<sup>2</sup> every 3 weeks for 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles followed by paclitaxel 80 mg/m<sup>2</sup> for 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC2 every week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0013" title="NCT01670500. Cisplatin vs. doxorubicin/cyclophosphamide in BRCA. clinicaltrials.gov/show/NCT01670500 (first received 22 August 2012). TungN , ArunB , HackerMR , HofstatterE , ToppmeyerDL , IsakoffSJ , et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). Journal of Clinical Oncology2020;38(14):1539-48. TungN , ArunB , HofstatterE , HackerMR , ToppmeyerDL , IsakoffSJ , et al. Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: results from the INFORM trial (TBCRC 031). Cancer Research2019;80(4 Suppl):GS6-03. ">INFORM</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin 75 mg/m<sup>2</sup> every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2–3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin 75 mg/m<sup>2</sup> every 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0014" title="LiuMC , SymmansWF , YauC , ChenYY , RugoHS , OlopadeOF , et al. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Research2016;76(4 Suppl):P3-07-49. NCT01042379. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). clinicaltrials.org/show/NCT01042379 (first received 5 January 2010). PrintzC . I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer2014;120(6):773. RugoHS , OlopadeOI , DeMicheleA , YauC , van't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. Van't VeerL , EssermanL , SanilA , GlasA , SeversonT , LinnSC , et al. DNA repair deficiency biomarkers and identification of ER positive breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 trial. Journal of Clinical Oncology2015;33(15 Suppl):521. WolfDM , YauC , SanilA , Brown-SwigartL , HirstG , BuxtonM , et al. Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research2016;76(14 Suppl):858. WolfDM , YauC , SanilA , DaemenA , HeiserL , GrayJ , et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL. Cancer Research2015;75(9 Suppl):P3-06-05. WolfDM , YauC , SanilA , GlasA , PetricoinC , WulfkuhleJ , et al. DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Cancer Research2017;77(4 Suppl):S2-06. ">I‐SPY2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly + veliparib 50 mg twice daily + carboplatin AUC6 every 3 weeks for 12 weeks followed by doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> weekly for 12 weeks followed by doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 or 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0015" title="LiQ , WangJ , MuY , ZhangT , HanY , LuoY , et al. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chinese Journal of Cancer Research2020;32(4):485-96. MuY , ZhangT , HanY , WangJ , LiQ , LuoY , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple negative breast cancer patients with high recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. NCT01378533. The trial comparing dose-dense AC-T with PC as adjuvant therapy for TNBC. clinicaltrials.gov/show/NCT01378533 (first received 22 June 2011). WangJ , LiQ , MuY , ZhangT , HanY , WangJ , et al. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk. Journal of Clinical Oncology2019;37(15 Suppl):528. ">Li 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 150 mg/m<sup>2</sup> + carboplatin AUC3 every 2 weeks for 8 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 80 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 weeks for 4 cycles followed by paclitaxel 175 mg/m<sup>2</sup> every 2 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC3 every 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0016" title="El KadyMS , El NasrK , Moneam OsmanMA , EllithyM . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: a phase III study. Journal of Clinical Oncology2015;33(15 Suppl):e12087. NasrKE , OsmanMA , ElkadyMS , EllithyMA . Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Annals of Translational Medicine2015;3(19):284. ">Nasr 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐fluorouracil 500 mg/m<sup>2</sup> + epirubicin 100 mg/m<sup>2</sup> + cyclophosphamide 500 mg/m<sup>2</sup> every 3 weeks for 3 cycles then docetaxel 80 mg/m<sup>2</sup> + carboplatin AUC5 every 3 weeks for 3 cycles, followed by postoperative radiotherapy, followed by cyclophosphamide 50 mg daily and methotrexate 2.5 mg twice daily on days 1, 2 of each week for 1 year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐fluorouracil 500 mg/m<sup>2</sup> + epirubicin 100 mg/m<sup>2</sup> + cyclophosphamide 500 mg/m<sup>2</sup> every 3 weeks for 3 cycles then docetaxel 80 mg/m<sup>2</sup> every 3 weeks for 3 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0017" title="NCT03154749. TC (docetaxel/carboplatin) versus EC-T (epirubicin/cyclophosphamide followed by docetaxe) as neoadjuvant chemotherapy for triple-negative breast cancer. clinicaltrials.gov/show/NCT03154749 (first received 16 May 2017). ZhangL , WuZ , LinY , LiJ , LiuZ , CaoY , et al. Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label, phase II trial. Journal of Clinical Oncology2022;38(15 Suppl):586. ZhangL , WuZY , LiJ , LinY , LiuZ , CaoY , et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial. International Journal of Cancer2022;150(4):654-62. ">NeoCART</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel 75 mg/m<sup>2</sup> + carboplatin AUC6 every 3 weeks for 6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles followed by docetaxel 100 mg/m<sup>2</sup> every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC6 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0018" title="NCT01216111. Comparison study of adjuvant chemotherapy for Chinese triple negative breast cancer. clinicaltrials.gov/show/NCT01216111 (first received 7 October 2010). NCT04031703. Study comparing paclitaxel plus carboplatin versus anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer (PATTERN). clinicaltrials.gov/show/NCT04031703 (first received 24 July 2019). YuKD , YeFG , HeM , FanL , MaD , MoM , et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncology2020;6(9):1390-6. ">PATTERN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 80 mg/m<sup>2</sup> + carboplatin AUC2 days 1, 8, 15, every 28 days for 6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide 500 mg/m<sup>2</sup> + epirubicin 100 mg/m<sup>2</sup> + fluorouracil 500 mg/m<sup>2</sup> every 3 weeks for 3 cycles followed by docetaxel 100 mg/m<sup>2</sup> every 3 weeks for 3 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC2 every week (days 1, 8, 15 every 28 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0019" title="MayerEL , AbramsonV , JankowitzR , FalksonC , MarcomPK , TrainaT , et al. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Annals of Oncology2020;31(11):1518-25. MayerEL , AbramsonVG , JankowitzRC , FalksonCI , MarcomPK , TrainaTA , et al. TBCRC 030: a randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC- evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2019;37(15 Suppl):507. MayerEL , Vaz-LuisI , RichardsonAL , PerouCM , TungNM , AbramsonVG , et al. TBCRC030: a randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC) – evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology2014;32(15 Suppl):TPS1145. NCT01982448. Cisplatin vs paclitaxel for triple negative breast cancer. clinicaltrials.gov/show/NCT01982448 (first received 13 November 2013). ">TBCRC 030</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin 75 mg/m<sup>2</sup> every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin 60 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 2 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin 75 mg/m<sup>2</sup> every 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0020" title="ChiCTR-TRC-14005019. Docetaxel combined with epirubicin and lobaplatin (TEL) in neoadjuvant chemotherapy for triple negative breast cancer: a prospective randomized controlled clinical study. www.chictr.org.cn/showprojEN.html?proj=4555 (first received 29 May 2014). WuX , TangP , LiS , WangS , LiangY , ZhongL , et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nature Communications2018;9(1):832. ">Wu 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lobaplatin 30 mg/m<sup>2</sup> for 4 cycles + epirubicin 80 mg/m<sup>2</sup> + docetaxel 75 mg/m<sup>2</sup> every 3 weeks presurgery and 2 cycles postsurgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 80 mg/m<sup>2</sup> for 4 cycles + docetaxel 75 mg/m<sup>2</sup> every 3 weeks presurgery and 2 cycles postsurgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lobaplatin 30 mg/m<sup>2</sup> every 3 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0021" title="NCT01276769. Comparison study of neoadjuvant paclitaxel plus carboplatin/epirubicin treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01276769 (first received 13 January 2011). ZhangP , YinY , MoH , ZhangB , WangX , LiQ , et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget2016;7(37):60647-56. ZhangP , YinY , XuB , WangX , ZhangB , LiQ , et al. Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer – a phase II clinical trial. Cancer Research2013;73(24 Suppl):P3-14-07. ">Zhang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 175 mg/m<sup>2</sup> + carboplatin AUC5 every 3 weeks for 4–6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 75 mg/m<sup>2</sup> + paclitaxel 175 mg/m<sup>2</sup> every 3 weeks for 4–6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0022" title="ZhaoY , LiJF , ChuGW . Neoadjuvant chemotherapy regimens for patients with triple-negative breast cancer: TE versus TC. Journal of Practical Oncology2014;29(6):576-8. ">Zhao 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided in translation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paclitaxel 175 mg/m<sup>2</sup> day 1, carboplatin AUC5 day 2, every 3 weeks for 2 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 75 mg/m2 day 1, paclitaxel 175 mg/m<sup>2</sup> day 2, every 3 weeks for 2 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided in translation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014805-bbs2-0023" title="DuF , WangW , WangY , LiM , ZhuA , WangJ , et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Research and Treatment2020;182(1):67-77. NCT01150513. Docetaxel+carboplatin vs epirubicin+cyclophosphamide followed by docetaxel as adjuvant treatment in triple-negative breast cancer. clinicaltrials.gov/show/NCT01150513 (first received 25 June 2010). YuanP , DuF , WangJ , MaF , FanY , XuB . Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer. Journal of Clinical Oncology2016;34(Suppl 15):1068. YuanP , XuB . A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients. Journal of Clinical Oncology2012;30(15 Suppl):TPS1135. YuanP , XuBH , WangJY , MaF , LiQ , ZhangP , et al. Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial. Chung Hua Chung Liu Tsa Chih 2012;34(6):465-8. ZhengF , DuF , WangW , WangY , LiM , ZhaoJ , et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Research and Treatment2022;191(1):97-105. ">Zheng 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel 75 mg/m<sup>2</sup> or paclitaxel 175 mg/m<sup>2</sup> + carboplatin AUC5 every 3 weeks for 6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin 90 mg/m<sup>2</sup> + cyclophosphamide 600 mg/m<sup>2</sup> every 3 weeks for 4 cycles, followed by docetaxel 75 mg/m<sup>2</sup> or paclitaxel 175 mg/m<sup>2</sup> every 3 weeks for 4 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin AUC5 every 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>AUC: area under the curve; IHC: immunohistochemistry.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of the included treatment comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014805-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Number of treatment comparisons by subgroup and efficacy outcomes</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="2" valign="top"></td> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Treatment comparisons n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>DFS n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>OS n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>pCR n (%)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (76%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Treatment setting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (76%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (5%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Subgroups</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BRCA mutation subgroup reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HRD status subgroup reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node positive reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (14%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (14%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (14%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Type of platinum agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (62%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (10%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lobaplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Type of regimen</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Different backbone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (67%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (33%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (33%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same backbone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (33%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (24%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Anthracycline content in intervention arm</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anthracycline present</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (33%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (47%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anthracycline free</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (29%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Schedule of platinum agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (67%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (57%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (24%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (14%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (24%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Hormone receptor IHC cut‐off</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1% or not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (24%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (43%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (47%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (33%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>DFS: disease‐free survival; HRD: homologous recombination deficiency; IHC: immunohistochemistry; n: number; OS: overall survival; pCR: pathological complete response. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Number of treatment comparisons by subgroup and efficacy outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/full#CD014805-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Neoadjuvant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.53, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Includes adjuvant and neoadjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.05, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.55, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Pathological complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3083</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.31, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Includes adjuvant and neoadjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [1.48, 6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Neoadjuvant all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.34, 1.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Neoadjuvant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adjuvant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.54, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Includes adjuvant and neoadjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.05, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.50, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Disease‐free survival without Wu 2018 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.54, 0.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adjuvant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">All studies: treatment adherence and toxicities</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Participants requiring chemotherapy delays <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1053</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.70, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Participants requiring dose reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.56, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Early cessation of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.04, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4849</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.43, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Febrile neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.89, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.20 [5.66, 11.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.59 [5.10, 11.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Neuropathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.95, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.30, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Renal impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Treatment‐related death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.14, 2.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Participants requiring dose reduction – random effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.08, 4.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Neutropenia – random effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4849</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.12, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">All studies: treatment adherence and toxicities</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">BRCA mutation status</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.52, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 BRCA wildtype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.50, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.41, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Pathological complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.17, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 BRCA wildtype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.21, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.91, 1.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">BRCA mutation status</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Homologous recombination deficiency (HRD) status</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 HRD positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.15, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 HRD negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.42, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Pathological complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.24, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Homologous recombination deficiency (HRD)+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.28, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 HRD−</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Homologous recombination deficiency (HRD) status</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Lymph node status</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.62, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Lymph node positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.54, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 Lymph node negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.55, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Pathological complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.47, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Lymph node positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.31, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Lymph node negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.35, 2.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Lymph node status</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Type of platinum agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.56, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.57, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Lobaplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.05, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.58, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Pathological complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.33, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 Carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.32, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 Cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.3 Lobaplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [1.48, 6.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Type of platinum agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Same backbone chemotherapy with or without platinum</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.56, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Same backbone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.55, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Different backbone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.51, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.56, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Same backbone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.57, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Different backbone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.47, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Pathological complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.33, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Same backbone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.38, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 Different backbone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.18, 1.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Same backbone chemotherapy with or without platinum</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Anthracycline content of chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.56, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Anthracycline‐containing platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.57, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 Anthracycline‐free platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.47, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.58, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Anthracycline‐containing platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.61, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 Anthracycline‐free platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.41, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Pathological complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.33, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Anthracycline‐containing platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.29, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 Anthracycline‐free platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.24, 1.89]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Anthracycline content of chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Schedule of platinum agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.56, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 3‐weekly platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.59, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 2‐weekly platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.14, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.3 Weekly platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.45, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.58, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 3‐weekly platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.64, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 2‐weekly platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.04, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.3 Weekly platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.39, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Pathological complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.33, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 3‐weekly platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.38, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.2 Weekly platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.19, 1.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Schedule of platinum agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Triple negative definition – hormone receptor immunohistochemistry cut‐off</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.56, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 Hormone receptor &gt; 1% or not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.59, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 Hormone receptor &lt; 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.50, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.58, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 Hormone receptor &gt; 1% or not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.2 Hormone receptor &lt; 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.49, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Pathological complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.33, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 Hormone receptor &gt; 1% or not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.30, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.2 Hormone receptor &lt; 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.26, 1.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Triple negative definition – hormone receptor immunohistochemistry cut‐off</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014805-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Platinum‐based chemotherapy versus platinum free chemotherapy without Nasr 2015 or BrigTNess comparison 1, and using bevacizumab‐free CALGB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.50, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.52, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Pathological complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.35, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Platinum‐based chemotherapy versus platinum free chemotherapy without Nasr 2015 or BrigTNess comparison 1, and using bevacizumab‐free CALGB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014805.pub2/references#CD014805-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014805.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD014805-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD014805-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014805-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014805-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD014805-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD014805-note-0017">Magyar</a> </li> <li class="section-language"> <a class="" href="id#CD014805-note-0015">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD014805-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD014805-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD014805-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014805-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014805-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014805\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014805\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014805\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014805\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014805\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014805.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014805.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014805.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014805.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014805.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728240947"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014805.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728240951"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014805.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebfa86a6ef46e',t:'MTc0MDcyODI0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 